Ublituximab as ini�al therapy for treatment -naive  follicular or marginal zone lymphoma with 
resp onse -driven addi�on of umbralisib for subop�mal response  
Protocol Number:  18-2128  
Principal Inves�gator:    Manali Kamdar , MD , MBBS  
IND/IDE:  149590  
Coordina�ng Center /Sponsor  and Lead 
Princip al Inves�gator /Sponsor -
Inves�gator :   
Univ ersity of Colorado, Manali Kamdar  
Funded by:  TG Therapeu�cs , Inc., (Tracking Number: U2-NTG -
009)  
Version Date:   Version 7.0, Dated  May  17, 2021 
  [STUDY_ID_REMOVED] 
  1 of 97  Ublituximab as initial therapy for treatment-naive follicular or 
marginal zone lymphoma with response- driven addition of 
umbralis ib for suboptimal response 
 
  
Protocol Number:  18-2128  
Principal Investigator:    Manali Kamdar , MD, MBBS  
IND/IDE:  149590 
Coordinating Center /Sponsor  and 
Lead Princip al 
Investigator /Sponsor -Investigator :   
Univ ersity of Colorado, Manali Kamdar  
Funded by:  TG Therapeutics , Inc., (Tracking Number: 
U2-NTG-009)  
Version Date:   Version 7.0, Dated  May  17, 2021 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
2 of 97 TABLE OF CONTENTS  
STATEMENT OF COMPLIANCE  ......................................................................................................... 5 
LIST OF ABBREVIATIONS  ................................................................................................................. 6 
Protocol Synopsis  ................................................................................................................................ 7 
SCHEMATIC OF STUDY DESIGN  ..................................................................................................... 10 
1  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ................... 11 
1.1 Background Information  ............................................................................................... 11 
1.1.1 Indolent non -Hodgkin (Follicular and Marginal Zone Lymphoma): Current Landscape 
and Challenges    ..................................................................................................... 11 
1.1.2 Novel Therapeutics  ........................................................................................ 13 
1.2 Rationale  ..................................................................................................................... 19 
2 POTENTIAL RISKS AND BENEFITS  ....................................................................................... 20 
2.1 Comprehensive Adverse Events and Potential Risks Lists (CAEPRS)  ................................. 20 
2.2 Known Potential Benefits  ............................................................................................... 21 
3 OBJECTIVES  ........................................................................................................................ 21 
4 STUDY DESIGN AND ENDPOINTS  ........................................................................................ 22 
4.1 Description of the Study Design  ...................................................................................... 22 
4.2 Study Endpoints  ........................................................................................................... 25 
4.2.1 Primary Endpoints  ....................................................................................... 25 
4.2.2 Secondary Endpoints   ..................................................................................................... 25 
5 STUDY ENROLLMENT AND WITHDRAWAL  ......................................................................... 25 
5.1 Inclusion Criteria .......................................................................................................... 25 
5.2 Exclusion Criteria  ......................................................................................................... 27 
5.3 Strategies for Recruitment and Retention  ........................................................................ 29 
5.4 Participant Withdrawal or Termination  .......................................................................... 29 
5.4.1 Reasons for Withdrawal or Termination  ............................................................. 29 
5.4.2 Handling of Participant Withdrawals or Termination  ............................................ 29 
5.5 Premature Termination or Suspension of Study (Study Stopping Rules)  ............................. 30 
6 STUDY AGENTS  ................................................................................................................... 30 
6.1 Study Agent and Control Description  .............................................................................. 30 
6.1.1 Dosing Schedules ........................................................................................... 34 
6.1.2 Dose Adjustments for Toxicity  ....................................................................... 35 
6.2 Study Agent Accountability Procedures and overview  ....................................................... 41 
6.3 Post-Study Access  ......................................................................................................... 43 
7 STUDY PROCEDURES AND SCHEDULE  ................................................................................ 43 
7.1 Study Procedures /Evaluations  ....................................................................................... 43 
7.1.1 Response Assessment  .................................................................................... 45 
7.2 Laboratory Procedures/Evaluations  ................................................................................ 50 
7.2.2 Specimen Preparation, Handling, and Storage  ................................................. 51 
7.3 Study Schedule  ............................................................................................................. 51 
7.3.1 Screening  .................................................................................................... 51 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
3 of 97 7.3.2 Induction Treatment with Single Agent Ublituximab  ........................................ 53 
7.3.3 End of Treatment Visit for Single agent therapy  ......................................................................... 54 
7.3.4 Combination Ublituximab and Umbralisib  ................................................................................ 55 
7.3.5 End of Treatment Assessment for Combination Therapy  .................................. 56 
7.3.7 Follow -Up   ..................................................................................................... 57 
7.3.8 Early Termination Visit  ................................................................................ 58 
7.3.9 Unscheduled Visit/Recurrence OR Progression at any Unscheduled visit  ............ 58 
7.4- Schedule of Events Table  ............................................................................................... 60 
7.5 Concomitant Medications, Treatments, and Procedures  .................................................... 63 
7.5.1 Precautionary Medications, Treatments, and Procedures  .................................. 63 
7.6 Prohibited Medications, Treatments, and Procedures  ....................................................... 63 
6.7 Prophylactic Medications, Treatments, and Procedures  .................................................... 64 
7.8 Rescue Medications, Treatments, and Procedures  ............................................................. 64 
7.9 Participant Access to Study Agent At Study Closure  ......................................................... 64 
8 ASSESSMENT OF SAFETY  .................................................................................................... 65 
8.1 Specification of Safety Parameters  .................................................................................. 65 
8.1.1 Definition of Adverse Events (AE)  .................................................................. 65 
8.1.2 Definition of Serious Adverse Events (SAE)  ..................................................... 66 
8.1.3 Definition o f Unanticipated Problems (UAP)  ................................................... 67 
8.2 Classification of an Adverse Event  .................................................................................. 67 
8.2.1 Severity of Event  .......................................................................................... 67 
8.2.2 Relationship to Study Agent  .......................................................................... 67 
8.2.3 Expected Adverse Events  .............................................................................. 68 
8.3 Time Period and Frequency for Event Assessment and Follow -Up ...................................... 68 
8.4 Reporting Procedures  .................................................................................................... 69 
8.4.1 Adverse Event Reporting  .............................................................................. 69 
8.4.2 Serious Adverse Event Reporting  ................................................................... 69 
8.4.3 Unanticipated Problem Reporting  .................................................................. 70 
8.4.4 Reporting of Pregnancy  ................................................................................ 71 
8.5 Study Halting Rules  ...................................................................................................... 72 
8.6 Safety Oversight  ........................................................................................................... 73 
9 CLINICAL MONI TORING  ...................................................................................................... 74 
10 STATISTICAL CONSIDERATIONS  ......................................................................................... 74 
10.1 Statistical and Analytical Plans  ....................................................................................... 74 
10.2 Statistical Hypotheses  .................................................................................................... 75 
10.3 Analysis Datasets  .......................................................................................................... 76 
10.4 Description of Statistical Methods  ................................................................................... 76 
10.4.1   General Approach  ....................................................................................... 76 
10.4.2   Analysis of the Primary Efficacy Endpoint  ..................................................... 76 
10.4.3   Analysis of the Secondary Endpoints  ............................................................. 76 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
4 of 97 10.4.4   Safety Analyses  ........................................................................................... 76 
10.4.5   Adherence and Retention Analyses  ................................................................ 77 
10.4.6  Baseline Descriptive Statistics  ........................................................................ 77 
10.4.7   Planned Interim Analyses  ............................................................................. 77 
10.4.8   Safety Review  .............................................................................................. 77 
10.4.9   Additional Sub- Group Analyses  ....................................................................... 77 
10.4.10  Exploratory Analyses  .................................................................................... 77 
10.5 Sample Size  .................................................................................................................. 78 
10.6 Measures to Minimize Bias  ............................................................................................ 78 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................. 78 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ................................................................ 79 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ....................................................................... 79 
13.1 Ethical Standard  ........................................................................................................... 79 
13.2 Institutional Review Board  ............................................................................................ 79 
13.3 Informed Consent Process  ............................................................................................. 79 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  .... 80 
13.3.2  Consent Procedures and Documentation  ......................................................... 80 
13.4 Participant and data Confidentiality  ............................................................................... 81 
13.4.1  Research Use of Stored Human Samples, Specimens or Data  ............................. 81 
13.5 Future Use of Stored Specimens  ..................................................................................... 82 
14 DATA HANDLING AND RECORD KEEPING  ........................................................................... 82 
14.1 Data Collection and Management Responsibilities  ............................................................ 82 
14.2 Study Records Retention  ............................................................................................... 84 
14.3 Protocol Deviations  ....................................................................................................... 84 
14.4 Publication and Data Sharing Policy  ............................................................................... 85 
16 CONFLICT OF INTEREST POLICY  ......................................................................................... 86 
17  LITERATURE REFERENCES  .................................................................................................. 87 
 
  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
5 of 97 STATEMENT OF COMPLIANCE  
 
This is an investigator -initiated study.  The principal investigator (PI), Manali Kamdar , MD,  is 
conducting the  study.  As the sponsor -investigator, both the legal/ethical obligations of a PI  and 
those of a sponsor will be followed. 
 The trial will be carried out in accordance with Good Clinical Practice (GCP) as required by 
applicable United States (US) laws and applications, including but not limited to United States 
(US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
  
The PI will assure that no changes to the protocol will take place without documented approval from the Institutional Review Board (IRB). All personnel involved in the conduct of this study have completed Human Subjects Protection Training.   I agree to ensure that all staff members involved in the  conduct of this study are informed about 
their obligations in meeting the above commitments.  
 
 
 
Sponsor -Lead Principal Investigator:           
                                     Print/Type Name  
  
Signed:          ___________   Date:        
 
 
  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
6 of 97 LIST OF ABBREVIATIONS  
 
ACRONYM  DESCRIPTION  
ADCC  Antibody -dependent cytotoxicity  
AE Adverse Event  
ATP  Acure thrombocytopenic purpura  
CDC  Complement -Dependent Cytotoxici ty 
CFR  Code of Federal Regulations  
CLL  Chronic Lymphocytic Le ukemia  
COMIRB  Colorado Multiple Institutional Review Board  
CR Complete response   
CT Computerized tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DOR  Duration of response  
ECOG  Eastern Cooperative Oncology Group  
ENMZL  Extra -nodal marginal zone lymphoma  
EoT End of therapy  
FDA  Food and Drug Administration  
FL Follicular  lymphoma  
FLIPI  Follicular Lymphoma International Prognostic Index)  
GELF  Groupe d’Etude Lymp homes Folliculaires  
ITT Intent -to-treat 
HIPAA  Health Insurance Portability and Accountability Act  
MRD  Minimal residual disease  
MTD  Maximum tolerated dose  
MZL  Marginal zone lymphoma  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NHL  Non-Hodgkin’s Lymphoma  
NOAEL  No-observed -adverse -effect -level  
ORR  Overall Response Rate  
OS Overall Survival  
PCD  Programmed cell death  
PD Progressive disease  
PET/CT  Positron Emission Tomography /computerized tomography  
PFS Progression -Free Survival  
PJP Pneumocystis jiroveci  pneumonia  
PR Partial response   
QC Quality Control  
QD Once a day  
QoL Quality of Life  
R Rituximab  
RT Radiation therapy  
SAE  Serious Adverse Event  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
7 of 97 SD Stable disease  
SJS Stevens -Johnson syndrome  
TEN  Toxic epidermal necrolysis  
TGT  TG Therapeutics , Inc.   
U2 Ublituximab + Umbralisib  
UAP  Unanticipated Problem  
Ub Ublituximab  
Um Umbralisib  
PROTOCOL SYNOPSIS  
Protocol Title:  Ublituximab as initial therapy for treatment -naive  follicular 
or marginal zone lymphoma with response-driven addition of 
umbralisib for suboptimal response 
 
Objectives:  
 Primary Objective s: 
To determine Best Complete response (CR)  rates at 
anytime during treatment with single agent or combination therapy  
Secondary Objectives:   
• To determine O verall response rates  (ORR) in the 
entire cohort
  
• To assess safety and tolerability profile of single agent and combination therapy  
 Exploratory Objectives  
• To determine ORR and CR rates after induction 
therapy in FL (Follicular lymphoma) and MZL 
(Marginal Zone Lymphoma) cohorts  
• To determine ORR and CR r ates after combination 
therapy in the entire FL and MZL cohorts  
• To determine Partial response (P R), Stable disease 
(SD), progressive disease ( PD) rate of single agent 
and combination therapy  
• To assess duration of remission of single agent and combination therapy
 
• To assess 2- yr progression free survival  (PFS)  and 
overall survival ( OS) of single agent and combination 
therapy  
 
 
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
8 of 97 • To explore baseline disease and patient factors that 
may predict response to ublituximab alone and with 
umbralisib .  
• To assess rates of transformation to aggressive lymphoma 
 
• To evaluate the health -related quality of life (QoL) of 
subjects as assessed by the following subject-reported 
questionnaire 
o FACT -Lym , a standardized instrument for use as 
a measure of health -related QoL as highlighted in 
the APPENDIX section     
• Correlative analysis : M7FLIPI testing at diagnosis 
may be performed which can help predict CR rates 
with single versus combination therapy. Patient 
samples will be tested in a CAP/CLIA -accredited 
laboratory on a custom next generation sequencing 
(NGS) panel.   This panel consists of 310 genes, which 
are recurrently mutated across clonal hematopoietic proliferations including clonal hematopoiesis of 
indeterminate potential (CHIP), acute and chronic 
myeloid neoplasms, B - and T-cell lymphomas, and 
plasma cell neoplasms.   Specifically included in this 
panel are the full coding sequences of the seven genes 
in the m7 -FLIPI clinopathologic riskmodel:  
ARID1A, CARD11 , CREBBP, EP300 , EZH2 , FOXO1 , 
and MEF2B. (Pastore et al. Lancet Oncol 2015) .
10 
Mutation data will be analyzed by a board- certified 
molecular pathologist and thes e results will be 
incorporated with clinical data to determine the m7 -
FLIPI score.   
• Minimal residual disease assessment may be 
performed on patient samples  
 
Endpoint:  Primary Endpoint s: 
• Best Complete response (CR)  rates at any  
timeanytime  during treatment with single agent or 
combination therapy as  defined  by the Lugano 
response Criteria for NHL (Cheson 2014) 
 
Secondary Endpoint s: 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
9 of 97  
  • To determine Overall response rates  (ORR) in the 
entire cohort   as defined  by the Lugano response 
Criteria for NHL (Cheson 2014)  
• Ublituximab tolerability as per CT CAE V5 .0 criteria  
• Umbralisib tolerability as per CTCAE V5.0 criteria  
 
Population:  
• Sample size 
o Maximum number of participants  that can be 
screened  is 30 (will allow for up to 20% screen 
failures /drop-out rate). 24 patients are required for 
this study.  
• Gender Male or Female  
• Age Range  ≥ 18yea rs 
• Demographic group  Any  
• General health status  ECOG 0 -2 
• Geographic location Participating medical center  
 
 
 
Phase:  II 
Number of      
Participating  Sites 
enrolling participants : 
1 
 
Description of Study Agent:   
 
AntiCD20 antibody and PI3K inhibitor  
 
Study Duration:   
Patient enrollment is expected to last for 2 years .  Patients 
will be followed for outcome measures for up to 2 years after 
enrollment in study.  
After last patient has completed end of Treatment (EOT) 
assessment , results will be analyzed and published.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
10 of 97 SCHEMATIC OF STUDY DESIGN  
 
     
 
      
 
  

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
11 of 97  
1  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE                                     
1.1 BACKGROUND INFORMATION  
1.1.1 INDOLENT NON- HODGKIN (FOLLICULAR AND M ARGINAL ZONE LYMPHOMA): 
CURRENT LANDSCAPE AND C HALLENGES  
 
Non-Hodgkin lymphoma (NHL) is the seventh most common cancer and the sixth leading cause 
of cancer deaths  in the United Stated. NHL is  further sub divided into aggressive and indolent 
lymphomas. Indolent lymphomas are slow growing, chronic, treatable, frequently relapsing cancers which  are considered incurable with currently available therapies .
1 Thus, the 
psychological and socio- economic burden of these indolent lymphomas is enormous to patients 
and healthcare facilities.  
 Follicular lymphoma (FL) is the most common indolent NHL in the western hemisphere.
2 FL is 
characterized by an indolent clinical course, typical morphology, and the presence of a chromosomal translocation, t(14;18)(q32;q21) or a variant pattern in 85% of patients which results in the overexpression of BCL-2 protein, a member of the family of proteins that blocks apoptosis.
3 Based on the proportion of centrocytes to centroblasts, FL is further divided into 3 
grades: Grade 1, Grade 2, Grade 3A and Grade 3B with evidence suggesting that Grade 1- 3A are 
biologically indolent whereas Grade 3B has an aggressive clinical course similar to diffuse large 
cell lymphoma .4,5 FL represents si gnificant heterogeneity , with some patien ts not requiring 
therapy for s everal years after diagnosis or  achieving long remissions with initial treatment, 
while other patien ts needing immediate therapy at diagnosis and relapse within a short time or 
are refr actory to treatment, resulting in shortened survival. Additionally , approximately 30% of 
FL p atien ts will transform to a more aggressive histology  during their disease course, often 
leading to rapid progression and the need for intensive therapy.6 
 In newly diagnosed FL, there are multiple clinical factors prognostic of outcome including age, 
LDH (Lactose Dehydrogenase), β2 -microglobulin, disease bulk, and stage of disease which have 
been used to develop prognostic tools such as the FLIPI (Follicular Lymphoma Int ernational 
Prognostic Index), FLIPI2, and guidelines to assist in making treatment decisions such as the GELF (Groupe d'Etude des Lymphome s Folliculaires) criteria  
7. In addition, newer markers such 
as response by positron emission tomography/computerized tomography (PET- CT), minimal 
residual disease (MRD)  and biomarkers like m7- FLIPI have been recognized to correlate with 
disease outcome.8,9,10  
 The present day approach outlined in the NCCN (National comprehensive cancer network) guidelines is based on stage and burden of FL. Recommendations listed in the NCCN guidelines for early -stage FL (Stage I -II) range from watchful waiting, radiatio n therapy to single- agent 
rituximab. Based on Lymphocare database, comparable outcomes have been found with either of 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
12 of 97 these approaches.11 However, none of these strategies have been compared head -to head in a 
prospective setting.  
 The NCCN guidelines for p atien ts with advanced- stage dis ease are based on  disease burden (i.e . 
low tumor burden versus high tumor burden). Patients with low tumor burden FL are most oft en 
observed with a watch -and- wait approach
12 or treated with single -agent rituximab.13 Patients 
with high tumor burden FL are most often treated with combination chemoimmunotherapy (R-chemotherapy), lenalidomide plus rituximab, single agent rituximab with the possi bility of 
rituximab maintenance . 
14-16 
 FL is considered an incurable disease in the majority of patien ts with currently available 
therapeutic options. For several years it appeared that the overall survival of low grade FL was around 10 years or under
17 and that it might not be significantly affected by therapy. However, 
more recent studies in the era of antiCD20 monoclonal antibodies have suggested a significant improvement in overall survival now almost approaching 20 years.
18,19 Overall survival of 
patients with FL grade 1 or 2 treated by physicians in the Nebraska lymphoma group between 1982 and 2014 suggested that patients treated before the advent of monoclonal antibodies experienced a decreased overall survival compared to patients treated after.
20  
 In order to improve overall outcomes of patients with FL it is important to identify risk -groups, 
which would derive most benefit from novel therapeutic approa ches. NCI (National Cancer 
Institute) Lymphoma Clinical Trials Planning Meeting Follicular Subcommittee  thus iden tified 
two populations of patients who are t hought to be the highest priority for further study. The first 
patient population pertains to patien ts with high- risk disease.  The second population of FL 
patien ts recommended for study is “watch and wait” group, or those considered low risk. In 
order to  assure that these patients are similar at diagnosis, the use of the GELF criteria is 
recommended to identify low -risk patients who are appropriate for observation. There are several 
trials currently ongoing that focus on high-risk groups with novel therapeutic interventions. However, very few to none are focused on low tumor burden FL patien ts.
21  Studies in FL take 
decades, and most of the studies suggesting no impact on survival in delaying therapy were done before the availability of monoclonal antibodies. Studies done in the era of monoclonal antibodies are few with a shorter follow up. The fact that there is no proof that delaying therapy does not decrease survival does not rule out the possibility that it could be true. We believe that in order to gain a better understanding of the natural history and biology of follicular lymphoma, it will also be important to study the “low -risk” group of patients as well . 
 Another subset of indolent lymphomas called marginal zone lymphoma (MZL) is the third most common lymphoma, accounting for 8-12% of all B -cell NHL . MZL is an indolent malignancy 
with three main subtypes of varying frequency: Extra-Nodal MZL of the mucosa- associated 
lymphoid tissue (ENMZL) (70%); splenic MZL (SMZL) (20%); and nodal MZL (NMZL) 
(10%).
22 ENMZL typically presents with localized disease whereas SMZL and NMZL present 
with disseminated disease . In the absence of standard treatment of both SMZL and NMZL, 
current treatment strategies for low tumor burden patients recommend watchful waiting or single 
agent rituximab therapy.23 In fact, the NCCN guidelines currently suggest therapy for NMZL and 
advanced MZL to be similar to FL p atien ts. Thus this subtype of lymphoma continues to  be 
understudied and poorly represented in clinical trials.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
13 of 97  
Rituximab, an anti-CD20 antibody therapy, is commonly used as single agent for the treatment of FL and MZL.
1 In patients with FL , single agent rituximab yields an overall response rate 
(ORR)  of 77% and a complete response rate (CR) of 36%.24 In patien ts with MZL , single agent 
rituximab has shown to yield an ORR of 52% and a CR of 12% . There have been few clinical 
trials focusing on subtypes of MZL. However, existing data shows that the use of single agent rituximab in NMZL  can achieve an ORR 60% and a CR 3 5%.
25 In ENMZL single agent 
rituximab has shown to achieve an ORR 73% CR 44%26 whereas in SMZL single agent 
rituximab has shown to yield an ORR of 90% and a CR rate of 50%.27 Based on these responses, 
it is clear that there is ample scope to improve  and deepen these responses by implementing 
novel therapeutics.   In patients with FL and MZL who achieve a partial response (PR) or stable disease (SD) to single agent rituximab induction therapy, no data currently exists to guide further management. Most treatment centers either implement a “watchful waiting” strategy for clinically 
asymptomatic patients while others recommend extended duration rituximab.
25 It is intuitive that 
these patients who do not achieve a CR are bound to have progressi ve disease earlier in their 
disease course thus potentially impacting outcomes adversely. This subset of patients has rarely been studied in clinical trials  and thus continues to be an unmet need.  
   
1.1.2 NOVEL THERAP EUTICS  
 
a. Ublituximab  
 
Ublituximab  is a novel third generation chimeric anti-CD20 monoclonal antibody 
bioengineered for potent activity, exhibiting a unique glycosylation profile with a low fucose 
content, designed to induce superior antibody-dependent cytotoxicity (ADCC).  Ublituximab exhibits competitive complement-dependent cytotoxicity (CDC), on par with rituximab, and 
has been demonstrated to induce programmed cell death (PCD) upon binding to the CD20 antigen on B-lymphocytes.  Ublituximab has a unique protein sequence, and targets epitopes on CD20 not targeted by rituximab or ofatumumab, both currently approved anti-CD20 antibodies (Esteves IT, 2011).  
 
Pre-Clinical Development of Ublituximab  
 
In Vitro Activity  
In an in-vitro assay using B-CLL cells from patient donors, ublituximab demonstrated an 
enhanced ability to kill CLL (chronic lymphocytic leukemia) cells compared to rituximab.  Ublituximab demonstrated improved Fcγ receptor IIIA (FcγRIIIA)/CD16 binding and FcγRIIIA dependent effector functions compared to rituximab.  Additionally, ublituximab induced higher in vitro ADCC against CLL cells, and a higher FcγRIIIA mediated interleukin-2 (IL2) production by FcγRIIIA+ Jurkat cells (de Ro meuf C, 2008).  Ublituximab demonstrated high 
ADCC against both patient- derived CLL cells and NHL cell lines.  Ublituximab’s engagement 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
14 of 97 to FcγRIIIA triggers a stronger natural killer ( NK) cell cytotoxicity against CLL as compared to 
rituxan (in vitro) despite CD20 density, likely related to the glycosylation pattern (de Romeuf 
C, 2008).   In Vivo Activity 
The antitumor effect of ublituximab was compared to that of rituximab with chemotherapy in 
follicular lymphoma (FL), and mantle cell lymphoma (MCL) xenograft murine models.  Single agent ublituximab demonstrated dose- related anti -tumor activity with 100% tumor growth 
inhibition in the FL xenograft at a dose of 100mg/kg, and a superior tumor growth delay (21 days) compared to rituximab. Ublituximab also demonstrated superior anti- tumor activity 
compared to rituximab against MCL xenografts at all dose levels.
28 
 Clinical Development of Ublituximab  
Ublituximab has been studied in a variety of patient populations, both as a single agent, and in combination with other agents, with over 1,000 patients having received ublituximab therapy to date across all studies.  Two single- agent Phase I/Ib trials have been conducted with 
ublituximab tre ating both NHL and CLL patients. Further, following demonstration of safety 
and tolerability in these early single agent studies, Phase I and II combination studies were undertaken with a variety of agents.  Given the number of patients who have received ublituximab in early -phase trials, the safety and side effect profile of the agent is well 
characterized.  Summaries of the single- agent experience are provided below .  
 In a two part, first-in human dose escalation study (protocol CD20-0703), patients with 
relapsed or refractory CLL received one weekly infusion of single agent ublituximab for 4 doses in a 3+3 dose escalation design through 5 sequential dose levels.  Part II of the study was a dose-confirmation component that  used an initial dose of 150 mg followed by 7 doses of 450 
mg (total dose 3300 mg). Median time from diagnosis to inclusion was 10.4 years [4.0–23.6] and median prior therapies was 3 [1–8].  Seven patients (58%) received at least one prior rituximab -containing regimen. The m ost frequent drug- related adverse events (AEs) reported 
were infusion related reactions (IRR) (75% of the patients, including 33% of patients with Grade 3 IRR).  Other Grade 3/4 AEs > 10% included: neutropenia (67%) and increase ALT/AST (17%).  All AEs were  reversible spontaneously or with supportive care intervention.  
None of the reported adverse events were considered as a dose- limiting toxicity. Therefore, the 
maximum tolerated dose was not reached in this study.  Significant blood lymphocyte depletion was observed in all patients:  median lymphocyte count at baseline was 46.6 (x 10
9/l); after 1 
month (M1) = 1.5 (↓94%); M4 = 1.4 (↓91%) and M6 = 2.0 (↓89%). No cases of serum anti -
ublituximab  antibodies were detected at any time point. Response was evaluated at month 4 for 
the 11 evaluable patients, with an initial response rate of 64% (7/11) with a confirmed response at month 6 in 5/11 patients (45%) patients (all PRs).  Four of the 11 patients achieved stable disease.  At the 1 -year follow -up, no responders had progressed, demonstrating all confirmed 
responses were durable despite no ublituximab maintenance therapy.  The median progression-free survival (PFS) was not reached at the 12 -month follow-up (Cazin B, 2013). 
 A Phase I trial of ublituximab ([STUDY_ID_REMOVED]) was subsequently undertaken in patients with B-cell lymphoma who relapsed or were refractory to a prior rituximab -containing regimen.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
15 of 97 This trial utilized a 3+3 design, assessing dose levels of 450, 600, 900, and 1200 mg.  No DLTs 
were observed amongst the 12 patients enrolled into the dose-escalation component, and expansion cohorts were subsequently undertaken at 600, 900, and 1200 mg. Induction therapy (doses of 450–1200 mg) consisted of 4 weekly infusions in cycle 1 for NHL and 3 weekly 
infusions in cycles 1 and 2 for CLL. Patients received ublituximab maintenance monthly during cycles 3 –5, then once every 3 months for up to 2 years. Enrolled patients wit h B-NHL (n=27) 
and CLL (n=8) had a median of 3 prior therapies. No dose- limiting toxicities or unexpected 
adverse events (AEs) occurred. The most common AEs were infusion- related reactions (40%; 
grade 3/4, 0%); fatigue (37%; grade 3/4, 3%); pyrexia (29%; grade 3/4, 0%); and diarrhea (26%; grade 3/4, 0%). Common hematological  AEs were neutropenia (14%; grade 3/4, 14%) 
and anemia (11%; grade 3/4, 6%). The overal l response rate for evaluable patients (n = 31) was 
45% (13% complete responses, 32% partial responses). Median duration of response and progression-free survival were 9.2 months and 7.7 months, respectively .
29 
  
b. Umbralisib  
Umbralisib is a highly specific and orally available dual inhibitor of phosphoinositide-3- kinase 
(PI3K) delta (δ) and casein kinase 1 epsilon ( CK1ε ) with Nano molar inhibitory potency, and 
high selectivity over the alpha, beta, and gamma Class I isoforms of PI3K.  The PI3Ks are a family of enzymes involved in various cellular functions, including cell proliferation and survival, cell differentiation, intracellular tr afficking and immunity.  The delta isoform of PI3K 
is highly expressed in cells of hematopoietic origin, and strongly upregulated, and often mutated in various hematologic malignancies.   
 Clinical D evelopment of Umbralisib  
 Single -Agent in Patients with R elapsed or Refractory Hematologic Malignancies  
Umbralisib has been evaluated in a single- agent Phase I dose -escalation study in patients with 
relapsed and refractory hematologic malignancies .
30  A total of 90  patients were enrolled and  
treated. The median age was 65 years (range 22 -85) and 63% were male.  Among all patients 
the median number of prior thera pies was 3 (with a range of 2 -5), with 44% refractory to  prior 
rituximab -based chemotherapy.  Histological diagnoses were as follows: FL (n=22), CLL 
(n=24), diffuse larg e B-cell lymphoma (DLBCL; n=16), Hodgkin’s lymphoma (HL; n=11), 
mantle cell lymphoma (MCL; n=6), MZL (n=5), WM (n=3), hairy -cell leukemia (HCL)  (n=1)  
and T- cell lymphoma  (n=2).  The majority of patients had an ECOG of 1 and 40/81 (49%) were 
refractory to  prior therapy. Patients self -administered an umbralisib oral tablet once per day in 
28-day cycles, with dose escalation done in a traditional 3+3 design to establish safety and determine the maximum tolerated dose. In initial cohorts, patients took umbralisib in a fasting state at a starting dose of 50 mg, increasing to 100, 200, 400, 800, 1200, and 1800 mg until the maximum tolerated dose was rea ched, or the maximal dose cohort was accrued without a dose-
limiting toxicity. In an effort to further improve the oral bioavailability of umbralisib  
subsequent cohorts self- administered a micronized  formulation of umbralisib tablet in a fed 
state at an in itial dose of 200 mg, increased in increments to 400, 800, 1200, and 1800 mg until 
the maximum tolerated dose or the maximal dose level was accrued.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
16 of 97 No maximum tolerated dose (MTD) reached. The most common treatment- emergent adverse 
events irrespective of causality were diarrhea (in 39 [43%] of 90 patients), nausea (38 [42%]), 
and fatigue (28 [31%]). The most common grade 3 or 4 adverse events were neutropenia (in 12 [13%] patients), anemia (eight [9%]) and thrombocytopenia (six [7%]). Serious adverse events 
considered at least possibly related to umbralisib occurred in seven patients: pneumonia in three (3%) patients, lung infection in one (1%), febrile neutropenia in one (1%), and colitis in two (2%), one of whom also had febrile neutropenia. The maximum tolerated dose was 1200 mg of the micronised formulation, with 800 mg of this formulation selected as the recommended phase 2 dose. Both cases of colitis occurred at above the recommended phase 2 dose. Thirty -
three (37%) of the 90 patients enrolled had an objective response to treatment with umbralisib.   Umbralisib was clinically active in most patients treated. Fifty -six (62%) of the 90 enrolled 
patients had reductions in disease burden as assessed by CT scan , 33 (37%) had an objective 
response, and 30 (33%) had a partial response. No objective responses were recorded in the eight patients treated with less than 800 mg per day of the initial non- micronized  formulation. 
Seventy -three patients were eligible for inclusion in the modified intention -to-treat p opulation 
for assessment of antitumor activity. Of these 73 patients, 53 (73%) had reductions in disease burden, including 33 (45%) patients with an objective response of reductions of 50% or more of which three (4%) were a complete response and 30 (41%) w ere a partial response.   
 In patients with follicular lymphoma, nine (53%) of 17 patients achieved an objective response, including two (12%) who achieved a complete response; the remainder had a partial response.  
Overall, umbralisib was well tolerated an d displayed promising signs of clinical activity at the 
higher dosing cohorts with 800 mg QD (once a day) selected as the Phase 2 dose in patients 
with previously treated CLL and NHL. Umbralisib is now in Phase 3 development for patients with CLL (UNITY -CLL study). In conclusion, the safety, activity, and pharmacological 
properties of umbralisib support investigations of its use as monotherapy or in combination with other novel targeted drugs for patients with hematological  malignancies.  
 
c. Ublituximab in Combination with Umbralisib  
 
The combination of ublituximab and umbralisib is currently under evaluation in registration 
trials in CLL and various B cell NHL histologies.  Results of a Phase I/Ib study in subjects with relapsed or refractory  NHL and CLL have been reported .
31  In early cohorts, patients received 
ublituximab on days 1, 8 and 15 of Cycles 1 & 2, then on day 1 of Cycles 4, 6, 9, and 12.  In later cohorts, the ublituximab administration schedule was amended to infusions on days 1, 8, and 15 of Cycle 1, followed by Day 1 of Cycles 2 through 6.  CLL patients receive Cycle 1, Day 1 infusions split over Days 1 and 2.  Umbralisib was taken once daily until patients are 
removed from study as per the protocol.     A 3+3 dose-escalation design is being utilized to evaluate sequentially higher doses of the combination agents as illustr ated below:  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
17 of 97 Cohort  Ublituximab NHL Dose  Ublituximab CLL Dose  Umbralisib  Dose (QD)  
1 900 mg  600 mg  800 mg  
2 900 mg  600 mg  1200 mg  
3 900 mg  900 mg  400 mg (micronized)  
4 900 mg  900 mg  600 mg (micronized)  
5 900 mg  900 mg  800 mg (micronized)  
6 900 mg  900 mg  1200 mg (micronized)  
 
Enrollment completed in March 2017 with 75 subjects evaluable for safety and 69 subjects 
evaluable for efficacy.  The MTD was not reached in the CLL (N = 22) or NHL cohort (N = 53).  The median age of all subjects was 64 years (range 26 – 86).  Subjects had a median of 3 prior therapies, and 57% were refractory to their immediate prior therapy.    
Diarrhea was the most prevalent adverse event (60% all grades; 8% G ≥ 3), followed by nausea 
(56% all grades; 4% G ≥ 3), fatigue (48% all grades; 3% G ≥ 3), neutropenia (32% all grades; 28% G ≥ 3), vomiting (31% all grades; 1% G ≥ 3), and infusion related reactions (31% all grades; 1% G ≥ 3).  The median time to onset and resolution of diarrhea was 21 days (range, 1 – 838 days) and 7 days (range, 1 – 191 days), respectively.  Diarrhea was Grade 3/4 in 6 
subjects.  Management of Grade 3/4 diarrhea included dose hold (5 cases) and anti- diarrheal 
medication (3 cases), and all cases resolved.  Biopsy -confirmed colitis was reported in 1 
subject, and it was managed with treatment hold and steroids.  Other Grade 3/4 events observed 
in greater than 5% of subjects included pneumonia (8%) and abdominal pain (7%).  Grade 3/4 
alanine transaminase (ALT) and aspartate transaminase (AST) elevations occurred in 3% and 
1% of subjects, respectively.  One subject with transaminitis received steroid treatment, and 1 case resolved without intervention.  ALT/AST elevations of any grade had a median time to onset of 55 days.  Pneumonitis was seen in 2 subjects with a median resolution time of 21 days 
(range, 15–28 days).  Treatment was discontinued due to adverse events in 13% of subjects and 
15% of subjects had their umbralisib dose reduced.  Efficacy data from all doses of the U2 regimen based on 68 out of 69 subjects evaluable for 
efficacy are presented in the waterfall plot below.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
18 of 97  
 
 
Response by histology in subjects receiving therapeutic dose levels and above of umbralisib (≥ 
1200mg non- micronized or ≥ 600mg micronized) in combination with ublituximab is shown in 
the following table. 
 
 
 
Safety profile supports continued investigation of ublituximab and umbralisib in combination 
and in other multi-drug regimens: triple therapy combinations adding novel agents to 
ublituximab and umbralisib are ongoing (including with ibrutinib, bendamustine, and 
pembrolizumab) with additional triple thera py studies planned. 

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
19 of 97  
The combination of ublituximab and umbralisib is in registration directed trials in CLL (Study 
UTX- TGR -304 [UNITY-CLL]; [STUDY_ID_REMOVED]), and various NHL subtypes, (Study UTX-
TGR -205 [UNITY-NHL]; [STUDY_ID_REMOVED]).  See the latest Investigator’s Brochure for updated 
information regarding the clinical development of ublituximab and umbralisib as single- agents 
or in combination. 
 
1.2 RATIONALE  
Despite improvements in the treatment of indolent lymphomas, the disease remains incurable . 
Thus, there  is a continued need to improve  treatment outcomes. The optimal treatment for newly 
diagnosed indolent lymphomas is  based on tumor burden with options ranging from watchful 
waiting to single agent rituximab  to chemoimmunotherapy regimens and most recently 
immunomodulator containing regimens .12-15 Very few prospective trials have been conducted in 
the low tumor burden subgroup of indolent lymphomas. The only trial in the rituximab era was a 
trial by Ardeshna et al wherein it was found that rituximab improved progression free survival , 
however, the study did not show any imp rovement in overall survival.24 Based on previously 
described efficacy outcomes of single agent rituximab there is clearly ample scope to increase response rates and overall outcomes after front line therapy. Toward achieving the goals of improving outcomes  in low tumor burden indolent lymphomas, we propose to use single agent 
ublituximab as induction therapy. Given the toxicity seen with standard combination treatment 
regimens in patients, an initial chemotherapy free regimen with a potent CD20 antibody suc h as 
ublituximab followed by a response driven addition of a chemotherapy -free targeted agent may be 
an attractive treatment option if found to be  well tolerated and to have significant anti -tumor 
activity.  
 Patients who achieve responses less than a CR ar e usually followed with an e xpect ant strategy or 
are treated with extended duration rituximab. It is obvious that these patients are at a high risk of progression. To date, there has not been much data -driven guidance on how to manage these “at -
risk” patie nts until frank progression occurs. Treating these patients with novel targeted inhibitors 
has the potential to halt expected progression and thus, preclude these patients from the receipt of more  toxic therapies at disease progression . Multiple targeted inhibitors are currently being tested 
in patients with lymphoma. The phosphatidylinositol -3-kinase (PI3K) pathway has an important 
role in many cellular functions, including B -cell antigen receptor signaling. Selective inhibition of 
PI3K isoform δ -dependent signaling has direct antitumor  activity and exerts pleiotropic  effects in 
the tumor microenvironment of B -cell malignancies, inducing apoptosis and reducing 
proliferation.
32 Idelalisib, a first- in-class drug targeting the PI3Kδ pathway, was approved for use 
in 2014 in the USA and the European Union after showing clinical  activity in patients with relapsed 
or refrac tory CLL and FL.33  Similar to other B -cell receptor inhib itors, idelalisib is  administered 
indefinitely until disease progression or  intolerable toxic ities occur. However, studies documented 
unexpected life- threatening adverse events with this drug, including an increased risk of  
autoimmune complications (e .g., colitis, pneumonitis, and transaminitis)  and infections (e .g., 
cytomegalovirus reactivation and Pneumocystis jirovecii pneumonia). These adverse events have 
driven the need for not only efficacious, but also safer therapies.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
20 of 97 Umbralisib , as shown in the multiple studies above , is associated with low rates of immune -
mediated  toxicity and exhibits a favorable long- term tolerability profile  at a median follow -up of 
1.3 years, with up to 5 years of  overall follow up. The mechanism for decreased immune -mediated 
toxicity is still being elucidated through ongoing pre -clinical and  correlative studies examining 
umbralisib's selectivity for PI3Kδ  over PI3Kγ, complimentary CK1ε inhibition, and enhancement  
of regulatory T- cell function  (Davids et al Abst ract # PF4 44 EHA 2018).  
 
In patients who do not achieve a CR , we propose to administer ublituximab plus umbralisib for a 
defined time duration (12 cycles ) to assess if the addition of umbralisib can convert suboptimal 
responses to a CR.  Ublituximab in combination w ith umbralisib is well tolerated and highly active 
in a broad population of heavily pretreated and high- risk patients with NHL and CLL .32 Most 
studies so far have been designed with fixed duration ublituximab and umbralisib being 
administered until progression or unacceptable toxicity. The unique feature of our proposed hypothesis is fixed duration administration of umbralisib with the hope of enhancing efficacy as well as mitigating toxicity.    Pastore et al have shown that a cl inicogenetic risk model (m -7FLIPI) includes the mutation status 
of seven genes ( EZH2 , ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11 ), the FL 
International Prognostic Index (FLIPI), and the Eastern Cooperative Oncology Group (ECOG) performance status, imp roves risk stratification for failure -free survival (FFS) and overall survival 
in patien ts with FL receiving first- line immunochemotherapy.
10 The utility of this risk model is 
unknown in patients with  FL who have been previously untreated or treated with chemotherapy -
free approaches . The correlative analysis will include identifying m -7FLIPI risk model for each 
FL, which can help predict CR rates to single and combination therapy. 
 
2 POTENTIAL RISKS AND BENEFITS  
 
2.1 P OTENTIAL  RISKS  
SINGLE AGENT UBLITUXIMAB  
Adverse Events  and Potential Risks : The Investigator’s Brochure (IB) is the primary source for 
safety information. The ublituximab IB includes a summary of adverse event data and discussion 
on potential risks that have been observed or may be predicted to occur with this study drug. Refer 
to the most recent IB, which is updated periodically, for current information on ublituximab. 
UBLITUXIMAB + UMBRALISIB COMBINATION 
Adverse Events and Potential Risks  
Refer to the most recent Investigator’s Brochure s IBs for  ublituximab and umbralisib , which are  
updated periodically, for current safety information on the combination of ublituximab  and 
umbralisib . 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
21 of 97 SINGLE AGENT UMBRALISIB  
Adverse Events and Potential Risks  
The Investigator’s Brochure (IB) is the primary source for safety information.  The umbralisib IB 
includes a summary of adverse event data and discussion on potential risks that have been observed or may be predicted to occur with this study drug.  Refer to the most recent IB, which is updated periodically, for current information on umbralisib.  
2.2 KNOWN POTENTIAL BENEFITS  
 
Ublituximab has demonstrated evidence of clinical activity in relapsed NHL’s including relapsed FL and MZL. Ublituximab may increase the likelihood of improved responses as compared to rituximab in indolent lymphomas. Furthermore , this trial also studies the combination of 
ublituximab and umbralisib in patients who do not achieve a CR to single agent therapy. The combination of ublituximab and umbralisib has shown to be safe and efficacious in relaps ed 
indolent lymphomas. This trial provides an opportunity to test this combination in patients who have a suboptimal response to ublituximab with the hope of improving outcomes. The risks to participants  are reasonable in relation to the anticipated benefits to participants and/or society, and 
in relation to the importance of the knowledge that may reasonably be expected to result, thereby falling in favor of performing the study:  
• To Participant : Potential to improve management and outcomes of 
malignancy  
• To Society:  Impro ved understanding of the role of Anti CD20 antibody and 
PI3K inhibitor in the management of indolent B cell NHL . Improved 
understanding of QOL assessments in indolent lymphomas  
• Justify the importance of the knowledge gained:  Anti-CD 20 antibody therapy 
and PI3K inhibitors have  led to improved outcomes in patients with  several 
subtypes of B -cell NHLs .  However, ther e is a relative paucity of information 
regarding the efficacy of these agents as single agents or in combination in newly diagnosed indolent B -cell NHLs. This protocol will provide valuable 
insights into the potential role of these agents in the management  of these 
lymphomas. 
  
3 OBJECTIVES  
Primary objective s:   
 
To determine Best Complete response  (CR) rates as measured by PET/CT scan at anytime 
during treatment with single agent or combination therapy  
 Secondary objectives:   
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
22 of 97  
• To determine overall response rates  (ORR) in the entire cohort  
• To assess safety and tolerability profile of single agent and combination therapy  
 
Exploratory objectives :   
• To determine ORR and CR rates after induction therapy in FL and MZL cohorts  
• To determine ORR and CR rates after combination therapy in the entire FL and MZL cohorts  
• To determine Partial response (PR), Stable disease (SD), progressive disease (PD) rate of single agent and combination therapy  
• To assess duration of remission of single agent and combination therapy  
• To assess 2 -yr progression free survival (PFS) and overall survival (OS) of single agent and 
combination therapy  
• To explore baseline disease and patient factors that may predict response to ublituximab alone and with umbralisib  
• To assess rates of transformation to aggressive lymphoma 
• To evaluate the health -related quality of life (QoL) of subjects as assessed by the following 
subject -reported questionnaire:  
o FACT -Lym, a standardized instrument for use as a measure of health- related QoL   as 
highlighted in the APPENDIX section     
• Correlative analysis : M7FLIPI testing at diagnosis may  be performed which can help predic t 
CR rates with single versus combination therapy. Patient samples will be tested in a 
CAP/CLIA -accredited laboratory on a custom next generation sequencing (NGS) panel.  This 
panel consists of 310 genes, which are recurrently mutated across clonal hematopoietic proliferations including clonal hematopoiesis of indeterminate potential (CHIP), acute and 
chronic myeloid neoplasms, B- and T- cell lymphomas, and plasma cell 
neoplasms.  Specifically included in this panel are the full coding sequences of the seven 
genes in  the m7 -FLIPI clinicopathologic 
riskmodel:  ARID1A, CARD11 , CREBBP, EP300 , EZH2 , FOXO1 , and MEF2B . (Pastore et 
al. Lancet Oncol 2015).
10 Mutation data will be analyzed by a board -certified molecular 
pathologist and these results will be incorporated with clinical data to determine the m7 -
FLIP I score.  
• Minimal residual disease assessment may be performed on patient samples.  
 
4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF THE STUDY DESIGN  
This is an  open- label, Phase II  interventional study in order to assess the safety and efficacy  of 
single agent ublituximab as ini tial therapy for FL and MZL with response driven addition of 
umbralisib for suboptimal response.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
23 of 97  
 
 Based on overall reporting in low tumor burden FL and MZL, CR rate of at least 30% was achieved when single agent rituximab was used in these subsets. We assume that by administering ublituximab  (both as a single agent and in combination for individuals who fail to 
achieve a CR with the single agent), the CR rate will increase to 50%. Effica cy will be assessed 
using the proportion of patients treated with ublituximab alone or with ublituximab administered in combination who have a complete response.  Thus, we will test the efficacy of ublituximab using a difference in proportions design by comparing an expected study population control rate of 50% to the comparison proportion being determined by the historical control CR rate of 30%.  In other words, the null hypothesis is that the true response rate is 30%, and it will be formally tested agai nst a one- sided alternative  that the response rate is 50%.   
 A total of 24 patients will need to  be accrued (assuming 73% power and a type I error of 0.10 
when the true response rate is 50%).  At study completion, the proportion of patients achieving a complete response will be calculated, along with 95% confidence intervals for this proportion. Assuming 20% screen fail/drop-out rate, 30 patients need to be screened for this study.   Patients will be followed for outcome measures up to 2 year s from study enrollment.  Study 
enrollment will continue until stopping endpoints.  Of note, the study will accrue continuously, and will not stop enrollment of patients while analysis of stopping endpoints are underway. 

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
24 of 97 Toxicity  
 
Treatment -related mortality:   If any patient experiences death due to an adverse event that is 
assessed as related to study treatment (by investigator and/or Sponsor), it will lead to temporary hold of study pending review by study team.  The study will be  terminated prematurely if at any 
point 2 patients experience treatment -related death secondary to the  study regimen (Ublituximab 
and/or umbralisib)  
Toxicities of special interest:    
a. Patients enrolled on the single agent  treatment  Ublituximab will be asse ssed for toxicities of 
special interest  for 30 days. The study will be halted prematurely if more than 5 patients 
experience the following toxicities :  
 
• Grade 4 Neutropenia 
• Neutropenic Fever  
 
b. The combination arm of Ublituximab + Umbralisib  is of special interest in this study. 
Patients enrolled on this arm will be assessed for toxicities of special interest for 90 days. 
The study will be halted prematurely if more than 3 consecutive patients enrolled on the combination arm experience any of the following toxicities:  
 
• Grade 3 or higher pneumonitis 
• Grade 3 or higher colitis 
• Grade 4 hepatitis  
• Grade 4 rash  
• Other grade 4 unmanageable events attributable to the study treatment. 
 
c. The study will be halted prematurely if a patient develops  progressive multifocal 
leukoencephalopathy on single agent / combination arm of the study.    Patients will continue  to receive study therapy as defined by the schema (4 weekly doses of 
ublituximab in the single agent treatment and ublituximab plus daily umbralisib for a total of 12 
cycles  in the combination arm) or until disease progression according to Cheson 2014, 
unacceptable toxicity, death due to an adverse event that is assessed as related to study treatment 
(by investigator and/or Sponsor) , patient or physician decision to withdraw, or pregnancy, 
whichever occurs first . The study will end when all patients enrolle d have completed planned 
treatment  or the Sponsor decides to end the trial , whichever occurs first.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
25 of 97 4.2 STUDY ENDPOINTS   
4.2.1 PRIMARY ENDPOINT S 
  
Efficacy:  Best Complete response (CR) rates at anytime during treatment with single agent or 
combination therapy as defined by the Lugano response Criteria for NHL (Cheson 2014)   
4.2.2 S ECONDARY  ENDPOINT S 
 Efficacy:  To determine Overall response rates (ORR) in the entire cohort  as defined  by the 
Lugano response Criteria for NHL (Cheson 2014)  Toxicity:  Ublituximab tolerability as per CT CAE V5 .0 criteria  
Umbralisib tolerability as per CT CAE V5 .0 criteria  
  
5 STUDY ENROLL MENT AND WITHDRAWAL  
5.1 INCLUSION CRITERIA  
Screening for eligible subjects will be performed within 28 days before study entry unless state d 
otherwise in the Schedule of Events. Prior to study entry, each potential subject must satisfy all of 
the following inclusion criteria . Obtaining pathology samples is not required prior to enrollment, 
but confirmation of availability is  required prior to enrollment. 
 Disease Related  
1. Subjects with histologically documented Follicular lymphoma CD20+ (Grade 1, 2 or 3a) 
OR Marginal zone lymphoma CD20+ (nodal, extranodal or splenic) according to World 
Health Organization (WHO) criteria .  
2. Ann Arbor Stage II (Non-contiguous), III or IV disease 
3. Patients mu st have a whole body or limited whole body PET/CT scan performed within 42 
days prior to registration. CT portion of PET/CT will be done with contrast based on current 
NCCN guidelines unless patient has borderline renal function or allergic to contrast dye.  
4. Patients  must have bone marrow biopsy performed within 6 months prior to registration 
5. Measurable node must have an LDi greater than 1.5 cms. In the absence of nodal lesions, 
measurable extranodal disease should have an LDi greated than 1 cm . In patients with 
Splenic Marginal Zone lymphoma, in the absence of nodal lesions, spleen size should should 
be over 14 cms with evidence of lymphoma in the bone marrow biopsy.  
 
6. For low tumor burden lymphomas (as determined by GELF criteria) 7: Include patients 
diagnosed within 2 years of diagnosis. Low tumor burden patients diagnosed more than 2 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
26 of 97 years from study entry will be allowed provided patients have documented progression.  
Prior Therapy Criteria  
1. Patients must be untreated advanced st age disease (Stage III or Stage IV) or Stage II (non -
contiguous). (Except ion: Involved field or involved site radiation given for localized 
diagnosis is not considered a line of therapy).  
 
Clinical/Laboratory  Criteria  
1. Patients must be ≥  18 years of age and be able to swallow and retain oral medication  
2. ECOG performance status of 0-2  
3. Patients must have adequate bone marrow function as evidenced by ANC ≥ 1000/µL and 
platelets ≥  50,000µ L and Hb >= 8g/dl within 28 days prior to registration unsupported by 
growth factors.   
4. Serum creatinine < 2.0 mg/dL or calculated creatinine clearance (CrCl) > 45 mL/min  
5. Patients must have adequate hepatic function obtained within 28 days prior to registration 
and documented by all of the following:  
∙ Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert’s 
syndrome, or medication related)  
∙ Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)  
∙ AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)  
6. Patients must be willing to receive Pneumocystis  jirovecii  prophylaxis with 
sulfamethoxazole/trimethoprim, dapsone, and atovaquone or inhaled pentamadine, if they initiate combination umbralisib plus ublituximab (not for single agent ublituximab) 
7. Patients must have a complete history and physical examination within 28 days prior to registration  
8. Patients with follicular lymphoma must have the following components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected 
again at time of registration:  
∙ Age  
∙ LDH  
∙ Number of nodal groups involved  
∙ Serum or plasma hemoglobin  
∙ Ann Arbor Stage  
Additionally, patients must have beta
2-microglobulin collected at time of registration  and 
response assessment . 
9. Female subjects of reproductive potential must have a negative serum pregnancy  
test within 3 days prior to  treatment start date . Female subjects who are of non-reproductive 
potential (i .e., post- menopausal  by history - no menses f or ≥1 year; OR history of 
hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy at 
least six weeks ago) are exempt from  pregnancy testing.  In the case of oophorectomy alone, 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
27 of 97 only when the reproductive status of the woman has been confirmed by follow up hormone 
level assessment is she considered not of child bearing potential.  
10. Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some 
intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a
 
barrier method (e .g., condoms, cervical ring, sponge, etc.) during the period of therapy.   
 
The following are UNACCEPTABLE forms of contraception for females of childbearing 
potential:   
• natural family planning (rhythm method) 
• breastfeeding  
• fertility awareness  
• withdrawal   
For subjects, these birth control requirements must be adhered to for 4 months (120 days) 
after the last dose of umbralisib or ublituximab, whichever is later.  
 Regulatory Criteria  
1. Patients must be informed of the investigational nature of this study and must sign and give 
written informed consent in accordance with institutional and federal guidelines.
 
 
5.2 EXCLUSION CRITERIA  
To be enrolled in the study, potential subjects must meet NONE of the following exclusion criteria:  
 
Disease -Related  
1. Transformed lymphoma; if clinical evidence of transformed lymphoma is prese nt, 
transformation should be ruled out by biopsy of the suspicious lymph node/lesion  
2. Prior treatment for follicular lymphoma or marginal zone lymphoma (Except : involved field 
or site radiation therapy is allowed)  
3. Medically apparent central nervous system lymphoma or leptomeningeal disease  
4. Tumor burden where administration of other FDA approved anti -CD20 antibodies like single-
agent rituximab would be inappropriate. 
5. Patients in need of immediate cytoreduction with chemotherapy based regimen . 
 Concurrent Conditions  
1. Evidence of chronic active Hepatitis B (HBV, not including patients with prior hepatitis B 
vaccination; or positive serum Hepatitis B antibody) or chronic active Hepatitis C infection 
(HCV), active cytomegalovirus (CMV), or known history of HIV (or positive HIV test during screening). If HBc antibody is positive , the subject must be evaluated for the presence 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
28 of 97 of HBV DNA by PCR.  If HCV antibody is positive, the subject must be evaluated for the 
presence of HCV RNA by PCR.  See Appendix:  HEPATITIS B SEROLOGIC TEST RESULTS.  If the subject is CMV IgG or CMV IgM positive, the subject must be evaluated for the presence of CMV DNA by PCR.  Subjects with positive HBc antibody and negative 
HBV DNA by PCR ar e eligible.  Subjects with positive HCV antibody and negative HCV 
RNA by PCR are eligible (s ubjects who are CMV IgG or CMV IgM positive but who are 
CMV DNA negative by PCR are eligible).     
2. For subjects with a prior known history of hepatitis B and for those with a positive anti- HBc 
with negative HBsAg at screening , contraindication or intolerance to antiviral agent s 
effective against hepatitis B . 
3. Ongoing drug-induced liver injury, alcoholic liver disease, non- alcoholic steatohepatitis, 
primary biliary c irrhosis, extrahepatic obstruction caused by stones, or cirrhosis of the liver  
4. Inflammatory bowel disease (such as Crohn’s disease or ulcerative colitis)  
5. Irritable bowel syndrome with greater than 3 loose stools per day as a baseline 
6. Active autoimmune dis ease requiring ongoing immunosuppressive therapy including 
systemic corticosteroids (prednisone or equivalent ≤10 mg daily allowed as clinically warranted)  within 12 months prior to enrollment . Patients are allowed to use topical or 
inhaled corticosteroids or levothyroxine for hypothyroidism or hypogylcemic agents for 
diabetes mellitis.     
7. Any severe and/or uncontrolled medical conditions or other conditions that could affect 
participation in the study such as: 
∙ Symptomatic, or history of documented congestive heart failure NYHA ( New York Heart 
Association ) functional classification III -IV [see Appendix: New York Heart Association  
Classifications]  
∙ Significant cardiovascular disease such as uncontrolled or symptoma tic arrhythmias, 
CHF, or myocardial infarction within 6 months of enrollment.  
∙ Concomitant use of medication known to cause QT prolongation or torsades de pointes should be used with caution and at investigator discretion. 
∙ Poorly controlled or clinically significant atherosclerotic vascular disease including 
cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, cardiac or 
vascular stenting within 6 months of enrollment. 
7.         Women who are pregnant or lactating  8. Live virus vaccines within 4 weeks prior to ublituximab therapy, or planned 
administration of live virus vaccines during ublituximab therapy 
9.         History of other malignancies (including myelodysplastic syndromes) except:   
∙ malignancy treated with curative intent and with no known active disease present for >2 years before the first dose of study drug and felt to be at low risk for recurrence by 
treating physician  
∙ adequately treated non- melanoma skin cancer without evidence of disease  
∙ adequately treated carcinoma in situ without evidence of disease 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
29 of 97 ∙ localized prostate cancer and PSA <1.0 mg/dL on 2 consecutive measurements at least 3 
months apart with the most recent one being within 4 weeks of study entry 
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
New ly presenting patients with treatment -naive follicular lymphoma and marginal zone lymphoma 
at the University of Colorado Blood Disorders Center (UCD BDC) will  be presented with the 
options of standard of care therapy versus study participation.  The study will also be posted on 
clinicaltrials.gov.  Given the benefit  observed for ublituximab and umbralisib in multiple indolent 
subtypes, we anticipate that patients may be referred to UCD BDC specifically to enroll in this 
trial. 
 
5.4 PARTICIPANT WITHDRAWAL OR T ERMINATION  
5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION  
 If a patient chooses to voluntarily withdraw from study, then documentation must be made 
regarding if patient chooses to simply discontinue study treatment, or if patient also no longer wants to be followed for treatment outcomes (and thus opts out of study related follow -up). 
 Patients will be discontinued from study treatment for any of the following reasons: 
• Patient experiences treatment related intolerable toxicities that persist despite following the guidelines for dose modifications and dose reductions, including supportive care measures . 
Treatment may be delayed to recover from toxicity for a maximum of eight weeks  (56 
days). 
• Disease progress ion assessed by Lugano response Criteria for NHL (Cheson 2014)  
• The subject may withdraw consent at any time for all or certain aspects of the study as follows:      
∙ Withdraw consent for study treatment, but allow Follow -up Period assessments and 
data collection on subsequent anti-lymphoma therapy and PFS 
∙ Withdraw consent for study treatment and Follow -up Period assessments, but allow 
data collection on subsequent anti-lymphoma therapy and OS 
∙ Withdraw all consent  
• Inability of the patient to comply w ith study requirements 
• Non-compliance/lost to follow -up 
• Conditions requiring therapeutic intervention not permitted by the protocol 
• Pregnancy  
• Discontinuation of the study 
• Investigator discretion  
 
5.4.2 HANDLING OF PARTICIPANT WITHDRAWALS OR T ERMINATION  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
30 of 97 Should a patient choose to withdraw voluntarily from the study at any time, study drug will be 
terminated , and the patient will proceed to be treated according to standard of care.  Study- related 
information accumulated prior to the patient’s withdrawal of c onsent will be analyzed according 
to intention to treat analysis.    
  
After withdrawal from protocol treatment, patients should be followed for AEs for 30 days after 
their last dose of either study drug.  All new AEs occurring during this period must be reported and followed until resolution, unless, in the opinion of the investigator, these values are not likely to improve because of the underlying disease.  Subjects that discontinue study drug will remain on study and continue to follow specified follow -
up procedures.  If a subject wishes to withdraw consent for all study- related follow -up, then the 
patient should notify the investigator of this request.  The patient’s request should be in writing if possible.  The investigator should document in the medical records in detail if the patient’s withdrawal is from study treatment or also from all study -related follow up.  However, an 
investigator may consult public records, such as those establishing survival status.   
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY (STUDY S TOPPING 
RULES)  
Teleconferences will be held with the study sponsor to exchange findings and unexpected results 
that may occur in patients participating in this study.  The s tudy will be terminated based on 
toxicity stopping rules as discussed in  section  8.5. Any new information suggesting the study 
intervention may be harmful in study population will be shared with the COMIRB . The principal 
investigator will discuss any such new information via conference  with TG Therapeutics , Inc., and 
if warranted , may choose to terminate study. 
 
6 STUDY AGENT S 
6.1 STUDY AGENT AND CONTROL DESCRIPTION  
Guidelines for Administration of Ublituximab  
 
• Method of Administration:  Ublituximab  will be administered as an intravenous infusion 
through a dedicated line. All infusions will be administered per institutional guidelines.  
During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours  (+ 30 minutes) . Cycle 1 days 8 and 15 will be over 3 hours (+ 30 
minutes) , and Cycle 1 Day 22 will be over 90 minutes (+ 20 minutes).  During 
combination treatment with umbralisib, ublituximab will be administered over 90 minutes  (+ 20 minutes).  
• Days of administration:   Ublituximab  at dosage of 900mg will be administered on C1D1, 
D8, D15 and D22 of induction therapy (total 4 doses).  During combination treatment 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
31 of 97 with umbralisib, ublituximab 900mg will be admini stered  on Days 1, 8 and 15 during the 
first cycle of combination treatment, on Day 1 of Cycle 2 through Cycle 6, followed by 
Day 1 of Cycle 9 and Cycle 12  
• Potential Drug Interactions :  No drug interactions have been reported to date. 
• Pre-medications:   Pre-medicatio ns should include an antihistamine (diphenhydramine 50 
mg or equivalent), and a corticosteroid (dexamethasone 10 -20 mg or equivalent).   
o If pre -medications are given  via IV route, the ublituximab infusion should begin 
approximately 30 minutes after the conclusion of the last pre -medication infusion 
If pre -medications are given via oral  administration , the ublituximab infusion 
should begin 45-60 minutes after ingestion of the oral pre- medications .If a pre -
medication is poorly tolerate d, consider decreasing its dose, using a different drug 
or discontinuing, if clinically appropriate.  Adjusting antihistamine and 
corticosteroid doses, adjusting the timing of administration and/or additional pre -
medications may be used at investigator discretion for additional prophylaxis  
against infusion related reactions.  
o Use of oral acetam inophen 650 mg (or equivalent) may be used in patients who 
experience fever or pyrexia after week 1 dose, or as clinically warranted  based on 
investigator discretion . 
• Patients with a prior known history of hepatitis B and for those with a positive anti- HBc 
with negative HBsAg at screening: Prophylaxis with an antiviral agent effective against hepatitis B is required.  Consider consulting clinicians with an expertise in managing subjects with a prior history of hepatitis B regarding monitoring and consideration of options for hepatitis B antiviral therapy for prophylaxis/treatment.  Monitor subjects closely as clinically indicated based on liver tests and any observed signs/symptoms such as jaundice, abdominal pain, dyspepsia, dark-colored urine often accompanied by lighter-than-normal colored stools, nausea, vomiting or fatigue. 
• Hypersensitivity and Infusion Reaction Precautions :  Medication and resuscitation 
equipment must be available per institutional guidelines prior to ublituximab administration for the emergency management of potential anaphylactic reactions.   
• Patient Care Implications :   
o Ublituximab should not be administered as an IV push or bolus. 
o Ublituximab may be administered on an outpatient basis. 
o Diluted ublituximab should be checked before administration for cloudiness, color, or deposits.  Ublituximab should not be administered if does not conform to the specifications. Immediately inform TG Therapeutics , Inc.  at 
productquality@tgtxinc.com  with a ny product quality concerns or questions. 
o No other treatment may be co -administered with ublituximab (other than for 
immediate intervention for adverse event).  
o Concurrent glucocorticoid therapy as long as started at least 7 days prior to study entry (< 10 mg per day of prednisone or equivalent) is allowed as clinically 
warranted.  
o Since infusion-related hypotension may occur, consider holding  antihypertensive 
medications 12- 24 hours prior to and throughout infusion of ublituximab.   
Decision to withhold antihypertensive medication is at investigator discretion . 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
32 of 97 o For patients at risk for tumor lysis syndrome, in the opinion of the treating 
investigator, prophylaxis with allopurinol or per recommended institutional standards should be considered. 
 Ublituxima b should not be mixed with other medicinal products.  Ublituximab should only be 
diluted in 0.9% NaCl before use.  No data are available for other solutions such as 5% dextrose and 5% mannitol.  Ublituximab is available in 150 mg (6 mL quantity vial) and 900 mg (36 mL quantity vial) single use vials as a 25 mg/mL concentrate for dilution.  Dilutions for ublituximab are as follows:  
Dose of ublituximab 
for infusion  Volume of 
ublituximab  
(25 mg/mL)  Volume of NaCl 
0.9% to be removed Final volume in 
perfusion bag  
900 mg  36 mL  36 mL  500 mL  
  Infusion  Rate Recommendations for Ublituximab Administration 
 Ublituximab monotherapy induction:  Cycle 1 Day 1 infusion over 4 hours (+ 30 minutes)  
Ublituximab 
Dose  Total volume 
to be infused Infusion rate  
T0 to 
T30’  T30' to T1H T1H to T2H T2H to T4H 
900 mg  500 mL  10 mL/H  20 mL/H  85 mL/H  200 mL/H  
 
Ublituximab monotherapy induction:  Cycle 1 Day 8 & 15 infusions over 3 hours (+ 
30minutes) 
Ublituximab 
Dose  Total volume to 
be infused  Infusion rate  
T0 to T1H  T1H to T2H  T2H to T3H  
900 mg  500 mL  50 mL/H  150 mL/H  300 mL/H  
 
 Ublituximab monotherapy induction:  Cycle 1 Day 22 infusion over 90 minutes (+ 20 minutes ) 
 Ublituximab combination treatment with umbralisib:  infusions over 90 minutes (+ 20 minutes)  Ublituximab 
Dose  Total volume to 
be infused  Infusion rate  
T0 to T30min  T30min to T90min  
900 mg  500 mL  200 mL/H  400 mL/H  
Ublituximab 
Dose  Total volume to 
be infused  Infusion rate  
T0 to T30min  T30min to T90min  
900 mg  500 mL  200 mL/H  400 mL/H  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
33 of 97  
Infusion Related Reactions and Infusion Rate Guidance – Ublituximab  
 Infusion related reactions including severe reactions have been reported with ublituximab administration.  Guidelines are provided below for patients who experience such reactions.  Symptomatic infusion reactions, despite premedication, may be treated at the discretion of the treating physician, including but not limited to: oral acetaminophen 650 mg (or equivalent), corticosteroids, antihistamines, oxygen, and bronchodilators.    If an infusion related reaction is observed at any time during the ublituximab treatment, the treating investigator may reduce the infusion rate at their discretion.  
 The following are recommended infusion rate reduction/delay guidelines for patients who experience severe Infusion Related Reactions (IRR’s) that result in treatment interruption.  Final decision for infusion rate reduction/delay or discontinuation reside s with the treating 
investigator.  1
st or 2nd Infusion Interruption:  
• Hold infusion and closely monitor patient, institute symptomatic medical management until resolution of IRR symptoms. 
• Following the judgment of the Investigator, and provided the patient is stable, the infusion may be resumed at no more than half the previous rate. 
• If the patient does not experience any further IRR symptoms, infusion rate escalation may resume at the increments and intervals as appropriate for the treatment cycle dose (see Flow Rate Recommendations for Ublituximab Administration).  
 3
rd Infusion Interruption (same day):  
• Discontinue infusion for that day – monitor patient for resolution of all symptoms.  Patient should have all vital signs completed as well as any other standard of care procedures completed as warranted by the Investigator prior to release of patient from study site. 
• Any remaining diluted investigational product should be discarded. 
 If an infusion is discontinued, the next scheduled dose should be administered according to the protocol dosing schedule.  Guidelines for Administration of Umbralisib  
 
• Dose of administration: 800 mg PO daily 
 
• Method of Administration: Umbralisib will be administered orally once daily with in 30 
minutes of starting a meal . 
• Potential Drug Interactions : No drug interactions have been reported to date.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
34 of 97 • Pre-medications:  Patients receiving umbralisib are required to start prophylaxis 
treatment with P neumocystis jiroveci  pneumonia ( PJP) and antiviral therapy prior to Day 
1 of Cycle 1.  
o Anti-viral Prophylaxis:  Valtrex 500 mg daily or Acyclovir 400 mg BID or 
equivalent.  
o PJP Prophylaxis:  Dapsone 100 mg daily or Trimethoprim-Sulphamethoxazole 
twice a week .  Other options include atovaquone or inhaled pentamadine.   
• Final choice of PJP  and anti-viral prophylactic therapy is per investigator discretion.  
• If PJP  or anti- viral therapy is not tolerated, alternate to a different PJP  or anti- viral 
therap y, discontinue, or reduce dose/schedule as per Investigator Discretion.  
Umbralisib will be dispensed by the research pharmacy  or designee at the site.  Patients must b e 
provided drug in its original container. Patients should be instructed to return all empty and 
partially filled bottles including any unused tablets when they return to the site.  Study drug compliance should be reviewed with the patient using a patient drug diary at the beginning of each new treatment cycle  and as needed.   
 Umbralisib should be taken at approximately the same time each day within 30 minutes of starting a meal. Patients should be instructed to swallow the tablets as a whole and should not chew or crush them.  If a dose of umbralisib is missed, it should be taken as soon as possible on the same day. If it is missed for a period of greater than 12 hours, it should not be replaced. If vomiting occurs, no attempt should be made to replace the vomited dose.  Dispensing of Umbralisib  
Before dispensing, the site pharmacist or his/her representative must check that the umbralisib is in accordance with the product specifications and the validity is within the re- test date.  
Immediately inform TG Therapeutics, Inc. at productquality@tgtxinc.com  with any product 
quality concerns or questions.  The pharmacist or his/her representative should record all umbralisib drug dispensations. 
 
6.1.1 DOSING  SCHEDULES  
 
1) Patients with Stage II (non -contiguous), Stage III and Stage IV Follicular lymphoma and 
Marginal zone lymphoma will receive  ublituximab 900 mg IV weekly for 4 doses (days 1,  
8, 15 and 22)  
2) At 8 weeks  after completion of ublituximab monotherapy, patients  will undergo PET -CT 
assessment.  
3) Patients who do not achieve a CR after u blituximab  monotherapy will receive a 
combination of ublituximab and umbralisib for a total of 12 cycles given as follows:  ublituximab 900 mg IV on Days 1, 8 and 15 during the first cycle of combination treatment,  
on Day 1 of each subsequent 28- day cycle  through C ycle 6 and then every 3 cycles (i.e. C9 
and C12) PLUS  umbralisib 800 mg PO daily on Days 1-28 of each 28- day cycle.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
35 of 97 4) Patients with CR on  either single or combination therapy will be followed with scans for 2 
years .  
 
6.1.2 DOS E ADJUSTMENTS FOR TOXICITY  
 
Patients should be assessed clinically for toxicity at each visit using the NCI CTCAE v5.0 (http://evs.nci.nih.gov/ftp1/CTCAE ) grading scale.  Dosing should occur only if a patient’s 
clinical assessment and laboratory test values are acceptable.   
 
Dose Delay/Modifi cations: Ublituximab  
• No reduction in the dose of ublituximab is permitted.  
• Supportive care should be considered for any patient who experiences Grade ≥ 2 
cytopenias, or Grade ≥ 1 non- hematologic toxicities.   
• Ublituximab should be discontinued if treatment is delayed for greater than 56 days due 
to toxicity .   
• If the patient withdraws consent or has documented progression, an end of study visit 
should be completed.  
• If Grade 4 anaphylaxis is observed at any point during ublituximab treatment, permanently discontinue ublituximab treatment and intervene as per investigator discretion.
 
• For patients with a prior history of hepatitis B and for those with a positive anti- HBc with 
negative HBsAg at screening who experience an increase in liver enzymes while on study, hold ublituximab immediately and assess for active hepatitis B infection.  
o If negative for hepatitis B, ublituximab may be resumed.  
o If reactivation of hepatitis B is confirmed, institute hepatitis B antiviral treatment. Ublituximab may be resumed at investigator discretion once hepatitis B infection has resolved, with continued monitoring as described above.  
 
Table 2: Ublituximab Dose Delay and/or Modifications Guidance  
 
NCI-CTCAE Grade  Dose Delay and/or Modification  
Hematologic Adverse Event  
Neutropenia  
Grade ≤ 3 neutropenia  Maintain current dose. Consider supportive care as 
warranted.  
Grade 4 neutropenia or occurrence of neutropenic fever or infection Delay ublituximab until Grade ≤ 3 and/or neutropenic fever 
or infection is resolved; consider growth-factor support as warranted; thereafter, resume at full dose.  If delay is > 56 
days, discontinue ublituximab.  
Thrombocytopenia  
Grade ≤  3 thrombocytopenia Maintain current dose and provide supportive care as 
clinically warranted.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
36 of 97 Grade 4 thrombocytopenia Delay ublituximab  until Grade ≤ 3; consider intervention 
with supportive care as warranted; thereafter resume at full 
dose.  If delay is > 56 days, discontinue ublituximab.  
Non-Hematological Adverse Events * 
Grade ≤  2 Maintain current dose.  
Grade ≥  3 Withhold ublituximab until Grade ≤ 2 at the discretion of 
the investigator; consider supportive care intervention as 
warranted.  Resume at full dose or if delay > 56 days, 
discontinue ublituximab.  
*See guidance above under Dose Delay/Modications: Ublituximab for patients with a prior 
history of hepatitis B and for those with a positive anti-HBc with negative HBsAg at screening 
who experience an increase in liver enzymes while on study  
 Dose Delay/Modifications: Umbralisib  
• Supportive care should be considered for any patient who experiences Grade ≥ 2 
cytopenias, or Grade ≥ 1 non- hematologic toxicities.    
• Umbralisib should be discontinued if treatment is delayed for greater than 56 days due to toxicity.  
 
• If the patient with draws consent or has documented progression, an end of study visit 
should be completed.  
 
Table 3: Umbralisib Dose Delay a nd/or Modifications Guidance  
 
NCI-CTCAE Grade  Dose Delay and/or Modification  
Neutropenia  
Grade ≤ 2 neutropenia  Maintain current dose. Consider supportive care as 
warranted.  
Grade 3 neutropenia Maintain current dose, consider supportive care.  If 
recurrence or persistent Grade 3, resume at next lower 
dose level at discretion of the investigator.  
Grade 4 neutropenia or occurrence of neutropenic fever or infection Delay umbralisib until Grade ≤  3 and/or neutropenic fever 
or infection is resolved; thereafter, resume at current dose.  
Consider supportive care.   
 
If recurrence after re -challenge, delay umbral isib until 
Grade ≤ 3 and/or neutropenic fever or infection is resolved; thereafter, resume umbralisib at current dose or 
at next lower dose level at discretion of the investigator.  
Thrombocytopenia  
Grade ≤  3 thrombocytopenia Maintain current dose level and provide supportive care as 
clinically warranted.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
37 of 97 NCI-CTCAE Grade  Dose Delay and/or Modification  
Grade 4 thrombocytopenia Delay umbralisib until Grade ≤  3; thereafter, resume at 
current dose.  Consider supportive care intervention as 
warranted.  If delay is > 56 days, discontinue umbralisib.     
 
If recurrence after re -challenge, delay umbralisib until 
Grade ≤ 3; thereafter, resume umbralisib at current dose or at next lower dose level at discretion of the 
investigator.  
Pulmonary & Related Infections*  
Grade 1 or 2 Provide supportive care as warranted.  
 Stop all therapy and hold until complete resolution.  Restart umbralisib at one lower dose level.  Restart ublituximab at full dose.   If recurrence after re -challenge, discontinue umbralisib. 
 
If applicable, hold ublituximab.  Upon resolution, resume 
ublituximab at full dose and schedule.   
Grade ≥  3 Provide supportive care as warranted.   
 
Discontinue umbralisib  and ublituximab .   
*For sinopulmonary infections clearly not related to immune -mediated pneumonitis, 
umbralisib may be continued at investigator’s discretion.  While pneumonitis has been 
minimal with umbralisib, it is a reported adverse event associated with other PI3K delta 
inhibitors.  Use of anti- pneumocystis and anti -herpetic viral prophylaxis is required  
prior to the start of therapy . 
 Liver Injury (ALT/SGPT, AST/SGOT, Bilirubin, Alkaline Phosphatase)  
Grade 1  Maintain current umbralisib dose.  
Assess concomitant medications and risk factors*. Monitor labs every 1- 2 weeks.  
 
Maintain full dose and schedule of ublituximab, if 
applicable. *** 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
38 of 97 NCI-CTCAE Grade  Dose Delay and/or Modification  
Grade 2  Maintain current umbralisib dose level.  
Assess concomitant medications and risk factors*.   
Begin supportive care (prednisone 0.5 -1.0 mg/kg/day 
or equivalent per investigator discretion) **.   Monitor labs at least weekly until Grade 1.   Once resolved to Grade ≤1, taper prednisone by 10 mg per week until off.  Maintain full dose and schedule of ublituximab, if applicable. *** 
 If liver toxicity recurs to Grade 2: 
o Re-initiate steroids.  
o Monitor labs at least weekly until Grade 1.   
o Consider delaying umbralisib.   
o If applicable, consider delaying ublituximab. ***  
o Once resolved to Grade ≤1 o If umbralisib was delayed, restart umbralisib at current dose. 
o If applicable:  if ublituximab was delayed, restart ublituximab at full dose and schedule. *** 
o Taper prednisone by 10 mg per week until off.  
Grade ≥  3 Delay umbralisib.  
Assess concomitant medications and risk factors*.   Begin/continue supportive care (prednisone 0.5-1.0 mg/kg/day or equivalent per investigator discretion) **.   Monitor labs at least weekly until Grade 1.   Once resolved to Grade ≤1:  
o Restart umbralisib at one lower dose level.  
o Taper prednisone by 10 mg per week until off. 
 
If applicable, delay ublituximab until ≤ grade 1; thereafter, resume ublituximab at full dose and 
schedule. *** 
* Assess for disorders of lipids and glucose, thyroid  disorders, alcohol use, viral infections, 
etc. 
 
**Supportive Care – Aggressive management of lipid, glucose, other metabolic disorders, 
viral infections, etc.  
Important: Before initiating steroids, check for viral hepatitis or CMV infection. 
***See guidance above under Dose Delay/Modications: Ublituximab f or patients with a 
prior history of hepatitis B and for those with a positive anti- HBc with negative HBsAg at 
screening who experience an increase in liver enzymes while on study . 
Diarrhea and/or Colitis  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
39 of 97 NCI-CTCAE Grade  Dose Delay and/or Modification  
Diarrhea Grade ≤  2 Provide supportive care as warranted.  
 
If tolerable, maintain current dose of umbralisib.  Otherwise, delay umbralisib until ≤ grade 1.   Resume umbralisib at current dose level.    If recurrence after rechallenge, delay umbralisib until ≤ grade 1; thereafter, resume umbralisib at current dose or at next lower dose level at discretion of the investigator.  NOTE : If persistent grade 2 diarrhea despite supportive 
care, delay umbralisib until ≤ grade 1; thereafter, resume umbralisib at current dose or at next lower dose level at discretion of the investigator.    If umbralisib is delayed for > 2 cycles at any time,  
discontinue umbralisib.   
If applicable, maintain full dose and schedule of ublituximab.  If intolerable or persistent grade 2 diarrhea despite supportive care, delay ublituximab until ≤ grade 1; thereafter, resume ublituximab at full dose and schedule.   If ublituximab is delayed for > 2 cycles at any 
time, discontinu e ublituximab.  
Diarrhea Grade ≥  3 Provide supportive care as warranted.  
 Delay umbralisib until Grade ≤ 2; thereafter, resume umbralisib at current dose or at next lower dose level at discretion of investigator    If recurrence after rechallenge, delay umbralisib until Grade ≤ 1; thereafter, resume umbralisib at current dose or at next lower dose level at discretion of the investigator.   If umbralisib is delayed for > 2 cycles at any time, discontinue umbralisib.  
 
If applicable, delay ublituxima b until ≤ grade 2 (or until ≤ 
grade 1 for recurrence after rechallenge) ; thereafter, 
resume ublituximab at full dose and schedule.  If 
ublituximab is delayed for > 2 cycles at any time, 
discontinu e ublituximab.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
40 of 97 NCI-CTCAE Grade  Dose Delay and/or Modification  
Colitis (all Grades)  Provide supportive care  as warranted.  
 
Delay umbralisib. Treat with supportive care and after resolution of colitis, resume umbralisib at next lower dose level.  
 If umbralisib is delayed for > 2 cycles at any time, discontinue umbralisib.  
If applicable, delay ublituximab until resolution; thereafter, resume ublituximab at full dose and schedule.   If ublituximab is delayed for > 2 cycles at any 
time, discontinue ublituximab.  
All Other Non -Hematological Adverse Events  
Grade ≤ 2  Maintain current dose level.  
 
Provide supportive care as warranted.  
Grade ≥ 3  Provide supportive care as warranted.  
 Delay umbralisib until Grade ≤ 2; thereafter, resume umbralisib at current dose.    If recurrence after re -challenge, delay umbralisib until 
Grade ≤ 2; thereafter, resume umbralisib at current dose or next lower dose level at discretion of the investigator.   If umbralisib is delayed for > 2 cycles at any time, discontinue umbralisib.  
Umbralisib Dose Reduction Recommendations  
Study Drug  Starting Dose  1st Dose Reduction  2nd Dose Reduction  
Umbralisib  800 mg  600 mg  400 mg  
 
A maximum of two dose level reductions are allowed for umbralisib .   
If a patient requires a dose reduction of umbralisib due to study drug related toxicity, the dose may not be re- escalated.  If further evaluation of the toxicity reveals the event was not related 
to umbralisib , this must be recorded in the medical record and dose re- escalation to the next 
higher dose level may be considered at the discretion of the investigator.     
On the combination treatment, if ublituximab is discontinued due to toxicity , umbralisib 
should be continued through 12 cycles as planned.  If umbralisib is discontinued due to toxicity , ublituximab may be continued at investigator discretion.  Any questions related 
to discontinuation of treatment should be directed to the Principal Investigator, and 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
41 of 97 NCI-CTCAE Grade  Dose Delay and/or Modification  
patients should not be discontinued from both ublituximab and umbralisib  due to 
toxicity without discussion with the Principal Investigator . 
 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  AND OVERVIEW  
Ordering Ublituximab and Umbralisib  
Ublituximab and TGR- 1202 (umbralisib) are available from TG Therapeutics , Inc.  Please allow 
5 to 7 business days between drug ordering and drug arrival.  Order ublituximab Monday 
through Wednesday to ensure shipment does not arrive on a weekend day.  E nsure staff will be 
available to unpack shipment immediately upon arrival.  Please direct drug orders to ISTdrugorder@tgtxinc.com .  The email should include the following: 
• Requested quantity of TG Therapeutics , Inc. study drug(s) 
• Date needed  
• Principal Investigator  name 
• Study title   
• TG Therapeutics, Inc. tracking number (U2- NTG-009)  
• Investigational drug pharmacy shipping address  
• Total number of study subjects enrolled to date 
• Number of study subjects currently receiving each TG Therapeutics agent  
 Upon receipt of this shipment, the clinical trial designee  at our site will update the accountability 
forms for both ublituximab and umbralisib.  If there is any abnormality in the supplied boxes (ublituximab) or bottles (umbralisib), the Pharmacist or designee will document it during the 
acknowledgement of receipt and contact TG Therapeutics , Inc. at productq uality@tgtxinc.com . 
 
The Drug Accountability Log will record the study drugs received, dosages prepared, time prepared, doses dispensed and doses/vials destroyed.  The Drug Accountability Log will be reviewed during any site visits and at the completion of the study.    
STUDY MEDICATION OVERVIEW  
Ublituximab 
 Chemical Name:  ublituximab   
Other Names:    TG-1101 
Classification:    Recombinant chimeric anti-CD20 monoclonal antibody    
Mode of Action: Targets CD20 antigen on B- cells  
Description: Ublituximab is a genetically engineered chimeric murine/human mAb 
directed against the CD20 antigen found on the surface of B lymphocytes.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
42 of 97 Ublituximab displays the typical structure of immunoglobulins, consisting 
of two gamma ( γ) heavy chains and two kappa ( κ) light chains linked by 
disulfide bridges. It is composed of a murine variable region (37.2% of total 
amino acids) fused onto human constant regions. 
How Supplied:  Concentration of 25mg/mL in 6 mL (150 mg) and 36 mL ( 900 mg) single -
use glass vials.   
Storage:  Ublituximab vials must be stored in a secured, limited- access, refrigerated 
area at a temperature ranging from 2 -8°C (36-46°F) .  Ubl ituximab must not 
be frozen.  Temperature should be monitored, documenting minimum and maximum daily . 
Stability:  Once a vial of ublituximab has been diluted, it must be used immediately  or 
be stored refrigerated.  The storage duration of ublituximab diluted in 
polyvinyl chloride (PVC) or non -PVC polyolefin (PO) material  is up to 24 
hours when refrigerated at 2- 8°C (36- 46°F). After allowing the diluted bag 
to come to room temperature, use immediately.   
Expiration memorandums will be provided noting lot expiration dates.  For questions about expiry email productquality@tgtxinc.com . 
Route of  Administration : Intravenous 
Packaging:   Ublituximab is packed in kits.  Each kit contains:  
• Six vials containing 150 mg solution of ublituximab in each 
or 
• One vial containing 150 mg solution of ublituximab (for 
replacement if needed) , or 
• One vial containing 900 mg solution of ublituximab  
The container closure system of ublituximab  is a type I glass vial closed by 
a siliconized chlorobutyl rubber stopper and a tamperproof protective cap  
crimped to the neck of the vial  
Availability:   Ublituximab is available from TG Therapeutic s, Inc. 
 
Umbralisib (TGR -1202) 
 Classification:    Dual inhibitor of Phosphatidylinositol-3- Kinase (PI3K) Delta and CK1 
epsilon  
Formulation:  See Investigator Brochure   
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
43 of 97 Mode of Action: Irreversibly inhibits activity of the Class I Delta isoform of PI3K   
How Supplied:   Umbralisib: 200 mg tablets  
Storage:  Umbralisib must be stored in a secured limited -access area between 20°C 
and 25°C.  Excursions permitted between 15°C and  30°C.  Do not freeze.  
Stability:  Expiration memorandums will be provided noting lot expiration dates.  For 
questions about product expiry email productquality@tgtxinc.com . 
Route of  
Administration : Oral 
Packaging:  Umbralisib is provided in HDPE bottles each containing 30 tablets and a silica gel canister as a desiccant.  
Availability:   Umbralisib is available from TG Therapeutics, Inc.  
 
6.3 POST -STUDY ACCESS  
At the end of the study period, TG therapeutics , Inc. will not continue to supply study drug to 
subjects/investigators unless the Sponsor-Investigator chooses to extend their study and TG 
Therapeutics , Inc. provides written approval. The investigator is responsible to ensure that the 
subject receives appropriate standard of care or other appropriate treatment in the independent medical judgment of the Investigator to treat the condition under study.
 
 
 
7 STUD Y PROCEDURES AND SCHEDULE  
7.1 STUDY PROCEDURES /EVALUATIONS  
PET/CT:  A scan is done at baseline as part of the initial staging evaluation. PET/CT scan 
performed within 42 days prior to registration. PET scans, in conjunction with diagnostic-quality 
CT scans , will be obtained in this study. PET-CT scans should include skull- base to mid -thigh. 
Full-body PET-CT scan should be performed when clinically appropriate.  
CT scans with oral and IV contrast should include neck, chest, abdomen, and pelvic scans . In 
patients for whom contrast is contraindicated, (e.g., patients with contrast allergy or impaired renal clearance or patient denial ), CT or combined PET- CT scans without contrast are permitted 
so long as they permit consistent and precise measurement of target lesions during the study treatment period . 
 For Follicular lymphoma patients: All response assessments will be PET/CT based.  
 For Marginal Zone lymphoma patiens: If Baseline PET/CT do es NOT  demonstrate uniformly 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
44 of 97 FDG avid lesions subsequent assessments on the study will be done with CT scans of the  neck, 
chest,abdomen and pelvic scan with contrast ONLY. If Baseline PET/CT demonstrates 
uniformly FDG avid lesions subsequent assessments on the study will be done with PET/CT scans.  
 A PET/ CT will be done 8 weeks post completion of induction therapy (EO I PET/ CT) with single 
agent ublituximab.   Patients who achieve a CR  (Lugano response Criteria for NHL (Cheson 2014)  will be followed 
by PET/CT done at the 6 months, 12 months, 18 months and 24 months post EO I (end of 
induction treatment)  PET/CT. After this , imaging will be performed at the discretion of the 
investigator.   Patients who do not achieve a CR will initiate ther apy with combination umbralisib and 
ublituximab. On this combination treatment , a PET/CT will be done prior to Cycle 4, cycle 8 and 
Cycle 12. Patients who achieve a CR during these time points will continue on combination therapy for the entirety of the 12 cycles course of treatment.  
 A PET/CT will be done 12 weeks post completion of combination therapy (EOT PET/ CT).  
 Patients on the combination treatment  who are post completion of 12 cycles  of therapy will enter 
the follow up period in which a PET/CT will be done at the 6 months, 12 months, 18 months and 24 months post EOT PET/CT.  
 
Bone Marrow Biopsy:  Patients with FL and MZL must have a bone marrow biopsy performed 
within 6 months prior to registration. For patient s with FL , response assessment of bone marrow 
involvement by lymphoma will be by PET scan only and  bone marrow aspirates and biopsies 
will not be required for assessment of disease response.. For patients with MZL a restaging bone marrow biopsy will be don e 8 weeks post completion of induction therapy with single agent 
ublituximab if a staging bone marrow biopsy was previously positive. On the combination arm, a bone marrow biopsy (if initially involved) will be done 12 weeks post completion of 12 cycles of therapy  if a staging bone marrow biopsy was previously positive. 
 
Post-Trial Assessments: Patients who go off study treatment at any time during the trial will 
complete end of treatment assessments per section 7.3. For all patients, drug- related SAEs and 
AEs will be followed until baseline or ≤ grade 1 levels  for a total of 30 days. Patients who 
responded or maintained stable disease during the study will be followed for date of disease progression. Patients may refuse to participate in the post- trial assessments.
 
 
Clinical Evaluations: Patients should be seen and evaluated by provider as follows:   
Single agent induction therapy: D ay 1, D ay 8, Day 15, D ay 22, 4 weeks and 8 weeks post 
completion of therapy. 
Patients achieving CR  to single agent therapy: Will be evaluated in clinic every 3 months for 2 
years .  
Patients not achieving a CR : Will start Combination therapy.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
45 of 97 Combination therapy: Patients will be evaluated on Day 1, Day 8 and Day 15 of C1, and on Day 
1 and Day 15 of C2; subsequently, they will be evaluated on Day 1 for cycles 3-12.  
After completion of combination therapy, patients will be evaluated in clinic 4 weeks post 
completio n of therapy, 12 weeks post completion of therapy, and then every 3 months for 2 years  
and every 6 months for years 2 through 5.  
 
Patients should be seen and evaluated by physician no less than one time every 16 weeks ( 4 
cycles) .  
 
7.1.1 R ESPONSE  ASSESSMENT  
 The timing of PET/CT and Bone marrow biopsy on each single agent and combination therapy arms of the trial have been outlined in 7.1.  Patients with a global deterioration of health status requiring permanent discontinuation of study treatment (taken off study) without objective evidence of disease progression and without evidence of other causes to attribute to deteriorating health  will be counted as progressive 
disease. Every effort should be made to document the objective progression even after discontinuation of treatment. Deaths of unknown cause and those related to malignancy or treatment -related toxicity will be counted as treatment  failure.  
 Patients will be analyzed with respect to imaging- based CR, overall survival (OS) and progression-
free survival (PFS). Overall survival is defined as time from the first chemotherapy administered 
on trial until death from any cause. For subject s who are still alive at the time of the study analysis 
or who are lost to follow -up, survival will be censored at the last recorded date that the subject was 
known to be alive. Progression- free survival is defined as time from therapy until relapse, 
progr ession, or death from any cause. Response will be determined by the principal investigator 
or the co -principal investigators.  
 
Definitions for clinical response for patients with lymphoma are from the Lugano response criteria 
(Cheson et al. 2014) .
34 Response assessment will be performed by treating provider, and will be 
performed at the University of Colorado.  
 Definitions of Tumor Response and Progression  Responses will be categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). In addition, a response category of nonevaluable (NE) is provided for situations in which there is inadequate information to otherwise categorize response status.   The screening measurement will be taken as a reference for determinations of response. The nadir measurement will be taken as a reference for PD; this measurement constitutes the smallest measurement recorded, including the screening measurement if this is the smallest measurement. For FDG -avid tumors, metabolic criteria for response by PET -CT will take precedence over 
anatomic criteria for response by contrast CT when assessing CR.    
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
46 of 97 For patients staged with PET- CT, focal uptake in nodal and extranodal sites that is in keeping 
with lymphoma, according to the distribution and/or CTcharacteristics, is considered 
involvement with  lymphoma, including spleen, liver, bone, thyroid, and so on. For patients 
staged with CT, up to six of the largest target nodes, nodal masses, or other lymphomatous 
lesions that are measurable in two  diameters (longest diameter [LDi] and shortest diameter) 
should be identified from different body regions representative of the patient’s overall disease 
burden and include mediastinal and retroperitoneal disease, if involved. A measurable node must have an  LDi greater than 1.5 cm. Measurable extranodal disease (eg, hepatic nodules) may be 
included in the six representative, measured lesions. A measur able extranodal lesion should have 
an LDi greater  than 1.0 cm. All other lesions (including nodal, extranodal, and assessable 
disease) should be followed as nonmeasured disease (eg, cutaneous, GI, bone, spleen, liver, kidneys, pleural or pericardial effusi ons, ascites). In patients in whom a discordant histology or 
malignant transformation is suspected, a PET-CT may identify the optimal site to biopsy for confirmation . 
 
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
47 of 97  
Revised Criteria for Response Assessment: Lugano Classification (cont.)  
 
Response  Site PET- CT-Based Response  CT-Based Response  
Complete   Complete metabolic response  Complete radiologic response (all of the following)  
Lymph nodes and 
extralymphatic sites  Score 1, 2, or 3a with or without a residual mass on 5PSb 
It is recognized that in Waldeyer’s ring or extranodal sites with 
high physiologic uptake or with activation within spleen or 
marrow (e.g., with chemotherapy or myeloid colony-stimulating factors), uptake may be greater than normal 
mediastinum and/or liver. In this circumstance, complete 
metabolic response may be inferred if uptake at sites of initial 
involvement is no greater than surrounding normal tissue even 
if the tissue has high physiologic uptake  Target node s/nodal masses must regress to <=  1.5 cm in 
LDi 
No extralymphatic sites of disease  
Nonmeasured lesion  Not applicable  Absent  
Organ enlargement  Not applicable  Regress to normal  
New lesions  None  None  
Bone marrow  No evidence of FDG -avid disease in marrow  
Normal by morphology; if indeterminate, IHC negative  Normal by morphology;  if indeterminate, IHC negative  
Partial   Partial metabolic response  Partial remission (all of the following)  
Lymph nodes and 
extralymphatic sites  Score of 4 or 5b with reduced uptake compared with baseline and 
residual mass(es) of any size  
At interim, these findings suggest responding disease  
At end of treatment, these findings indicate residual disease  >= 50% decrease in SPD of up to 6 target measureable nodes 
and extranodal sites  
When a lesion is too small to measure on CT, assign 5 mm 
x 5 mm as the default value  
When no longer visible, 0 x 0 mm 
For a node > 5mm x 5 mm, but smaller than normal, use 
actual  measurement for calculation  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
48 of 97 Revised Criteria for Response Assessment: Lugano Classification (cont.)  
 
Response  Site PET -CT-Based Response  CT-Based Response  
Partial (cont.)  Nonmeasured lesions  Not applicable  Absent/normal, regressed, but no increase  
Organ enlargement  Not applicable  Spleen must have regressed by >=  50% in length beyond 
normal.  
New lesions  None  None  
Bone marrow  Residual uptake higher than uptake in normal marrow but 
reduced compared with baseline (diffuse uptake compatible with 
reactive changes from chemotherapy allowed). If there are 
persistent focal changes in the marrow in the context of a nodal 
response, consideration should be given to further evaluation 
with MRI or biopsy or an interval scan.  Not applicable  
No 
response  
or Stable 
Disease   No metabolic response  Stable disease  
Target nodes/nodal 
masses, extranodal 
lesions  Score 4 or 5 b with no significant change in FDG uptake 
from baseline at interim or end of treatment  > 50% decrease from baseline in SPD for up to  
6 dominant, measurable nodes and extranodal sites; no 
criteria for progressive disease are met.  
Nonmeasured lesions  Not applicable  No increase consistent with progression  
Organ enlargement  Not applicable  No increase consistent with progression  
New lesions  None  None  
Bone marrow  No change from baseline  Not applicable  
 
  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
49 of 97  
Revised Criteria for Response Assessment: Lugano Classification (cont.)  
Response  Site PET-CT- Based Response  CT-Based Response  
Progressive 
Disease   Progressive metabolic disease  Progressive disease (requires at least 1 of the following)  
Individual target 
nodes/nodal lesions  
Extranodal lesions  Score 4 or 5b with an increase in intensity of uptake 
from baseline and/or  
new FDG- avid foci consistent with lymphoma at 
interim or end -of-treatment assessment  PPD progression:  
An individual node/lesion must be abnormal with:  
• LDi > 1.5 cm AND 
• Increase by >=  50% from PPD nadir AND  
• An increase in LDi or SDi from  nadir  
• 0.5 cm for lesions <=  2 cm 
• 1.0 cm for lesions > 2 cm 
Nonmeasured 
lesions  None  New or clear progression of preexisting nonmeasured lesions  
Organ enlargement   In the setting of splenomegaly, the sp lenic length must increase by > 
50% of the extent of its prior increase beyond baseline (e.g.,  15-cm 
spleen must increase to > 16 cm). If no prior splenomegaly, must 
increase by at least 2 cm from baseline.  
New or recurrent splenomegaly  
New lesions  New FDG -avid foci consistent with lymphoma 
rather than another etiology (e.g., infection, 
inflammation). If uncertain regarding etiology of 
new lesions, biopsy or interval scan may be 
considered.  Regrowth of previously resolved lesi ons A 
new node >  1.5 cm in any axis  
A new extranodal site > 1.0 cm in any axis; if <  1.0 cm in any axis, its 
presence must be unequivocal and must be attributable to lymphoma 
Assessable disease of any size unequivocally attributable to lymphoma.  
Bone marrow  New or recurrent FDG -acid foci  New or recurrent involvement  
5-PS = 5 -point scale; CT = computed tomography; FDG = fluorodeoxyglucose; IHC = immunohistochemistry; LDi =  longest transverse diameter of a 
lesion; MRI  = magnetic  resonance  imaging; PET = positron  emission  tomography  (scan);  PPD = cross product  of the LDi and perpendicular  diameter;  SDi 
= shortest axis  perpendicular  to the LDi; SPD = sum of the product  of the perpendicular  diameters  for multiple  lesions.  
a A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time of an interim scan.  However, in trials involving 
PET where de -escalation is investigated, it may be preferable to consider a score of 3 as inadequate response (to avoid under treatment).  
b PET 5PS: 1, no uptake above background; 2, uptake <=  mediastinum; 3, uptake  > mediastinum but < liver; 4, uptake moderately liver; 5, uptake 
markedly higher than liver and/or new lesions; X, new areas of uptake unlikely to be related to lymphoma.
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
50 of 97  
7.2 LABORATORY PROCEDURES/EVALUATIONS  
Local laboratory assessments as specified  on the schedule of events table will include the 
following: 
• Hepatitis B virus (HBV) testing will include hepatitis B surface antigen (HBsAg), antibody 
to the hepatitis B surface antigen (anti -HBs), and antibody to the hepatitis B core antigen 
(anti-HBc). If a subject is anti -HBc or HBsAg positive, a quantitative polymerase chain 
reaction  test to measure viral DNA load will be performed. Interpretation of this test is 
described in the Appendix  section  
• Testing for HCV (testing for antibody; if positive then quantitative polymerase chain reaction test to measure viral RNA load). 
• HIV testing will be performed per institutional guidelines.  
• Testing for CMV, If CMV IgG or IgM is reactive, the subject must be evalu ated for the 
presence of CMV DNA (by PCR).  
• Hematology: Complete Blood C ount (CBC) with absolute differential , including 
hematocrit,  hemoglobin, white blood cell count (WBC) with differential, and platelet 
count. 
• Chemistry : Comprehensive Metabolic Panel including albumin, alkaline  phosphatase, 
alanine aminotransferase (ALT/SGPT), aspartate transaminase (AST/SGOT), bilirubin  
(total and direct) , calcium, chloride, creatinine, glucose,
 phosphorous, potassium, sodium, 
total protein, serum urea/blood urea nitrogen (BUN), LDH, Uric acid.  
• Serum beta 2-microglobulin. 
• Thyroid function tests will inclu de thyroid stimulating hormone (TSH) and free  thyroxine 
(fT4).  
• Calculated creatinine clearance (CrCl) will be estimated using the Cockcroft -Gault  
formula: CrCl (mL/min) = (140 – age) (weight [kg]) / 72 (serum creatinine [mg/dL]; for 
females, the formula is  multiplied by 0.85 (Cockcroft, 1976). 
• Coagulation tests will include prothrombin time,  international normalized ratio (INR) and 
partial thromboplastin time (PTT or activated PTT).  
• Urinalysis (a urine dipstick may be used) will include color, appearance, s pecific gravity, 
pH, glucose, ketones, blood, bilirubin, and protein. A microscopic examination will be performed if urinalysis result is abnormal. Pregnancy testing will be performed for females of child- bearing potential.  A serum 
pregnancy test must be done ≤  3 days of starting treatment with single agent ublituximab  
induction.  
 
 
7.2.1 Clinical Laboratory Evaluations (R esearch P rocedures)  - Pathology 
Baseline standard of care diagnostic pathology samples will be performed as clinically indicated. Pathological materials including H&E stain , all IHC slides , and any leftover  FFPE tissue block 
along with the pathology report from initial diagnosis should be sent to be reviewed, and the diagnosis confirmed by the University of Colorado pathology department (retrospective diagnostic review  – treatment may commence prior to the University of Colorado review).  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
51 of 97  
Obtaining pathology samples is not required prior to enrollment, but confirmation of availability 
is required prior to enrollment. 
 
Initial diagnostic materials should be submitted within  30 days  of patient enrollment . A copy of 
the pathology report should be sent when the sample is shipped.  
 
The diagnostic slides and any leftover material will be returned after review.  
 
7.2.2 SPECIMEN PREPARATION, HANDLING, AND STORAGE  
Pathology 
H&E stain and IHC slides  and any leftover  FFPE tissue block along with the pathology report 
from initial diagnosis should confirmed by the University of Colorado hematopathology 
department . 
Specimens f rom the tissue block will be stored in the HCTU bank for MRD studies, next 
gene ration  sequencing and m7FLIPI test ing. 
 
Research Blood Samples  
Research blood samples will be banked, and MRD studies , next generation sequencing and 
m7FLIPI te sting may be conducted.  
 Research samples will be collected and stored under the University  of Colorado Hematology 
Lymphoid Malignancy Tissue Bank (LTB) protocol. Patients must be tissue bank consented prior to sample collection and samples will be collected by the tissue banking team.  
 Correlative Analysis Blood Samples 
Peripheral blood will be collected at the follo wing time points (see study schedule for specifics):  
° Baseline – within 28 days prior to first day of first cycle of study treatment  
° Peripheral blood will be collected every time  a PET CT assessment visit is conducted.  
° For Example:  
o On single treatment : At the EO I PET/ CT visit 
o On the combination treatment :  Prior to Cycle 4, 8 and 12 of therapy  
o On the combination treatment : At the EOT PET/ CT visit  
o For both single and combination treatments: At 6 months, 12 months, 18 months 
and 24 months post completion of therapy – last dose of ublituximab (for single 
agent treatment ) and umbralisib (for combination therapy) 
o At recurrence or progression  
  
7.3 STUDY SCHEDULE  
 
7.3.1 SCREENING  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
52 of 97  
Informed Consent must be obtained prior to beginning any assessments solely for the  purpose of 
this study. Informed consent will be reviewed with patient in detail  by the physician or designee , 
with the physician or designee  addressing all questions and concerns of the patient. Informed 
consent will be signed by patient and authorized consenting personnel should the risks/benefits be 
deemed acceptable to patient.  
 Screening evaluations will be performed for all subjects to determine study eligibility after  signing 
the informed consent form. These evaluations must be completed within 28 days prior to  
administration of the first dose (Cycle 1 Day 1 [C1D1]) unless noted otherwise below.  The following wi ll be performed or assessed at screening as specified in  section 7.4: 
 
• Complete medical history will be documented by a qualified clinician at the time of  the 
Screening Visit. The medical history will be general enough to document common comorbid conditions as well as specific enough to confirm any condition against the 
eligibility criteria, and will document whether the identified c onditions are active or 
inactive at the time of enrollment.  Disease history will include specific information regarding diagnosis and histology including grade. 
 
• Physical examination including evaluation of lymph nodes, spleen and liver will be performed.  
 
• Demographics will include date of birth, sex, race, and ethnicity.  
• Adverse event assessment (baseline AEs) . 
 
• Concomitant medications reviewed and documented. 
 
• ECOG performance status will be recorded.  
 
• Vital signs will include blood pressure, pulse, respiratory rate and body temperature. 
 
• Body weight and height (height at the screening only) will be measured. 
 
• Body surface area (BSA) will be calculated using the subject’s height and weight according to l ocal pharmacy practice.  
 
• Serum p regnancy testing (in WOCBP) </= 3 days of starting treat ment  
 
• Counseling about pregnancy precautions and the potential risks of fetal exposure will be given to females  of child-bearing potential and to all males . 
 
• Tumor tissue sample for confirmation of diagnosis and correlative rese arch (submitted 
within 30 days after registration – confirmation of availability  is required ). Patients 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
53 of 97 whose tissue is not available may still be eligible to go on trial if they choose to hav e a 
SOC biopsy during the screening period.  
 
• Hematology (as outlined in section 7.2) 
 
• Chemistry (as outlined in section 7.2)  
 
• Urinalysis ( as outlined in section 7.2)  
 
• TSH  and free  T4 
 
• PT/INR and PTT  
 
• Serum beta 2-microglobulin 
 
• HIV, HBV, HCV, CMV screen (as outlined in section 7.2)  
• Creatinine Clearance  
 
• PET- CT will be performed within 42 days of C1D1 of treatment  
 
• 12-lead single electrocardiogram (ECG) will be recorded.  
 
• Bone marrow biopsy analysis will be performed for p atients with FL and MZL within 6 
months prior to study registration) 
 
• Subject self -reported health related quality of life will be assessed at Screening  using the 
FACT -Lym  questionnaire 
 
• Research blood tubes will be collected for correlative analysis  as described in this 
protocol.  
 
Inclusion/exclusion criteria will be reviewed in detail to ensure that the patient is a study candidate prior to enrollment and subsequent treatment.  If it is not clear if patient qualifies for study, the principal investigator should be notified for review of patient candidacy.    
7.3.2 INDUCTION TREATMENT WITH SINGLE AGENT UBLITUXIMAB  
 
Cycle 1 D1, D8, D15 and D22 
 If screening assessments are performed within 48 hours of Cycle 1 Day 1, safety laboratory and physical examinations need not be repeated at Cycle 1 Day 1.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
54 of 97 Upon starting treatment, patients will be seen and evaluated by t reating provider on C1D1, D8, 
D15 and D22. All laboratory, safety, and physical examinations should be performed by a 
provider or nurse within 48 hours of the start of every dose.   The following evaluations will be performed a t these visits: 
 
• Physical examination with vital signs and weight 
 
• Adverse event assessment  
 
• Concomitant medications  
 
• Hematology (as outlined in section 7.2) 
 
• Chemistry  (as outlined in section 7.2) 
 
• Ublituximab administration  
 
7.3.3 END OF TREATMENT  VISIT  FOR SINGLE AGENT THERAPY  
The End of Induction v isit will occur at 8 weeks after completion of 4 doses of Induction 
Ublituximab and will include the following assessments:  
• History and physical examination with vital s igns and weight  
 
• Adverse event assessment  
 
• Concomitant medications  
 
• ECOG performance status will be recorded  
 
• Hematology (as outlined in section 7.2) 
 
• Chemistry  (as outlined in section 7.2) 
 
• Urinalysis ( as outlined in section 7.2)  
 
• Serum beta
2-microglobulin 
 
• End of induction treatment PET -CT and tumor response assessment 8 weeks after 
completion of 4 doses of single agent ublituximab. ( For marginal zone lymphoma patients, 
If Baseline PET/CT does not demonstrate uniformly FDG avid lesions subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY)  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
55 of 97 • If PET positive after the completion of induction therapy, a biopsy of PET positive area 
may be done at MD discretion.  
 
• Bone marrow biopsy (for MZL patients ) (this will be arranged ± 7 days of this visit)  will 
be done 8 weeks post completion of induction therapy with single agent ublituximab if a staging bone marrow biopsy was previously positive.  
 
• Subject self -reported health related quality of life will be assessed after completion of 
induction therapy using the FACT -Lym  questionnaire 
 
• Survival status will be assessed  and subsequent therapy will be assessed 
 
• Research blood tubes may be collected for biomarker analysis  as described in this 
protocol 
 
7.3.4 COMBINATION UBLITUXIMAB AND UMBRALISIB  
 Patients undergoing combination ublituximab and umbralisib will receive 12 cycles of treatment as follows:  ublituximab 900mg IV on Days 1, 8 and 15 during the first cycle , on Day 1 of each 
subsequent 28- day cycle through C ycle 6, and then every 3 cycles (i.e. C9 and C12) and 
umbralisib 800mg daily .  Patients will be seen by a provider or nurse  within 7 days of every 
infusion (a physician must evaluate the patient at least every third cycle, i.e.  no less than every 
12 weeks during combination phase) , and the following assessments will be performed: 
 
• History and physical examina tion with vital signs and  weight on D1 of all Cycles 1-12  
 
• Adverse event assessment  on D1 of all Cycles 1- 12 
 
• Concomitant medications  on D1 of all Cycles 1- 12 
 
• Additionally, physical exam, vital signs and weight, hematology (as outlined in section 
7.2), chemistry (as outlined in section 7.2), adverse event assessment and concomitant 
medications on D8 and D15 of C1, and physical exam , vital signs and weight, adverse 
event assessment and conco mitant medications on D15 of C2  
 
• ECOG performance status will be recorded  on D1 of all Cycles 1-12 
 
• Hematology (as outlined in section 7.2) on D1 of all Cycles 1-12 
 
• Chemistry  (as outlined in section 7.2) on D1 of all Cycles 1-12 
 
• CMV surveillance by PCR every 3 cycles  
 
• Serum beta 2-microglobulin on D1 of all Cycles 1-12 
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
56 of 97 • Patients will be monitored for  signs/symptoms of thyroid disorders, colitis, pneumonitis, 
hepatitis rash/dermatologic toxicity, changes in neurologic function.  Patients will be  
monitor ed for infusion reactions. 
 
o Monitor subjects with a prior history of hepatitis B closely as clinically indicated 
based on liver tests and any observed signs/symptoms such as jaundice, abdominal pain, dyspepsia, dark- color ed urine often accompanied by lighter -than-normal 
colored stools, nausea, vomiting or fatigue. 
 
• PET-CT and tumor response assessment prior to C4, C8 and C12 of combination therapy 
• (For marginal zone lymphoma patients, If Baseline PET/CT does not demonstrate uniformly FDG avid lesions subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY) 
 
• Subject self -reported health related quality of life will be assessed prior to C4, C8 and C12 
of combination therapy using the FACT -Lym  questionnaire 
 
• Research blood tubes may be collected for biomarker/correlative analysis as described in the protocol prior to C4, C8 and C12 of combination therapy 
 
 
7.3.5 END OF TREATMENT  ASSESSMENT FOR C OMBINATION THERAPY  
 The End of Treatment  visit will be completed  for subjects who are withdrawn  from treatment 
for any reason as soon as possible (preferably within 3 weeks post last dose of treatment) after the decision to permanently discontinue treatment has been made.  If a patient decision  to 
withdraw from treatment occurs at a specific time point in the protocol, then that time point would be considered the EOT visit. For patients who come off treatment while on combination therapy  prior to completing 12 cycles, the end of treatment visit will be as soon as possible. For 
patients on combination therapy who  complete 12 cycles, the end of treatment visit will be on 
D+3 months (± 14 days) post last dose of treatment . 
 The following evaluations will b e performed at the EOT  visits: 
 
• History and physical examina tion with vital signs and  weight  
 
• Adverse event assessment  
 
• Concomitant medications  
 
• ECOG performance status  
 
• Hematology (as outlined in section 7.2) 
 
• Chemistry (as outlined in section 7.2) 
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
57 of 97 • Urinalysis (as outlined in section 7.2)  
 
• Serum beta 2-microglobulin  
 
End of treatment PET-CT and tumor response assessment (D+3 months (± 14 days)) post 
last dose of treatment . (For marginal zone lymphoma patients, If Baseline PET/CT does 
not demonstrate uniformly FDG avid lesions subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY)  
• Subject self -reported health related quality of life will be after completion of combination 
therapy using the FACT -Lym  questionnaire  
 
• Bone marrow biopsy (for MZL patients only if screening  marrow was involved) (this will 
be arranged ±7 days of this visit)  
 
• Survival status and subsequent therapy will be assessed  
 
• Research blood tubes may be collected for biomarker analysis  as described in this 
protocol  
 
7.3.7 FOLLOW -UP 
 
The follow-up p eriod begins upon all study treatment discontinuation or completion as per  
protocol. This includes subjects who complete the full course of treatment  and who discontinue  
treatment due to progression or toxicity, as well as those who discontinue before progression to  
pursue a ne w anti -lymphoma therapy. 
 
All subjects will be followed by provider for AEs  and concomitant medications/procedures for 30 
days after the last dose of ublituximab (for single agent treatment) and for 30 days after the latest 
of last dose of ublituximab or the last dose of umbralisib (for combination therapy).  
 The following eva luations will be performed at the follow-up visits: 
 
• History and physical exam including vital signs and weight 
 
• Laboratory evaluation (Hematology and Chemistry) 
 
• AEs and concomitant medications will be evaluated  
 Patients will be seen  in follow up every 3 months for the first 2 years post completion of therapy 
(last dose of ublituximab (for single agent treatment) and umbralisib (for combination therapy).   
PET/CT scans will be performed at the 6 months, 12 months, 18 months and 24 months post 
completion of therapy (last dose of ublituximab for single agent treatment ) and umbralisib (for 
combination therapy).  (If Baseline PET/CT for marginal zone lymphoma patients d oes not 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
58 of 97 demonstrate uniformly FDG avid lesions subsequent assessments on the study will be done with 
CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY)  At this time , patients  
will be seen by a provider for follow up of PD, subsequent anti -lymp homa therapy, or  death. If at 
any point a patient decides to withdraw from long- term follow -up, there must be documentation 
of this decision by the provider, nurse or coordinator.  Subject self -reported health related quality of life using FACT -Lym  questionnaire will be assessed 
at the 6 months, 12 months, 18 months and 24 months post completion of therapy (last dose of ublituximab (for single agent treatment) and the latest of last dose of ublituximab or the last dose of umbralisib (for combination therapy). 
 
Research blood tubes  may be  collected at the 6 months , 12 months, 18 months and 24 months post 
completion of therapy (last dose of ublituximab (for single agent treatment ) and t he latest of last 
dose of ublituximab or the last dose of umbralisib (for combination therapy) for correlative 
analaysis as described in this protocol  
7.3.8 EARLY TERMINATION VISIT  
 Early termination visits will be performed with the same requirements as the end of treatment visit 
(see section 7.3.6).  (Imaging studies may be withheld if the last scan was done within 21 days  of 
visit) .  
 Note : if a patient chooses to voluntarily withdraw from study, then documentation must be made 
regarding if patient chooses to simply discontinue study treatment, or if patient also no longer wants to be followed for treatment outcomes (and thus opts out of study related follow up). 
7.3.9 UNSCHEDULED VISIT /RECURRENCE OR PROGRESSION  AT ANY UNSCHEDULED 
VISIT  
 The following eva luations will be performed  if possible  at all unscheduled visits:  
 
• History  and physical exam including vital signs and weight 
 
• Laboratory evaluation and imaging as clinically indicated 
 
• AEs and concomitant medications will be evaluated  
 The following evaluations will be performed at visits indicative of recurrence:  
• History and physical exam including vital signs and weight 
 
• Laboratory evaluation and imaging as clinically indicated 
 
• Imag ing study and biopsy if deemed fit by the clinical investigator  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
59 of 97  
• Research samples may be drawn at this time for correlative analysis as described in this 
protocol
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
60 of 97 7.4- SCHEDULE OF EVENTS TA BLE 
 
Trial Period  
Screening  C1  
(Single Agent 
Induction)29  End of 
Induction  Combination Treatment  
(Patients with < CR)  EOT16 &18  Follow -up 
(On Single Agent OR 
Combination Treatment)    C115 C2 C3-
12  12 Weeks Post 
Completion of 
Combination 
Tx Treatment 
Cycle/Title  -28 to D0  D19 D8 D15 D22 4 weeks 
post 
Induction 
Tx  8 Weeks 
Post 
Induction 
Tx D1 D8 
and 
D15 D1 D15 D1  D+4 weeks 
post 
combination 
Tx 3 M  6, 9, 12, 
15, 18, 21 
& 24 M  30 M+ 
Q6M Yrs. 
2-5 
Sche duling 
Window    ± 1D  +7 days  ± 7D  ± 2D  +7 days  ± 14D  ± 28D  
Written Informed 
Consent  X                 
Medical History   X      X X  X  X      
Demographics  X                 
Physical Exam  X X X X X X28 X X X X X X X28 X X X X 
Vitals and weight20 X X X X X X28 X X X X  X X28 X X X X 
Height  X                 
ECOG Status  X      X X  X  X  X    
ECG7  X                 
PET with 
diagnostic quality 
CT Assessment10  X5      X14     X19  X17  X21 X21 
Bone Marrow 
Biopsy  X6      X11       X11    
Adverse Event 
Assessment  X X X X X X28 X X X X X X X28 X20 X X X 
Concomitant 
Medications  X X X X X X28 X X X X X X X28 X20 X X X 
Survival Status & 
Subsequent 
Therapy        X       X X X X 
Ublituximab - 900 
Mg IV   X12 X12 X12 X12   X X X  X30      
Umbralisib - 800mg 
PO Daily         X      
Hematology13 X X X X X X28 X X X X  X X28 X X X X 
Chemistry1 X X X X X X28 X X X X  X X28 X X X X 
TSH and fT4  X                 
Creatinine 
Clearance  X                 
Coagulation - 
PT/INR and PTT4 X                 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
61 of 97 Trial Period  
Screening  C1  
(Single Agent 
Induction)29  End of 
Induction  Combination Treatment  
(Patients with < CR)  EOT16 &18  Follow -up 
(On Single Agent OR 
Combination Treatment)    C115 C2 C3-
12  12 Weeks Post 
Completion of 
Combination 
Tx Treatment 
Cycle/Title  -28 to D0  D19 D8 D15 D22 4 weeks 
post 
Induction 
Tx  8 Weeks 
Post 
Induction 
Tx D1 D8 
and 
D15 D1 D15 D1  D+4 weeks 
post 
combination 
Tx 3 M  6, 9, 12, 
15, 18, 21 
& 24 M  30 M+ 
Q6M Yrs. 
2-5 
Sche duling 
Window    ± 1D  +7 days  ± 7D  ± 2D  +7 days  ± 14D  ± 28D  
Urinalysis24 X      X       X    
HIV Testing23 X                 
Hep B22 X                 
Hep C23 X                 
CMV23 X       X23    X23      
Serum beta2 -
microglobulin  X      X X  X  X  X    
Pregnancy Test2 X                 
Research Blood 
Samples8  X      X     X25  X  X26  
Pathology Review3 X                 
QOL Questionnaire 
(FACT -Lym) X      X     X27  X  X27  
 
1. Chemistry will include uric acid, phosphorus, LDH and direct bilirubin. See section 7.2 for full list or required labs to be collected.  
2. A serum pregnancy test  for females of childbearing potential  must be done ≤  3 days of treatment start date  with single agent ublituximab induction. . A female of childbearing 
potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 
consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).  Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.  
3. Central review of pathology is required for confirmation of diagnosis. Completion of central pathology review is not required prior to registration for patients; however , confirmation 
of availability is required prior to enrollment  and materials for central review must be submitted within 30 days  after registration. Pathology material: H&E stain and IHC s lides or a 
representative FFPE tissue block from initial diagnosis, including additional material for correlative analysis. Please NOTE:  the diagnostic H&E slide and IHC slides will be 
returned after review. In addition, patients whose tissue is not available may still be eligible to go on trial if they choose to have an SOC biopsy prior to treatment . 
4. PT/INR assessment frequency (for patients on Coumadin) is per investigator discretion to keep within therapeutic range. 
5. Imaging must be done ≤ 42 days  prior t o study registration.  
6. Screening bone marrow biopsy must be performed ≤6 months  prior to study registration.  
7. 12-lead single electrocardiogram (ECG) will be recorded.  
8. Research blood samples (may be collected at  screening and at all time- points when a PET CT is performed (i.e EOInduction, Prior to C4,8,12 of combination therapy, EOT, 
6,12,18 and 24 months  and at recurrence/progression) for correlative analysis as described in this protocol . Research samples will be collected and stored under the LTB 
protocol. Patients must be tissue bank consented prior to sample collection and samples will be collected by the tissue banki ng team.  
9. If screening assessment are performed within 48 hours of C1D1, safety laboratory and physical examinations need not be repeated at Cycle 1.  
10. Measurements can be done off the CT images of a PET/CT.  (If Baseline PET/CT for marginal zone lymphoma patients does not demonstrate uniformly FDG avid lesions 
subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
62 of 97 11. Repeat bone marrow only required for MZL patients  to confirm CR if initial bone marrow was positive.  This will be arranged +/ - 7 days of this visit . On the combination arm, a bone 
marrow biopsy (if initially involved for MZL ) will be done 3 months post completion of 12 cycles  of therapy.  
12. During the induction treatment, patients will dose according to Dosing Schedule. 
13. Hematology blood draws can be done before administration (not more than 2 days apart)  
14. EOI PET CT will be performed within 8 weeks (+/ - 7 days) post completion of single agent induction therapy. If PET positive  after the completion of s ingle agent induction therapy , 
a biopsy of PET positive area may be done at MD discretion.   (If Baseline PET/CT for marginal zone lymphoma patients does not demonstrate uniformly FDG avid lesions 
subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY ) 
15. The first  cycle of Combination therapy  will start (+ 2 week) after  End of  Induction imaging scan for patients not in CR. P atients on combination therapy will be seen at D1, D8  and 
D15 for C1, and D1 and D15 for C2 and then seen every 4 weeks  for the remaining duration of therapy .  
16. An end of treatment visit will be completed for subjects who are withdrawn from treatment for any reason as  soon as possible after the decision to permanently discontinue 
treatment has been made – this includes patients who continue on Combination therapy and come off treatment prior to completion of 12 cycles. For pat ients who continue 
combination therapy and complete 12 cycles, the end of treatment visit will be 12 weeks (+/ -2 weeks)  post last dose of  umbralisib . 
17. EOT PET CT will be performed within 12 weeks (+/ - 7 days) post completion of combination therapy . (If Baseline PET/CT for marginal zone lymphoma patients does not 
demonstrate uniformly FDG avid lesions subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pelvic scan with contrast ONLY ) 
18. All subjects will be followed for AEs and concomitant medications/procedures for 30 days after the last dose of ublituximab (for single agent treatment ) and umbralisib (for combination 
therapy).  In addition, patients will be seen at 6 months, 12 months, 18 months and 24 months post completion of therapy (last dose of ublituximab (for single agent treatment ) and 
umbralisib (for combination therapy) with PET/CT scans. At this time, they will be seen by a provider for follow up of PD, subsequent anti -lymphoma therapy or death. If at any point 
a patient decides to withdraw from long- term follow -up, there must be documentation of this decision by the provider, nurse or coordinator.  
19. On the combination arm, a PET/CT will be done after  prior to Cycle 4, cycle 8 and Cycle 12 ( If Baseline PET/CT for marginal zone lymphoma patients does not demonstrate 
uniformly FDG avid lesions subsequent assessments on the study will be done with CT scans of the  neck, chest,abdomen and pel vic scan with contrast ONLY ) 
20. Vital signs include blood pressure, pulse , respiratory rate  and temperature.  
21. Patients who achieve a CR will be followed by PET/CT done at the 6 months, 12 months, 18 months and 24 months post EOI PET/CT. After this PET/CT will be performed at the 
discretion of investigator judgement.  Patients on the combination arm who are post completion of 12 cycles  of therapy will enter follow up period in which case a PET CT will be 
done at the 6 months, 12 months, 18 months and 24 months post EOT PET/CT . After 24 months on either arms PET/CT can be performed based on investigator discretion.  
22. Hepatitis B virus (HBV) testing will include hepatitis B surface antigen (HBsAg), antibody to the hepatitis B surface antigen (anti -HBs), and antibody to the hepatit is B core antigen 
(anti-HBc). If a subject is anti -HBc or HBsAg positive, a quantitative polymerase chain reaction test to measure viral DNA load.  
23. Testing for HCV (testing for antibody; if positive then quantitative polymerase chain reaction test to measur e viral RNA  load),  CMV testing by PCR every 3 cycles during treatment.  
HIV testing will be performed per institutional guidelines.  
24. A microscopic examination will be performed if urinalysis result is abnormal.  
25. Research samples to be collection prior to C4,C8 and C12 on combination therapy for correlative analysis as described in this protocol  
26. 6 months, 12 months, 18 months and 24 months post completion of therapy – last dose of ublituximab (for single agent treatment ) and umbralisib (for combination therapy)  
27. Subject self -reported health related quality of life (FACT -LYM) will be assessed at screening and at all time- points when a PET CT is performed (i.e EOInduction, Prior to C4,8,12 
of combination therapy, EOT, 6,12,18 and 24 months)  
28. 4 weeks after last dose of Single agent Induction and Combination therapy patients will be seen in clinic for history and physical exam including vital signs and weight, lab evaluation 
including CBC and chemisty and AEs and concomitant medications.  
29. All laboratory, safety, and physical examinations should be performed by a provider or nurse within 48 hours of the start of every dose.  
30. Ublituximab will be administered every cycle (28 days)  through Cycle 6, and then every 3 cycles (i.e. at Cycle  9 and Cycle 12).  
 
  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 63 of 97 7.5 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the 
case report forms (CRFs).  For this protocol, a prescription medication is defined as a medication that 
can be prescribed  only by a properly authorized/ licensed clinician. Medications reported in the CRF 
are concomitant prescription medications .. 
 In addition, examples of acceptabl e methods of contraception include the following (also listed in 
section 5.1): 
° Bilateral tube ligation  
° Male sterilization  
° Hormonal contraceptives that inhibit ovulation 
° Hormone- releasing intrauterine devices  
° Copper intrauterine devices 
NOTE: Periodic abstinence (e.g. calendar, ovulation, symptothermal, or post -ovulation methods) 
and withdrawal are NOT acceptable methods of contraception. 
   
7.5.1 PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDURES  
° Antiemetics may be used at the discretion of  the attending physician. 
° Tumor lysis syndrome prophylaxis will be used at the discretion of the treating physician.  
° Blood products and growth factors should be utilized as clinically warranted and following institutional policies and recommendation s. Gro wth factors should not be used to meet 
eligibility criteria. Pegfilgrastim support may be given  during therapy. Treat as needed.  
° Patients should receive full supportive care while on this study. This includes blood product support, antibiotic treatment, and treatment of other newly diagnosed or concurrent medical conditions.  
° All blood products and concomitant medications such as anti-diarrheals, analgesics, and/or antiemetics received from the first day of study treatment administration until 30 days after the final dose of study treatment will be recorded in the medical records.  
 
7.6 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDUR ES  
The following medications are prohibited while on study treatment (exceptions noted): 
° Treatment with immuno -suppressive medications ( except as used to treat drug -related 
adverse events ) will not be permitted unless discussed with and approved by the study 
principal investigator.  This will be documented in the EMR system. 
° Patients will also not be allowed to be treated with any concurrent anti-neoplastic therapy, including chemotherapy, non-palliative radiotherapy, and Chinese medications used for cancer treatment.   
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 64 of 97 Treatment needs to be administered in collaboration with an oncology -trained pharmacist .  
Drugs that interact  with ublituximab and umbralisib should be used with caution or avoided 
as per institutional guidelines.  
 
7.7 PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES  
• Prophylactic medications, treatments and procedures should be performed according to institutional guid elines. This includes prophylactic antibiotics, anti-fungals, or PJP 
prophylaxis. 
• Topical, inhaled, articular, intra- nasal corticosteroids are permitted.  A brief (<3 weeks) 
course of steroids is permitted for purposes of prophylaxis (e.g. contrast) or treatment of non-auto-immune conditions (e.g. anaphylaxis).  
• Patients receiving umbralisib are required to start prophylaxis treatment with pneumocystis jiroveci pneumonia ( PJP) and antiviral therapy prior to Day 1 of Cycle 1 of 
combination treatment. 
• Anti-viral Prophylaxis:  Valtrex 500 mg daily or Acyclovir 400 mg BID or 
equivalent.  
• PJP Prophylaxis:  Dapsone 100 mg daily.  Other acceptable options include 
trimethoprim-s ulphamethoxazole twice a week , atovaquone, or inhaled 
pentamadine. 
• Final choice of PJP  and anti- viral p rophylactic therapy is per investigator discretion. 
• If PJP  or anti- viral therapy is not tolerated, alternate to a different PJP  or anti- viral 
therapy, discontinue, or reduce dose/schedule as per Investigator Discretion. 
• Prophylaxis with an antiviral agent effective against hepatitis B is required in subjects with a prior known history of hepatitis B and for those with a positive antiHBc with negative HBsAg at screening.  
• Promptly consult clinicians with an expertise in managing subjects with a prior history of hepatitis B regarding monitoring and consideration of options for hepatitis B antiviral therapy for prophylaxis/treatment. 
   
7.8 RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES  
Patients with adverse events while on study drug should be treated as indicated in section 6 of protocol.  Other medical conditions that arise while patients are on study should be treated according to standard of care.  The principal investigator should be made aware of serious adverse events occurring while patients are  on study.  Inquiries regarding handling of adverse events occurring while 
on study that are not described in this protocol should be directed towards the principal investigator.  
  
7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  
At the end of the study period, TG  Therapeutics , Inc. will not continue to supply study drug to 
subjects/investigators unless the Sponsor-Investigator chooses to extend their study and TG 
Therapeutics , Inc. provides written approval. The investigator is responsible to ensure that the 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 65 of 97 subject receives appropriate standard of care or other appropriate treatment in the independent 
medical judge ment  of the Investigator to treat the condition under study.  
  
8 ASSESSMENT OF SAFETY  
8.1 SPEC IFICATION OF SAFETY PARAMETERS  
8.1.1 DEFINITION OF ADVERSE EVENTS (AE)  
 
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
 An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
A non- serious adverse event  is an AE not classified as serious.  
Laboratory Test Abnormalities: 
All laboratory test results captured as part of the study should be recorded following institutional 
procedures. Test results that constitute SAEs should be documented and reported to TG Therapeutics , 
Inc. as such.  
The following laboratory abnormalities should be documented and reported appropriately: 
• any laboratory test result that is clinically significant or  meets the definition of an SAE 
• any laboratory abnormality that required the participant to have study drug discontinued or 
interrupted 
• any laboratory abnormality that required the subject to receive specific corrective therapy  
 
Overdose:  
An overdose is defined as the accidental or intentional administration of any dose of a product that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE.  
 Other Safety Considerations:  
Any significant worsening noted during interim or final physical examinations, electrocardiograms, X-rays, and any other potential safety assessments, whether or not t hese procedures are required by 
the protocol, should also be recorded as a non- serious or serious AE, as appropriate, and reported 
accordingly.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 66 of 97 8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
A Serious Adverse Event (SAE)  is any untoward medical occurrence that at any dose:  
• results in death  
• is life -threatening (defined as an event in which the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it 
were more severe)  
• requires inpatient hospitalization or causes prolongation of existing hospitalization 
• results in persistent or significant disability/incapacity  
• is a congenital anomaly/birth defect  
• is an important medical event (defined as a medical event(s) that may not be immediately life -
threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require i ntervention [e .g., medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization.)  
• suspected transmission of an infectious agent (e.g., pathogenic or nonpathogenic) via the study drug is an SAE  
Although pregnancy, overdose, potential drug-induced liver injury (DILI), and cancer are not 
always serious by regulatory definition, these events must be handled as SAEs. 
Any component of a study endpoint that is considered related to study therapy should be reported 
as an SAE (e.g., death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported).  
 
The following are NOT  considered serious adverse events:  
° A visit to the emergency room or other hospital department < 24 hours, that does not result in admission (unless considered an important medical or life- threatening event)  
° Elective surgery, planned prior to signing consent 
° Admissions as per protocol for a planned medical/surgical procedure 
° Routine health assessment requiring admission for baseline/trending of health status (e .g., 
routine colonoscopy) 
° Medical/surgical admission other than to remedy ill health and planned prior to entry into the 
study. Appropriate docum entation is required in these cases.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 67 of 97 ° Admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver respite, family circumstances, administrative reason).  
° Admission for administration of anticancer therapy in the absence of any other SAEs 
 
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UAP)  
 This study will use the COMIRB definition of UAP. An unanticipated problem is any event or information that was unforeseen and indicates that the research procedures caused harm (including physical, psychological, economic, or social harm) to participants or others or indicates that participants or others are at increased risk of harm t han was previously known or recognized .  
 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
8.2.1 SEVERITY OF EVENT  
For AEs not included in the protocol -defined grading system, the following guidelines will be used 
to describe severity.  
• Grade 1: Mild  – Events require minimal or no treatment and do not interfere with the 
participant’s daily activities.  
• Grade 2: Moderate – Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning. 
• Grade 3: Severe  – Events interrupt a participant’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually potentially life -
threatening or incapacitating. 
• Grade 4: Life- threatening  
• Grade 5: Death  
8.2.2 RELATIONSHIP TO STUDY AGENT  
The causal relationship to study drug is determined by a physician and should be used to assess all 
adverse events (AE). The casual relationship can be one of the following: 
Related : There is a reasonable causal relationship between study drug administration and the AE. 
Not related : There is not a reasonable causal relationship between study drug administration and 
the AE.  The term "reasonable causal relationship" means there is evidence to suggest a causal relationship.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 68 of 97 Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. In order to prevent reporting bias, subjects should not be questioned regarding the specific occurrence of one or more AEs. 
8.2.3 EXPECTED A DVERSE  EVENTS  
 Expectedness will only be documented for SAEs . An SAE will be considered unexpected if the 
nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agent.  
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate CRF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the training and 
authority to make a diagnosis), and time of resolution/ stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of rel ationship. All AEs will be 
followed to adequate resolution. All AE outcomes will be recorded as resolved or resolved without 
sequelae.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and n ot reported as an AE. However, if the study participant’s condition deteriorates at 
any time during the study, it will be recorded as an AE. UAPs will be recorded in the data collection system throughout the study.  Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each episode.  The investigator will record all reportable events with start dates occurring any time after informed 
consent is obtained (for SAEs) or  from initiation of study treatment (AEs) until 30 days  after the last 
day of study treatment . At each study visit, the investigator will inquire about the occurrence of AE/ 
SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 69 of 97 8.4 REPORTING PROCEDURES  
8.4.1 ADVERSE EVENT REPORTING  
ADVERSE EVENTS  
Adverse events can be spontaneously reported or elicited during open- ended questioning, 
examinatio n, or evaluation of a subject. In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs. 
Adverse events will be documented in clinic notes at all sch eduled visits.  Adverse events will be 
graded by investigator according to CTCAE v5.0. 
NON- SERIOUS ADVERSE EVENT S 
Non-serious Adverse Events (AE) are to be provided to TG Therapeutics , Inc.  in aggregate via 
interim or final study reports as specified in th e agreement or, if a regulatory requirement [ e.g., IND 
US trial] as part of an annual reporting requirement. The collection of non -serious AE information 
should begin at initiation of the s tudy. All non- serious adverse events (not only those deemed to be 
treatment -related) should be collected continuously during the treatment period and for a minimum 
of 30 days following the last dose of study treatment. All non- serious adverse events can be assessed 
by telephone communication.  Non-serious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious. Follow -up is also required for non- serious AEs that cause interruption or 
discontinuation of study drug and for those present at the end of study treatment as appropriate.  
 
8.4.2 SERIOUS ADVERSE EVENT REPORTING  
Although pregnancy, overdose, potential drug- induced liver injury (DILI), and new cancer are not 
always serious by regulatory definition, these events must be handled as SAEs.  
Any component of a study endpoint that is considered related to study therapy should be reported as 
an SAE ( e.g., death is an endpoint ; if death occurred due to anaphylaxis, anaphylaxis must be 
reported).  
 SAE Reporting to TG Therapeutics, Inc.  
SAEs require expeditious handling and reporting to TG Therapeutics , Inc. in order to comply with 
regulatory requirements.  All SAEs (regardless of  causality assessment) occurring from the time of 
consent through 30 days post last study treatment should be immediately reported to TG 
Therapeutics , Inc.  at safety@tgtxinc.com  (copy gabriel.green -lemons@tgtxinc.com and 
donna.gesumaria@tgtxinc.com ) within 24 hours of the first knowledge of the event by the treating physician or research personnel on an SAE Form (MedWatch FORM FDA 3500 or equivalent) and followed until resolution (with autopsy report if applicable).  Include the TG Therapeutics, Inc. 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 70 of 97 tracking number , U2-NTG -009 on the SAE report  to TG Therapeutics, Inc., and indicate 
whether or not the SAE was designated a SUSAR . 
SAE Reporting to the FDA and IRB   
Investigator is responsible for reporting relevant SAEs to the FDA.  Investigator is responsible for 
reporting unexpected fatal or life -threatening events associated with the use of the study drugs to the 
FDA within 7 cal endar days after being notified o f the event.  Investigator will report all related but 
unexpected SAEs including non-death/non- life-threatening related but unexpected SAEs (SUSAR) 
associated with the use of the study medications to the FDA by a written safety report within 15 calendar days of notification.  Investigators must report SUSARs and follow -up information to their 
responsible Institutional Review Board (IRBs)/Independent Ethics Committee according to the policies of the r esponsible IRB (Research Ethics Committee).  
The following are events of special interest, and will need to be reported expeditiously:  
Study Drug Overdose  
Any accidental or intentional overdose with the study treatment (either umbralisib or ublituximab) that is symptomatic, even if not fulfilling a seriousness criterion, is to be reported to TG Therapeutics , 
Inc. immediately (within 24 hours of awareness) on an SAE form , and following the same process 
described for SAEs .  If a study drug overdose occurs, patients should stop study drug dosing and be 
clinically monitored as appropriate, managing symptoms/side effects that may occur.  Overdose:  An overdose  as evaluated by investigator  is defined as the accidental or intentional 
administration of any dose of a product that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE. 
In addition, all SAEs MUST also be sent to the following : 
o The PI at manali.kamdar@cuanschutz.edu  
o The OCRST at CPDM.IIT@cuanschutz.edu  
o The DSMC at DSMC@ucdenver.edu  
All SAEs will be followed until satisfactory resolution or until the site PI  deems the event  to be 
chronic or the adherence to be stable. Other supporting documentation of the event may be requested 
by the study sponsor and should be provided as soon as possible.  
 
8.4.3 UNANTICIPATED PROBLEM REPORTING  
Incidents or events that meet the COMIRB criteria for UAPs require the creation and completion of 
a UAP report form. It is the site PI ’s responsibility to report UAPs to their IRB , using the IRB’s 
standard UAP form. The Lead PI  is responsible for reporting the UAP to the UCCC DSMC, if 
applicable. If an IRB UAP  form is not provided, the UAP  report will include the following 
information: 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 71 of 97 • Protocol- identifying information: protocol title and number, PI’s name, and the IRB 
project num ber; 
• A detailed description of the event, incident, experience, or outcome; 
• An explanation of the basis for determining that the event, incident, experience, or 
outcome represents a UAP;  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UAP. 
 
To satisfy the requirement for prompt reporting, UAPs will be reported using the following timeline:  
• UAPs that are SAEs will be reported to the IRB and to the D SMC  within 5 calendar days  
of the investigator becoming aware of the event.  
• Any other UAP will be reported to the IRB and to the DSMC  within 5 calendar days  of 
the investigator becoming aware of the problem.  
8.4.4 REPORTING OF PREGNANCY  
 
Pregnancy , Abortion, Birth Defects/Congenital Anomalies  
During the course of the study, all female patients of childbearing potential ( the definitions of 
“females  of childbearing potential” are listed in Appendix - Contraceptive Guidelines and 
Pregnancy ) must contact the treating investigator immediately if they suspect that they may be 
pregnant (a missed or late menstrual period should be reported to the treating investigator).   
If an investigator suspects that a patient may be pregnant prior to administration of study drug(s), the 
study drug(s) must be withheld until the result of the pregnancy test is confirmed.  If a pregnancy is confirmed, the patient must not receive any study drug(s), and must be discontinued from the study.   
If an investigator suspects that a patient may be pregnant after the patient has been receiving study 
drug(s), the study drug(s) must immediately be withheld until the result of the pre gnancy test is 
confirmed.  If a pregnancy is confirmed, the study drug(s) must be immediately and permanently stopped, the patient must be discontinued from study treatment , and the investigator must submit a  
Pregnancy Report Form to TG Therapeutics , Inc. within 24 hours of the first knowledge of the event 
by the treating physician or research personnel  following the same process described for SAEs .  
Abortions (spontaneous, accidental, or therapeutic) must also be reported to TG Therapeutics , Inc.  
within 24 hours of awareness  using the Pregnancy Report Form  following the same process described 
for SAEs . 
Congenital anomalies/birth defects always meet SAE criteria, and should therefore be expeditiously 
reported as an SAE, using the previously described process  for SAE reporting, including reporting 
to TG Therapeutics, Inc. 
In the event a subject’s partner becomes pregnant, a Pregnancy Report Form should be completed 
and submitted to TG Therapeutics, Inc. within 24 hours  of the first knowledge of the event by the 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 72 of 97 treating physician or research personnel  following the same process described for SAEs , and the 
partner will be requested to consent to access to medical records.  After the subject’s partner provides 
consent, the pregnant partner and baby will be followed to see what effect the drug(s) under study may have on the outcome of the pregnancy or  the health of the newborn.  Additionally, medical 
information must be collected on the newborn for 6 months after birth, as permitted by local regulations. 
Please see APPENDIX: CONTRACEPTION GUIDELINES AND PREGNANCY for additional 
information pertaining to following the pregnant female (and infant, if applicable). 
 
8.5 STUDY HALTING RULES  
Efficacy  
Due to the small sample size, there will be no study halting rules based on efficacy. 
 
Toxicity If any patient experiences death due to an adverse event that is  assessed as related to study 
treatment (by investigator and/or Sponsor), it will lead to temporary hold of study pending review 
by study team.  Treatment -related mortality:   If any patient experiences death due to an adverse event that is 
assessed as related to study treatment (by investigator and/or Sponsor), it will lead to temporary hold of study pending review by study team.  The study will be terminated prematurely if at any point 2 patients experience treatment -related death secondary to the  study regimen (Ublituximab and/or 
umbralisib)  
 Toxicities of special interest:    
a. Patients on the single agent treatment  Ublituximab  will be assessed for toxicities of special 
interest  for 30 days. The study will be halted prematurely if more than 5 patients experience the 
following toxicities :  
 
• Grade 4 Neutropenia 
• Neutropenic Fever  
 b. The combination arm of Ublituximab + Umbralisib is of special interest in this study. Patients enrolled on this arm will be as sessed for toxicities of special interest  for 90 days. The study will be 
halted prematurely if more than 3 consecutive patients enrolled on the combination arm experie nce 
the following toxicities: 
 
• Grade 3 or higher pneumonitis 
• Grade 3 or higher colitis 
• Grade 4 hepatitis  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 73 of 97 • Grade 4 rash  
• Other grade 4 unmanageable events attributable to the study treatment. 
 
c. The study will be halted prematurely if a patient develops progressive multifocal 
leukoencephalopathy on single agent / combination arm of the study.   Patients will continue to receive study therapy as defined by the schema (4 weekly doses of ublituximab in the single agent treatment and ublituximab plus daily umbralisib for a total of 12 
cycles  in the combination arm) or until disease progression according to Lugano response Criteria 
for NHL (Cheson 2014), unacceptable toxicity, death due to an adverse event that is assessed as 
related to study treatment (by investigator and/or Sponsor), patient or physician decision to withdraw, 
or pregnancy, whichever occurs first. The study will end when all patients enrolle d have completed 
planned treatment  or the Sponsor decides to end the trial, whichever occurs fir st 
 
8.6 SAFETY OVERSIGHT  
Monitoring and Oversight 
The sponsor investigator will be responsible for monitoring the trial per the trial monitoring plan, in 
addition to overseeing the safety and efficacy of the trial including any specimens collected, executing the data and safety monitoring (DSM) plan, and complying with all reporting requirements to local and federal authorities. This oversight will be accomplished through additional oversight from the Data and Safety Monitoring Committee (DSMC) at the University of Colorado Cancer Center (CU Cancer Center) .  The DSMC is responsible for ensuring data quality and study participant 
safety for all clinical studies at the CU Cancer Center, which is the coordinating institution of this trial.     A summary of the DSMC’s activities is as follows: 
• Conduct of internal audits  
• Ongoing review of all serious adverse events (SAEs) and  unanticipated problems (UAPs)  
• May submit recommendations for corrective actions to the CU Cancer Center’s Executive 
Committee  
 
Per the CU Cancer Center Institutional DSM Plan, SAEs  and UAPs  are reported to the DSMC, IRB 
and the sponsor investigator per protocol.  All SAEs  and UAPs are to be reported to the DSMC 
within 7 (for fatal or life -threatening events) or 15 (non- life-threatening events) calendar days of the 
sponsor  investigator recei ving notification of the occurrence. 
 Each subject’s treatment outcomes will be discussed by the site PI and appropriate staff at regularly scheduled meetings.  Data regarding number of subjects, significant toxicities, dose modifications, and treatment responses will be discussed and documented in the meeting’s minutes . 
 The sponsor investigator will provide a DSM progress report to the CU Cancer Center DSMC on a 
recurring basis (either every six or twelve months based on DSMC vote). The DSM re port will 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 74 of 97 include a protocol summary; current enrollment numbers; summary of toxicity data to include 
specific SAEs, UAPs and AEs; any dose modifications; all protocol deviations; and protocol amendments. The DSM progress report submitted to the DSMC will also include, if applicable, the 
results of any efficacy data analysis conducted.  Results and recommendations from the review of the progress report by the DSMC will then be provided to the sponsor investigator in a DSMC review letter.  The sponsor invest igator is then responsible for ensuring this letter is submitted to the site’s 
IRB of record at the time of IRB continuing review. 
 
Quality Control and Quality Assurance 
Site monitoring visits will be performed by the sponsor investigator’s authorized repr esentative on a 
regular basis, pursuant to the Monitoring Plan. During these visits, information recorded on the CRFs 
will be verified against source documents.   Independent auditors from the sponsor investigator’s authorized representative will be allowe d by 
the site’s PI to audit.  In addition, audits may be conducted at any time by appropriate regulatory authorities and/or the IRB. 
 
 
9 CL INICAL MONI TORING 
Clinical site monitoring will be conducted to ensure that the rights and well- being of human 
participants  are protected, that the reported trial data are accurate, complete, and verifiable, and that 
the conduct of the trial is in compliance with the currently approved protocol/ amendment(s), with GCP, and with applicable regulatory requirement(s).   Monitoring for this study will be performed by a CU Cancer Center Clinical Monitor in accordance 
with the clinical monitoring plan (CMP), incorporated herein by reference. The CMP describes in 
detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of the monitoring reports.   
10 STATISTICAL CONSIDERATIONS  
10.1 STATISTICAL AND ANALYTICAL PLANS  
Based on overall reporting in low tumor burden FL and MZL, CR rate of at least 30% was achieved when single agent rituximab was used in these subsets.   We assume that Best CR Rates, i.e, CR rates at anytime during therapy —during single agent 
antibody therapy OR during combination therapy—will increase to 50% as compared to this 30% historical control CR rate .  Sample size is determined using inference to a known proportion.  
Under a null hypothesis of 30% CR rate an d an alternative hypothesis of 50%, then given a Type I 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 75 of 97 error rate of 0.10, a one- sided test, and a sample size of 2 4, then we have 7 3% power to detect a 
difference in complete response rate.  Efficacy will be assessed using the proportion of patients 
who have a complete response.  The null hypothesis that the true response rate is 30% will be tested against a one -sided alternative.  95% c onfidence intervals for the true complete response rate 
will also be calculated  
 Twenty -four patients are required for t his single-stage design.  Assuming 20% screen fail/drop-out 
rate, 30 patients need to be screened for this study.   
10.2 STATISTICAL HYPOTHESES  
Primary E ndpoints  
 Efficacy:  Best Complete response (CR) rates at anytime during treatment with single agent or 
combination therapy as defined by the Lugano response Criteria for NHL (Cheson 2014)  
Efficacy will be measured by the proportion of patients who achieve a complete response to ublituximab  alone or ublituximab plus umbralisib combination. Under cu rrent treatment 
protocols, if less than  30% of patients experience a complete response, then the treatment is 
considered a failure.  Thus, for the experimental treatment, we define failure as an observed complete response rate less than 30%, and we define the null hypothesis as follows: H
0: p0 
≤ 0.30.  Under the assumption that treatment with single agent or combination therapy will result in an observed complete response rate of at least 50%, we define the following alternative hypothesis: H
1: p1 ≥ 0.50.  Complete response rate and associated 95% 
confidence intervals will be computed for the study. 
 
 
Secondary E ndpoints  
 Efficacy:  
Overall response rates (ORR)  (ie CR+ PR)  in the entire cohort as  defined by the Lugano response 
Criteria for NHL (Cheson  2014) 
  
 Rate of overall response in the entire cohort will be calculated, and a 95% confidence  
interval for ORR in the cohort will be calculated.  
 
Toxicity:  Ublituximab tolerability as per CTC AE V5 .0 criteria  
Umbrasilib  tolerability as per CTC AE V5 .0 criteria  
 Regimen toxicities, as defined by CTCAE V5.0 will be summarized using tables and descriptive statistics.  For each drug, the proportion of individuals experiencing toxicity events will be calculated, and 95% confidience intervals for these toxicity proportions will also be calculated.  No formal hypothesis tests will be conducted with toxicity rates 
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 76 of 97  
10.3 ANALYSIS DATASETS  
The primary efficacy analyses will be performed on the Intent- to-treat (ITT) population, whic h will 
include all subjects who have been enrolled for the study.  
 
10.4 DESCRIPTION OF STATISTICAL METHODS  
10.4.1  GENERAL APPROACH    
 
The proportion of patients achieving a complete response (and associated 95% confidence intervals 
for this proportion) will be calculated for the patients being treated in this study.  Three different complete response rates and associated 95% confidence intervals will be computed:  
1—complete response rate to ublituximab alone 2—complete response to combination therapy 3—complete response to any therapy administered (i.e. complete response rate guided by the algorithmic approach set forth in this protocol)   The proportion of patients experiencing a drug- related SAE or grade 4 -5 non- hematologic toxicity 
will be calculated for the patients being treated in this study along with 95% confidence intervals around this proportion.  
10.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT  
 The proportion of patients achieving a complete response will be calculated f or the patients being 
treated in this study.  This proportion will be formally compared to a null proportion of 30%.  The population proportion and associated 95% confidence intervals will be calculated at study completion.  
10.4.3  ANALYSIS OF THE SECONDA RY ENDPOINTS  
 Secondary endpoints will be descriptive in nature, and no formal statistical analyses will be conducted on them.  The proportion of patients achieving an overall response and an accompanying 95% confidence interval will be calculated for the patients being treated in this study.  The proportion of patients experiencing a drug- related SAE or grade 4 -5 non- hematologic toxicity 
will be calculated for the patients being treated in this study, and 95% confidence intervals around this proportion will also be reported. .  
10.4.4  SAFETY ANALYSES  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 77 of 97  
Regimen to xicities, as defined by CTCAE V5.0 will be summarized using tables and descriptive 
statistics.  
 
10.4.5  ADHERENCE AND RETENTION ANALYSES  
 The PI will provide a DSM report to the UCCC DSMC on a six -month basis.  The DSM report will 
include summaries of minutes taken at meetings  (if applicable) , the participants’ demographic 
characteristics, expected versus actual recruitment rates, treatment retention rates, any quality assurance or regulatory issues (including a summary of any protocol deviations).  
10.4.6  BASELINE DESCRIPTIVE STATISTICS  
 
Demographic data will be compiled for participants in the study at baseline, including age, gender, ethnicity, disease status, and comorbid conditions.  
10.4.7  PLANNED INTERIM ANALYSES  
 No interim analyses are planned for this study.   
 
10.4.8  SAFETY REVIEW  
10.4.8.1  TOXICITY REVIEW 
Response an d toxicity data from the 24 treated patients will be assessed and the number of 
responses achieved  will be tabulated.  
10.4.8.2  EFFICACY REVIEW  
 
After all 24 patients have been treated, efficacy will be assessed by complete response rate—regardless of treatment with ublituximab alone or in combination.  Complete response rate to the treatment algorithm (as well as 95% confidence intervals around this complete response) will be calculated.  In addition, complete response to ublituximab alone 
will be calculated (along with 95% confidence intervals), and complete response and 95% confidence intervals will also be computed for combination therapy alone. 
 
10.4.9  ADDITIONAL SUB -GROUP ANALYSES  
 
Though sample size is small, we plan to investigate complete response rates (and associated 95% confidence intervals) in the FL and MZL cohorts.  Confidence intervals will likely be wide given that these cohorts will be subgroups of the original 24 patients.  
10.4.10 EXPLORATORY ANALYSES  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 78 of 97  
Secondary endpoints may lead to exploratory analyses outlined in 10.4.3. 
 Overall response rate, CR rate, PR rate, PD rate, and SD rate will be summarized for both the FL and MZL cohorts upon study completion.  Progression free survival (PFS) is defined as time from enrollment to PD or death of any cause.  Patients who pass away without PD will be counted as if PD occurred on date of death.  Patients without PD and did not pass away but are lost to follow up will have their information censored at date of most recent tumor assessment . 
 Overall survival is defined as time from enrollment to death due to any cause.   Median measures for 2 -yr PFS and OS as well as remission duration will be assessed by 
conducting survival analysis. Kaplan- Meier survival methods will be used to estimate the survival 
function of these time- to-event outcomes. 
 Baseline disease and patient factors  will be summarized.  
 Rates of transformation to aggressive lymphoma will be calculated.  
 Any assessment of minimum residual disease or assessment of next-generation sequencing will be analyzed.  
 
QOL analysis will be performed : The change in Quality of lif e (QoL) scores as measured by 
FACT -Lym  at the start of therapy and  at the end of study will be assessed using a paired t- test and 
a null hypothesis of no change in QoL over the course of the study. Assessment of EuroQOL 
questionnaire has been shown in the Appendix  section . 
 
10.5 SAMPLE SIZE  
The study will enroll 24-30 patients.  
 
10.6 MEASURES TO MINIMIZE BIAS  
In this non-blinded phase II study  outcomes will be assessed  by the principal investigator. 
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
To ensure the privacy and confidentiality of data for this protocol, the data will be stored on a restricted access server. Access to the project directory containing the data will be limited to the investigators and research staff. Information about data security awareness is promoted through user training and education and supplemented by policies and procedures. Password protection will 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 79 of 97 be used for all transactions that involve viewing, editing, and analyzing the data or that provide 
acces s to data fields derived from the original source documents.   
 
12 QUALITY ASSURANCE AND QUALITY CONTROL  
Quality Control (Q C) procedures will be implemented beginning with the data entry system and data 
QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/ resolution.  
 Following wri tten SOPs, the study monitor will verify that the clinical trial is conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 The investigational site will provide direct access to all trial- related sites, source data/ documents, 
and reports for the purpose of monitoring and auditing by the DSMC audit team, and inspection by local and regu latory authorities.  
 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
13.1 ETHICAL STANDARD  
The PI  will ensure that this study is conducted in full conformity with r egulations for the Protection 
of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56. ICH E6 may also be followed to the extent it has been adopted by and is in accordance with FDA regulations.  
13.2 INSTITUTIONAL REVIEW BOARD  
The protocol, informed consent form(s), recruitment materials, and all subject materials will be submitted to the Colorado Multiple Institutional Review Board (COMIRB) for review and approval. Approval of both the protocol and the consent form must be obtained before any subject is enrolled. Any amendment to the protocol will require review and approval by TG Therapeutics , Inc.  and by 
COMIRB before the changes are implemented to the study. All changes to the consent form will COMIRB approved; a determination will be made regarding whether previously consented participants  need to be re -consented. 
 
13.3 INFORMED CONSENT PROCESS  
The Consent Forms must be signed and dated by the patient or the patient’s legally authorized representative before his or her participation in the study. The case history or clinical records for ea ch patient shall document the informed consent proce ss and that written informed  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 80 of 97 consent was obtained prior to participation in the study. 
 The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes a vailable that may affect the willingness of the patient to  
participate.  
 Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum i n accordance with applicable laws and  
IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised  
Consent Forms for continued participation in the study.  A copy of each signed Consent Form must be provided to the patient or the patient’s legally authorized representative. All signed and dated Consent Forms must remain in each patient’s  
study file or in the site file and must be available for verification by study monitors at any time.  
 Consent Form may also include patient authorization to allow use and disclosure of personal health information in comp liance with the U.S. Health Insurance Portability and 
Accountability Act (HIPAA) of 1996. If the site utilizes a separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other processes outlined above apply except that IRB review and approval may not be required per study site policies.  
13.3.1 CONSENT/ ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
 Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and written documentation of informed consent is required prior to starting intervention/ administering study product.   
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION 
Informed consent process will be initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families.  
 Consent forms will be IRB -approved and the participant will be asked to read and review the 
document. The investigator will explain the research study to the par ticipant and answer any 
questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Particip ants will have the opportunity to carefully review the written consent 
form and ask questions prior to signing. The participants will have the opportunity to discuss the 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 81 of 97 study with their surrogates or think about it prior to agreeing to participate. The pa rticipant will sign 
the informed consent document prior to any procedures being done specifically for the study.  
 The participants may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to the participants for their records. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.  The study allows the inclusion of non- English speaking and non -reading participants. Witnesses to 
these consent processes will be individuals not associated with the trial and will not have a conflict of interest.  
 
13.4 PARTICIPANT AND DATA CONFIDENTIALITY  
Participant confidentiality is strictly held in trust by the participating PI s, their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized t hird party 
without prior written approval of the sponsor and by TG Therapeutics, Inc.  The study monitor, other authorized representatives of the sponsor, representatives of the IRB or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 The study participant’s contact information will be securely stored at each clinical site for internal 
use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by local IRB and Institutional regulations.  
 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the University of Colorado Cancer Center .  This will not include 
the participant’s co ntact or identifying information. Rather, individual participants and their research 
data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by the University of Colorado Cancer Center research 
staff will be secured and password protected. At the end of the study, all study databases will be de-identified and archived at the University of Colorado Cancer Center.  
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS  OR DA TA 
 Intended Use:  Samples and data collected under this protocol may be used to assess biomarkers associated with  
response to therapy, for m7FLIPI testing, MRD analysis and for next generation sequencing.   
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 82 of 97  
Storage:  
Access to stored samples will be limited to research personnel only. Samples and data will be stored using codes assigned by the investigators /designee . Data will be kept in  password- protected  
computers. Only investigators /designees  will have access to the samples and  data.  
 Disposition a t completion of the study:  
Consent will be obtained from all patients for tumor tissue banking. Patients can withdraw consent for tumor banking at any time. All stored samples will be sent to the  University  
of Colorado Hematology Lymphoid Malignancy Tissue Bank (LTB). Study subjects who request 
destruction of samples will be  notified of  compliance with such  request and all supporting details 
will be maintained for tracking.  
 
13.5 FUTURE USE OF STORED SPECIMENS  
Data collected for this study will be analyzed and stored at the University of Colorado Cancer Center. After the study is completed, the de -identified, archived data will be transmitted to and stored at the , 
under the supervision of  the primary investigato r of the Hematology Lymphoid Malignancy T issue 
Bank (LTB).   With the participant’s approval and as approved by local IRBs, de -identified biological samples will 
be stored at the  Hematology Lymphoid Malignancy Tissue Bank with the same goal as the sharing 
of data with the  Hematology Lymphoid Malignancy Tissue Bank. These samples could be used for 
research into the causes of NHL  its complications and other conditions for which individuals with 
NHL  are at increased risk, and to improve treatment. The Hematology Lymphoid Malignancy Tissue 
Bank  will also be provided with a code -link that will allow linking the biological specimens with the 
phenotypic data from each participant, maintaining the masking of the identity of the participant.  During the conduct of the study, and individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to biosample storage will not be possible after the study is completed.  When the study is completed, access to study data and/ or samples will be provided to research personnel with permission from the Principal Investigator or desginee  through the  Hematology 
Lymphoid Malignancy Tissue Bank.   
14 DATA HANDLING AND RECORD KEEPING  
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site unde r the supervision of 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 83 of 97 the site PI. The PI is responsible for ensuring the accuracy, completeness, legibility, and timelines of 
the data reported.  
 
Source Documentation : 
All source documents should be completed in a neat, legible manner to ensure accurate  
interpretation of data. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 Source documents (paper or electronic) are those in which patient data are recorded and  
documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, patient-reported outcomes, evaluation checklists, p harmacy dispensing records, recorded data from automated instruments, copies of 
transcriptions that are certified after verification as being accurate and complete, microfiche,  
photographic negatives, microfilm or magnetic media, X-rays, patient files, and records kept  
at pharmacies, laboratories, and medico -technical departments involved in a clinical trial.  
This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or 
electronic record of the data) and considered source data.  
 Source documents that are required to verify the validity and completeness of data entered  into the 
eCRFs must not be obliterated or destroyed and must be retained.  eCRF reported data will be submitted to TG Therapeutics , Inc. as requested.  
 When clinical observations are entered directly into a study site’s computerized medical  record 
system (i.e., in lieu of original hardcopy records), the electronic record can serve as the  source 
document if the system has been validated in accordance with health authority requirements 
pertaining to computerized systems used in clinical research.  An acceptable computerized data collection system allows preservation of the original  entry of data. 
If original data are modified, the system should maintain a viewabl e audit  trail that shows the original 
data as well as the reason for the change, name of the person making the change, and date of the 
change.  
 Electronic Case Report Forms (eCRF) : 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data)  
and clinical laboratory data will be entered into an electronic data capture system provided by  
the University of Colorado.  eCRFs are to be completed through use of a Sponsor-Investigator designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 84 of 97 be entered directly from the source documents. All eCRFs should be completed by designated, 
trained site staff.  
 At the end of the study, any hard copy of patient data received by the investigator for his or her site must be stored safely with the study records. Acknowledgement of receipt of the compact disc is required.  
 Copies of the electronic CRF (eCRF) will be provided for use as source documents and maintained for recording data for each subject enrolled in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the subject’s official electronic study record.  
 Data Quality Assurance:  The Sponsor-Investigator will be responsible for data management of this study, including quality checking of the data. Data entered manually will be collected via EDC through use of eCRFs. Site will be responsible for data entry into the EDC system.  eCRFs  and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for data stored by the Sponsor-Investigator and records retention for the study data will be consistent with the Sponsor-Investigator’s standard procedures.   
14.2 STUDY RECORDS RETENTION  
Study documents should be retained for a minimum of 2 years after the last approval of an investigational marketing application and until there are no pending or contemplated marketing applications or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by local regulations , or institution policies . No records will be destroyed without 
the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the PI when these documents no longer need to be retained.  
 
14.3 PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or SOP requirements. The noncompliance may be either on the part of the subject, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly. These practices are consistent with ICH E6, sections:  
 • 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3. • 5.1 Quality Assurance and Quality Control, section 5.1.1. • 5.20 Noncompliance, sections 5.20.1 and 5.20.2.  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 85 of 97 It is the responsibility o f the study team to use continuous vigilance to identify and report 
deviations. Deviations will be reported to the DMSC and IRB according to UCCC DSM plan 
and institutional policy.  
14.4 PUBLICATION AND DATA SHARING POLICY  
This study will comply with the N IH Public Access Policy, which ensures that the public has access 
to the published results of NIH -funded research. It requires scientists to submit final peer -reviewed 
journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance 
for publication.  The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human participants  to intervention or concurrent 
comparison or control groups to study the cause -and-effect relationship between a medical 
intervention and a health outcome. Medical interventions include drugs, surgical procedures, de vices, 
behavioral treatments, process -of-care changes, and the like. Health outcomes include any 
biomedical or health -related measures obtained in patients or participants, including pharmacokinetic 
measures and adverse events. The ICMJE policy, and the Section 801 of the Food and Drug Administration Amendments Act of 2007 requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine. Other biomedical journals a re considering adopting similar policies. For interventional clinical trials 
performed under NIH IC grants and cooperative agreements, it is the grantee’s responsibility to register the trial in an acceptable registry, so the research results may be consid ered for publication 
in ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to publish.   FDA AA (Food and Drug Administration Amendments Act)  mandates that a “responsible party” (i.e., 
the sponsor or designated PI ) register and report results of certain “applicable clinical trials”.  
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I 
investigations, of a product subject to FDA regulation; 
• Trials of Devices: Controlled trials with health outcomes of a product subject to FDA 
regulation (other than smal l feasibility studies) and pediatric post- market surveillance 
studies. 
 
All manuscripts, abstracts, or other presentation materials generated by site investigators must be reviewed and approved by TG Therapeutics , Inc. prior to submission. 
  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 86 of 97 16 CONFLICT OF  INTEREST POLICY  
Independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical. Any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect  of this trial will be disclosed and managed  by the University of 
Colorado Denver’s (UCD) Office of Regulatory Compliance Conflict of Interest and Commitment 
Management (COIC) program. Persons with a perceived conflict of interest will have such conflicts managed in a way that is appropriate to their participation in the trial. Conflict of Interest management plans are project -specific and are reviewed at least annually. UCD has integrated the 
institutional conflict of interest management program with its e xisting program. 
 
  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 87 of 97 17  LITERATURE REFERENCES  
 1. Gribben JG: How I treat indolent lymphoma. Blood 109:4617 -26, 2007  
 2. Kahl BS: Follicular lymphoma: are we ready for a risk- adapted approach? Hematology Am Soc 
Hematol Educ Program 2017:358- 364, 2017  
 3. Relander T, Johnson NA, Farinha P, et al: Prognostic factors in follicular lymphoma. J Clin Oncol 
28:2902- 13, 2010  
 4. Campo E, Swerdlow SH, Harris NL, et al: The 2008 WHO classification of lymphoid neoplasms and 
beyond: evol ving concepts and practical applications. Blood 117:5019- 32, 2011  
 5. Horn H, Schmelter C, Leich E, et al: Follicular lymphoma grade 3B is a distinct neoplasm according to 
cytogenetic and immunohistochemical profiles. Haematologica 96:1327 -34, 2011  
 6. Link BK, Maurer MJ, Nowakowski GS, et al: Rates and outcomes of follicular lymphoma 
transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized 
Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272- 8, 2013  
 7. Solal -Celigny P, Lepage E, Brousse N, et al: Doxorubicin -containing regimen with or without 
interferon alfa -2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des 
Lymphomes Follic ulaires 86 Trial. J Clin Oncol 16:2332- 8, 1998 
 8. Solal -Celigny P: [Treatment of malignant low -grade lymphoma. Follicular Lymphoma Study Group]. 
Rev Med Interne 19 Suppl 1:18S- 20S, 1998  
 9. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognostic index 2: a 
new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555- 62, 2009  
 10. Pastore A, Jurinovic V, Kridel R, et al: Integration of gene mutations in risk prognostication for 
patients receiving first -line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective 
clinical trial and validation in a population -based registry. Lancet Oncol 16:1111 -1122, 2015 
 11. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: first report of 
the national LymphoCare study. J Clin Oncol 27:1202 -8, 2009 
 12. Horning SJ, Rosenberg SA: The natural history of initially untreated low -grade non -Hodgkin's 
lymphomas. N Engl J Med 311:1471 -5, 1984  
 13. Kahl BS, Hong F, Williams ME, et al: Rituximab extended schedule or re -treatment trial for low -
tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 32:3096 -102, 
2014  
 14. Morschhauser F, Fowler NH, Feugier P, et al: Rituximab plus Lenalidomide in Advanced Untreated 
Follicular Lymphoma. N Engl J Med 379:934 -947, 2018  
 15. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus CHOP plus 
rituximab as first -line treatment for patients with indolent and mantle -cell lymphomas: an open- label, multicentre, 
randomised, phase 3 non- inferiority trial. Lancet 381:1203 -10, 2013  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 88 of 97  16. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 y ears in patients with high 
tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised 
controlled trial. Lancet 377:42 -51, 2011  
 17. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients  with recurrent follicular 
lymphoma: a 20 -year study from a single center. J Clin Oncol 13:140 -7, 1995  
 18. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients 
with follicular lymphoma. J Clin Oncol 23:8447 -52, 2005  
 19. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in 
the United States. J Clin Oncol 23:5019- 26, 2005  
 20. Armitage JO, Longo DL: Is watch and wait still acceptable for patients with low -grade follicu lar 
lymphoma? Blood 127:2804- 8, 2016  
 21. Maddocks K, Barr PM, Cheson BD, et al: Recommendations for Clinical Trial Development in 
Follicular Lymphoma. J Natl Cancer Inst 109, 2017  
 22. Kamdar MK, Smith SM: Extranodal Marginal Zone Lymphoma: No Longer Just  a Sidekick. J Clin Oncol 
35:1872- 1878, 2017  
 23. Thieblemont C: Improved biological insight and influence on management in indolent lymphoma. 
Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program 2017:371-
378, 2017  
 24. Ardeshna KM, Qian W, Smith P, et al: Rituximab versus a watch -and-wait approach in patients with 
advanced -stage, asymptomatic, non -bulky follicular lymphoma: an open- label randomised phase 3 trial. Lancet Oncol 
15:424 -35, 2014  
 25. Williams ME, H ong F, Gascoyne RD, et al: Rituximab extended schedule or retreatment trial for low 
tumour burden non- follicular indolent B -cell non -Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol 
E4402. Br J Haematol 173:867 -75, 2016  
 26. Conconi A, Martinelli G, Thieblemont C, et al: Clinical activity of rituximab in extranodal marginal 
zone B -cell lymphoma of MALT type. Blood 102:2741 -5, 2003 
 27. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al: Treatment of splenic marginal zone lymphoma. 
Best Pract Re s Clin Haematol 30:139 -148, 2017  
 28. Esteves IT DC, Herveau S, Reslan L, Brune F, Van Overtvelt L, Salcedo M, Fournes B: LFB -R603 
(ublituximab), a third- generation monoclonal anti -CD20 antibody, displays additive antitumor activity with 
antileukemic chemo therpeutic agents in mouse xenograft models. American Society of Hematology:abstract 1660, 
2011  
 29. Sawas A, Farber CM, Schreeder MT, et al: A phase 1/2 trial of ublituximab, a novel anti- CD20 
monoclonal antibody, in patients with B -cell non -Hodgkin lymphoma or chronic lymphocytic leukaemia previously 
exposed to rituximab. Br J Haematol 177:243- 253, 2017  
 30. Burris HA, 3rd, Flinn IW, Patel MR, et al: Umbralisib, a novel PI3Kdelta and casein kinase -1epsilon 
inhibitor, in relapsed or refractory chronic lymp hocytic leukaemia and lymphoma: an open- label, phase 1, dose -
escalation, first -in-human study. Lancet Oncol 19:486 -496, 2018  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 89 of 97  31. Lunning MA, Vose JM, Schreeder MT, et al: Ublituximab, a novel glycoengineered anti -CD20 mAb, in 
combination with TGR- 1202, a next generation once daily PI3Kdelta inhibitor, demonstrates activity in heavily pre -
treated and high- risk chronic lymphocytic leukemia and B -cell lymphoma, American Society of Hematology. San 
Francisco, CA, 2014  
 32. Lannutti BJ, Meadows SA, Herman SE, et  al: CAL -101, a p110delta selective phosphatidylinositol -3-
kinase inhibitor for the treatment of B -cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117:591- 4, 
2011  
 33. Gopal AK, Kahl BS, de Vos S, et al: PI3Kdelta inhibition by idelalisib in patients with relapsed indolent 
lymphoma. N Engl J Med 370:1008- 18, 2014  
 34. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and 
response assessment of Hodgkin and non- Hodgkin lympho ma: the Lugano classification. J Clin Oncol 32:3059- 68, 
2014  
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 90 of 97  
 

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 91 of 97  
QoL Instrument – FACT -Lym Questionnaire  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 92 of 97  

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 93 of 97  

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 94 of 97  

Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 95 of 97 APPENDIX:  NEW YORK HEART ASSOCIATION CLASSIFICATIONS 
Class  Functional  Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting 
limitations of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpitation, 
dyspnea, or anginal pain. No objective evidence of 
cardiovascular  disease.  
II Patients with cardiac disease resulting in slight 
limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Objective evidence of 
minimal cardiovascular 
disease.  
III Patients with cardiac disease resulting in marked 
limitation of physical activity. They are comfortable 
at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnea, or anginal pain. Objective evidence of 
moderately severe 
cardiovascular disease.  
IV Patients with cardiac disease resul ting in inability to 
carry on any physical activity without discomfort. 
Symptoms of heart failure or the anginal syndrome 
may be present even at rest. If any physical activity is 
undertaken, discomfort is increased. Objective evidence of 
severe cardiovascu lar 
disease.  
Source: The Criteria Committee of New York Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. Boston, MA: Little, Brown & Co; 
1994:253 -256. 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 96 of 97 APPENDIX:  CONTRACEPTION GUIDELINES AND PREGNANCY 
 Females Not of Childbearing Potential are Defined as Follows:  Females are considered post -menopausal and not of child bearing potential if they have had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.  Contraceptive Guidelines for Females of Child -Bearing Potential: 
 Females of child -bearing potential, defined as all females physiologically capable of becoming 
pregnant, must use effective contraception during the study and for 120 days after the last dose of study treatment.  Effective contraception is defined as either: 
• True abstinence: When this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 
• Sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.  
• Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).  For female patients on the study, the vasectomised male partner should be the sole partner for that patient. 
• Oral contraception, injected or implanted hormonal methods. 
• Use of a combination of any two of the following (a+b): 
a) Placement of an intrauterine device (IUD) or intrauterine system (IUS).  
b) Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.  
 
The following are unacceptable  forms of contraception for females of childbearing potential: 
• Female condom  
• Natural family planning (rhythm method) or breastfeeding 
• Fertility awareness  
• Withdrawal  
• Cervical shield  
 Females of child -bearing potential must have a negative serum pregnancy te st ≤ 3 days prior to 
initiating treatment.  
  Fertile Males  
 
Protocol # 18- 2128   
PI: Manali Kamdar, MD   
Version Date:  May 17, 2021  
CONFIDENTIAL   Page 97 of 97 Fertile males, defined as all males physiologically capable of conceiving offspring must use 
condom during treatment and for 120 days after the last dose of study treatment. They should also not father a child during this period.  Pregnancies  
 To ensure patient safety, each pregnancy in a patient on study treatment must be reported to TG Therapeutics, Inc. within 24 hours of learning of its occurrence as outlined in the Safety Reporting section of this protocol.  The pregnancy, both pregnant female and infant (if applicable), should be followed up for 6 months after the termination of the pregnancy to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.  
 Pregnancy outcomes must be collected for the female partners of any males who took study treatment in this study.  Consent to report information regarding these pregnancy outcomes should be obtained from the mother. 
Consent and Authorization Form
Page 1 of 23Principal Investigator: Manali Kamdar, MD, MBBS 
Phone: 720-848-0752
COMIRB No: 18-2128
Version
 Date: 05/17/2021
Study Title: Ublituximab as initial therapy for treatment-
naive follicular or marginal zone 
lymphoma 
with response-driven addition of umbralisib 
for suboptimal response
_____________________________________________________________________
Key Information
_______________________________________________________________
Please read all the information below and ask questions about anything you 
don’t understand before deciding if you
 want to take part.
You are being asked to be in a research study. Participation in Research is 
voluntary.
Purpose of the Study : We are doing this  study to learn more about drugs to 
treat two types of Non-Hodgkin lymphoma (NHL). The two chemotherapy-free 
drugs are called Ublituximab and Umbralisib (the study drugs).  The study drugs 
are not FDA approved to treat cancer and are considered to be investigational.
Procedures: If you agree to participate, the following will happen:
You
 will have a screening visit to see if you are eligible for the study. This 
may include a bone marrow biopsy, PET/CT scan, and/or a 
tumor 
biopsy.
If you are eligible and agree to participate, you will enter single phase 
induction, receiving Ublituximab through an intravenous infusion
 over 
several visits. You will have a bone marrow biopsy at the end of this 
treatment phase.
If the single phase induction doesn’t eliminate visible disease, 
Combination therapy will begin. Ublituximab will
 be administered 
intravenously on several days during the first cycle of combination 
treatment, and on Day 1 of each subsequent cycle through Cycle 6 and 
then every 3 cycles (i.e. Cycle 9 and Cycle 12) through Cycle 12. 
Umbralisib will be administered orally once a day. You will have a bone 
marrow biopsy at the end of this treatment phase.
After combination therapy ends, the study doctor may continue you on single 
COMIRB
APPROVED
For Use
02-Jul-2021
08-Jun-2022
Consent and Authorization Form
Page 2 of 23phase or combination treatment for a varying length of time. You will be followed 
for two years after treatment ends.
 If you agree to participate, you will also be asked to participate in optional parts 
of this study.
You may continue receiving study drugs
 for up to 12 cycles 
(approximately 6 months), and be followed
 every 3 months for the next 2 
years.
Risks: Participation in research involves  risks, including the following:
Risks associated with Ublituximab include: changes in your blood 
count; fever;
 infusion related reaction; headache; digestive problems; 
fatigue and weakness; swelling of hands and/or feet; pain; liver disease, 
shingles; changes in taste; high blood pressure; throat problems; allergic 
reaction, itchy, red, and peeling rash that can be fatal; skin cancer; 
metabolic disorder; Hepatitis B reactivation; serious brain infection that 
can lead to death.
Risks associated with the Ublituximab+Umbralisib Combination 
include: changes in
 your blood count; digestive problems; fatigue; 
infusion related reaction; decreased appetite; heart problems; ear 
problems; eye problem; chills; swelling; inflammation through the entire 
body; lung inflammation, infection, fluid build-up; liver problems; 
dehydration; failure to thrive;  bone weakness; dizziness; change in taste; 
headache; anxiety; kidney problems; scrotal cyst; hair loss; high blood 
pressure; allergic reaction; itchy, red and peeling rash that can be fatal; 
skin cancer; serious metabolic disorder; serious brain infection that can 
lead to severe disability and death.
Risks associated with bone marrow biopsy include: allergic reaction, 
pain, infection.
Benefits: There is no guarantee that your
 health will improve if you join this 
study. This study may lead to information that could help patients and health 
care providers in the future.
Alternatives: Please discuss standard treatment and care options with your 
doctor.
_______________________________________________________________
Detailed Consent
Consent and Authorization Form
Page 3 of 23_______________________________________________________________
You are being asked to participate in a research study. A member of the 
research team will explain what is involved in this study
 and how it will 
affect you. This consent form describes the study procedures, the risks and 
benefits of participation, as well as how your confidentiality will be 
maintained. Please take your time to ask questions and feel comfortable 
making a decision whether to participate or not. This process is called 
informed consent. If you decide  to participate in this study, you will be asked to 
sign this form.
Why is this study being done?
The purpose of this study is to learn more about  drugs to treat two types of 
Non-Hodgkin lymphoma (NHL). The two chemotherapy-free drugs are called 
ublituximab and umbralisib. Ublituximab will be used to treat the tumor first, if 
the tumor does not respond well a second drug called umbralisib, will be 
added. You are being asked to be in this research study because you have 
been diagnosed with a type of NHL, follicular lymphoma (FL) or marginal zone 
lymphoma (MZL). 
Neither drug is FDA approved for any type of cancer. These drugs and this drug 
combination are therefore considered to be experimental.
Throughout the rest of this consent form, ublituximab and umbralisib will 
be called the “study drugs”.
How many people will participate?
Up to 30 people from your area will participate in
 the study.
What happens if I join this study?
If 
you join the study, you will be asked to sign this consent form. You will 
be given a copy to keep and the original form will 
be kept at the clinic. You 
can withdraw from the study at any time and without giving a reason. This 
will not affect the standard medical care you receive.
There are either 3 or 4 parts to the study (step 3 is skipped when disease is 
eliminated by step 2):
1.Screening (before beginning the study drugs)
2.Single Phase Induction (attempt to
 eliminate visible disease in your body)
3.Combination therapy (used if single agent treatment doesn’t eliminate visible 
disease)
4.Follow-up
By enrolling in this study you are forgoing  standard of care therapy that has 
potential to decrease the amount of disease in your body. 
Consent and Authorization Form
Page 4 of 23The next section of this form lists what will be expected of you if you join this study. 
Study Procedures
The screening tests and procedures will be done to see if you are eligible to 
join this study. You may have had some of these tests and procedures 
done recently as standard care for your cancer, and they may not need to 
be repeated.
Informed Consent 
This informed consent form will be discussed with
 you and you will 
be given a copy of this document. If you join the study, you will be 
asked to sign this consent form before you receive any study 
related tests or procedures.
Medical and Cancer History 
Before you start the study we will record your date of birth, race, 
ethnicity, and complete medical history. This history 
will look at the 
background and progress of your cancer and any treatments you 
have received for your disease.
Physical Examination 
A physical examination will be completed as part 
of your standard of 
care. We will also assess if the study drug
 is affecting your body 
functions including lungs, heart, abdomen, extremities, skin, head 
(eyes, ears, nose, hair, etc.) and neurologically.
Vital Signs 
We will take your blood pressure, heart rate, respiratory rate, body 
temperature and weight. Height will be 
measured only during 
screening.
ECOG Performance Status 
We will assess how well you are performing your daily activities.
Review of Current Medications 
Your study doctor will let you know which medications you can and 
cannot take while taking part in this study. From the time you first 
receive the study drugs through 30 days after the last dose, we will 
record medications you may be taking.
Review of Side Effects 
Some risks have been identified because of the disease process or 
through use 
of the study drugs themselves and these will be followed 
very closely by the Principal Investigator and study staff. More 
information will be provided in the Risks section of this consent.
Consent and Authorization Form
Page 5 of 23Routine Blood and Urine Samples 
These tests are sometimes called safety labs so the
 study doctor 
can be sure it is safe for
 you to take part in this study and to be 
given the study drugs.
oPregnancy test: Women who are able to become pregnant 
will be given either a urine or a blood pregnancy test. A 
positive pregnancy test prior to being given the study drugs 
will exclude you from starting or continuing to take part in 
the study. This test must be performed within 3 days prior 
to starting treatment.
oComplete blood count (CBC)
oComprehensive metabolic panel  (CMP)
oBlood clotting tests (PT/INR, and PTT)
oThyroid function tests (TSH)
oCreatinine Clearance
oTesting for HIV (human immunodeficiency virus)*, HBV 
(hepatitis B virus), HCV (hepatitis C virus), and EBV 
(Epstein-Barr virus)
oImmune Function (CMV)
oTumor Assessment (B2MG) 
oUrinalysis
*Positive HIV test result reported to the Colorado Department of 
Public Health and Environment as required by state law
Research Blood Samples for Banking (Optional) 
These tests are being done specifically because you are participating in this 
study. These
 tests will be done to understand better how the drug is working. 
We will ask later in this form if you agree to allow these samples to be banked 
for future use. 
Questionnaire on quality of life  
These questionnaires will ask about you, your
 health, and how the treatment 
affects your day-to-day life.  
Electrocardiogram (ECG or EKG) 
This is a simple, noninvasive procedure that records 
the electrical activity of the 
heart. Electrodes are placed on the
 skin of the chest and connected in a specific 
order to a machine. Output usually appears on a long scroll of paper that 
displays a printed graph.
Bone Marrow Biopsy/Aspirate 
Consent and Authorization Form
Page 6 of 23At various time points during the study, you will have bone marrow 
examined. This involves placing a hollow needle into your hip bone 
near the
 small of your back and taking a small sample of the bone 
(bone marrow biopsy) and 2-3 tablespoons of the liquid bone 
marrow inside the bone (bone marrow aspirate).
If a screening bone marrow biopsy is required, it needs to be done 
within 6 weeks 
prior to study enrollment. A repeat bone marrow 
biopsy prior to Cycle 3 would only be required to assess response 
if initial biopsy was positive for disease.
Imaging (CT) 
These tests will be performed to check the status of your disease. 
These tests must be 
performed 4 weeks prior to study enrollment.
oCT: A computed tomography scan uses x-rays to make 
detailed pictures of 
parts of the body and the structures 
inside the body.
Positron Emission Tomography (PET/CT) Scan 
Positron emission tomography (PET) scan is a test that uses 
radioactive glucose (sugar) and a computer to
 create images of how 
organs and tissues in the body are functioning. Abnormal cells in the 
body use glucose at a different rate than normal cells and this allows 
the scanner to create a detailed picture of how your body is working. 
A PET/CT scan will be done before and after treatment. A CT scan 
may be performed in place of a PET/CT scan at other time points 
during the study, depending on your insurance carrier.
Tumor Tissue Samples 
Archived Tissue:  If you had surgery for your cancer in the 
past, we will need to
 request a portion of your tumor tissue 
from the institution where you had your surgery and that they 
have stored so we may use it for this to confirm your 
diagnosis of FL or MZL. Also, if you agree, we would like to 
store your tissue for future research.
Tumor tissue biopsy during screening: If archived tissue is not 
available, we will ask you to allow us to take
 a fresh biopsy of your 
tumor tissue prior to treatment to confirm your diagnosis. This biopsy 
may be core needle, excisional, or incisional since fine needle 
aspirations are typically inadequate to make a diagnosis of FL or 
MZL. We will also ask you for permission to store it for optional future 
research.
Receiving the Study  Drugs 
Consent and Authorization Form
Page 7 of 23Ublituximab monotherapy: You will receive Ublituximab through an 
intravenous 
infusion, using a central venous catheter. This involves 
the insertion of a catheter, or small tube, into a large vein in the arm, 
or into a vein under your collar bone. This may be done under local 
anesthesia. Thirty-60 minutes prior to the Ublituximab infusion, you 
will receive an antihistamine and a corticosteroid. You will receive 
Ublituximab over a 4 hour infusion on day 1, a 3 hour infusion (days 
8 and 15) and a 90 minute infusion on day 22. 
Ublituximab combination therapy: Ublituximab will be administered 
intravenously on days on Days 1, 8 and 15 during the 
first cycle of 
combination treatment, and on Day 1 of each subsequent cycle 
through Cycle 6, and then every 3 cycles (i.e. Cycle 9 and Cycle 12) 
through Cycle 12.
Umbralisib: Umbralisib will be administered orally once daily  within 
30 minutes of starting a meal and should be taken at approximately 
the same time each day. Premedication treatments to prevent an 
allergic reaction will be given prior to day one of cycle 1. 
Study Visits
Please refer to Study Calendar for schedule  of events. In addition, 
please note the following information.
Screening
If screening tests and procedures are performed  within 48 hours of Cycle 1 
Day 1, routine lab testing and physical exams do not need to be repeated.
Induction Cycles
All screening tests and procedures must be done prior to treatment (up to 
28 days prior to treatment, with the exception of PET/CT which can be 
done up to 42 days prior to treatment) and may be performed from up to 1 
day prior to treatment.
If after your treatment with Ublituximab during the Induction cycles, the 
PET/CT scan shows evidence of disease, combined therapy of 
Ublituximab and
 Umbrasilib will be administered. The PET/CT scan 
should be within 8 weeks of cycle 1 day 1. 
End of Treatment
For patients with no detectable disease as measured by PET/CT 8 
weeks after  induction with Ublituximab treatment ends.
 
For patients receiving combination therapy of Ublituximab and 
Consent and Authorization Form
Page 8 of 23Umbralisib, the end of therapy is reached 12 weeks after completion (last 
dose) of combination treatment. 
Follow-Up
The follow-up period starts after the end of treatment visits. Patients 
will be seen in follow up every 3 months for the first 2 years post 
completion of therapy (last dose of ublituximab (for single agent 
treatment) and umbralisib (for combination therapy).  
PET/CT scans will be performed at the 6 months, 12 months, 18 
months and 24 months post completion of therapy (last dose of 
ublituximab for single agent treatment) and umbralisib (for combination 
therapy). At this time, patients will be seen by a provider for follow up 
of any progressive disease, subsequent anti-lymphoma therapy, or 
death. 
Consent and Authorization Form
Page 9 of 23Abbreviations: C = cycle; CT = computed tomography; D = day; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; HIV = 
human immunodeficiency virus; IV = intravenous; fT4 = free thyroxine ; M = month;  PET = positron emission tomography; PT/INR =  prothrombin time and international 
normalized ratio; PTT = partial thromboplastin time; TSH = thyroid stimulating hormone; Tx = treatment.
a.. Ublituximab will be administered every cycle (28 days) through Cycle 6, and then every 3 cycles (i.e. at Cycle 9 and Cycle 12). Trial Period Combination EOTScreeningC1 
Single AgentEnd 
of 
Induction
C1 C2 C3-12aFollow-up
(On Single Agent OR Combination 
Treatment)
Treatment Cycle/Title -28 to D0 D1 D8 D15 D224 weeks 
post
Induction 
Tx 8 Weeks 
Post
 
Induction 
TxD1D8 
and 
D15D1 D15 D1 D+4 weeks 
post 
combination 
Tx12 
Weeks 
Post 
Completion 
of 
Combination 
Tx3 M 6, 
9, 12, 15, 
18, 21 & 24
 
M30 
M+ Q6M 
Yrs. 2-5
Written Informed
 Consent X
Medical History  X X X X X “i
Demographics/Height/
ECGX
Physical Exam/Vitals
Adverse Event Assessment 
Current MedicationsX X X X X X X X X X X X X X X X X
ECOG Performance Status X X X X X X
PET with diagnostic quality CT 
Assessment X X X X X X
Bone Marrow
 Biopsy X X X
Survival 
Status & Subsequent 
TherapyX X X X X
Ublituximab - IV
 Weekly X X X X X X X X
Umbralisib - Oral Daily X X X X X
Routine 
Blood Tests X X X X X X X X X X X X X X X X
Need to TSH and fT4
Creatinine Clearance
Coagulation -
 PT/INR and PTT
Pregnancy Test
HIV Testing/ Hep B/ Hep CX
Urinalysis X X X
Research Blood Samples
 for 
bankingX X X X X
Tumor Tissue
 Review X
Questionnaire X X X X X
Consent and Authorization Form
Page 10 of 23How long will I be in the study?
You may continue receiving study drugs for up
 to 12 cycles (approximately 6 months) 
and be followed every 6 months for the
 next 2-5 years.
What are the possible discomforts or risks?
Given that this combination of therapy  is currently considered experimental, it may not 
improve treatment outcomes, and there is a chance it could increase side effects or worsen 
cancer recurrence risk.  
There is a risk that if the combination of treatments being tested in this study caused 
severe side effects. 
If the treatment being tested in this study was found to be less effective 
than current standard of care, it could reduce the chance of cancer cure, or increase risk of 
cancer death. 
You may have side effects while you are in this study, but you will be carefully checked by 
the study doctor for any problems.
 There may be risks or side effects of the study 
treatment that are unknown at this time. You should tell the study doctor about anything 
that is bothering you or any side effects that you have, even if you do not think they are 
related to the study treatment. Many side effects go away shortly after the medications are 
stopped, but in some cases side effects can be serious, long lasting, permanent, or lead to 
death.
You should talk to your study doctor about any side effects or discomfort you may have. The 
study doctor may give you some medicine that will help with some side effects. The study 
doctor may also interrupt or discontinue the study drugs or study procedures.
Risks of the Study Drugs
Risks of Ublituximab
Very Common (more than 10%  of people):
Decreased number of white blood  cells that fight infection, decreased number of 
platelets that help with clotting 
Fever
Infusion related reaction
Headache
Common (greater than or equal to 2% to less than 10% of subjects):
Consent and Authorization Form
Page 11 of 23Decreased number of red blood cells, decrease in red blood cells, white blood cells 
and platelets all at the same time
Diarrhea, pain in the abdomen, nausea or feeling queasy, itching in the mouth
Tiredness,
 weakness, chills, swelling of the hands and/or feet, pain
A liver disease causing  cell
 destruction
Shingles
Increase in liver enzymes,  elevated bilirubin
Muscular weakness
Change in taste
Irritation in the throat, tightness in the throat
Itching, sweating more than usual
High blood pressure
Although rare, the following cases have been  reported in subjects treated with ublituximab: 
Drug-induced hepatitis (inflammation of the liver due to toxic  exposure to medication) 
Allergic reaction 
Erythrodermic eczematous rash (itchy, red and peeling rash that  can be fatal) 
Malignant melanoma (skin cancer)
Tumor lysis syndrome (a serious metabolic disorder caused by the breakdown of 
cancer cells and their release in the bloodstream) 
Progressive multifocal leukoencephalopathy
 (a serious  brain infection that can lead to 
severe disability and death)
Hepatitis B reactivation, an infection of the  liver in people who have a history of 
hepatitis B infection, which may include symptoms such as yellowing of the eyes or 
skin, pain on the right side of the abdomen below the ribs, indigestion, loss of 
appetite, dark-colored urine often accompanied by lighter-than normal colored stools, 
nausea, vomiting or fatigue, and may be life-threatening or lead to death.
Serious infections including life-threatening and fatal cases have been observed in studies 
with ublituximab taken alone. Contact your study doctor immediately if you have any of the 
following signs or symptoms that may be associated with an infection: 
changes in body temperature 
fever 
chills 
nausea or vomiting 
cough 
shortness of breath 
body ache 
weakness or fatigue 
stiff neck 
confusion 
Consent and Authorization Form
Page 12 of 23sensitivity to light
Risks of Ublituximab+Umbralisib Combination
Very Common (greater than or equal to 10%  of people):
Decreased number of red blood cells, decreased number  of white blood cells
Diarrhea, nausea or feeling queasy, vomiting, constipation
Tiredness
Infusion related reaction
Decreased appetite
Insomnia (trouble sleeping)
Chills, fever
Cough, headache, dizziness
Upper 
respiratory infection, lung infection (pneumonia)
Inflammation or pain that comes from inside a joint, back pain
Abdominal pain
Swelling of your lower legs or hands
Sensation of
 difficult or uncomfortable breathing
Low potassium  levels  in the blood
Increase in liver enzymes  (alanine aminotransferase and aspartate aminotransferase) 
found in the blood (indicates damage to the liver)
Common (1% to less than 10% of people):
Decreased number of platelets
Decrease in
 the hearts ability to  pump blood
Ear congestion, feeling discomfort in the ear
Paleness in the lining of the eye, infection  in the eye, eye swelling, blurred vision
Discomfort in the abdomen, swollen abdomen, pain  in the abdomen, constipation, 
indigestion, passing gas, gastric reflux, blood in stool, increase production of saliva, 
inflammation in the mouth
Weakness, swelling of the face, pain  at the site of the infusion, swelling in one area, 
inflammation throughout the entire body
Increase in level of bilirubin in the blood
Low levels of all types of gamma
 globulins (proteins) in the blood 
Inflammation of the lungs (bronchitis), infection under the skin,  inflammation of the 
large intestine caused by a bacteria that can cause severe diarrhea, infection and 
swelling of the small and large intestine,  fungal infection in or around the mouth, 
herpes in or around the mouth, ear infection, , common cold, infection in your blood 
stream that may cause your organs to fail, inflammatory response throughout the 
body that can cause organs to fail, sinusitis, infection of the skininfection of the urinary 
Consent and Authorization Form
Page 13 of 23tract
Wound
Increase in the levels of creatinine in the blood, abnormal  CT scan of the chest, 
decrease in the proteins of the immune system, decreased weight
Dehydration, failure to thrive, high levels of sugar in the blood, high levels of uric acid 
in the blood, low levels of potassium in the blood, low levels of phosphate in blood 
which may lead to bone weakness
Swelling in the joints, involuntary muscle movements, muscular weakness, pain in the 
muscles, pain in the arms and/or legs
Change in taste, lacking energy, sinus headache, sleepiness
Agitation, anxiety
Having a sudden urge to urinate,
 decreased kidney function, a sudden decrease in 
kidney function
Scrotal cyst, discolored semen
Choking, difficulty speaking, shortness of breath, bloody nose, low levels of oxygen in 
the blood, pain in the throat, inflammation of the lungs, cough that produces mucus, 
sinus congestion
Hair loss, cold sweat, areas on the skin that look like acne, blistering of the skin, dry 
skin, bleeding under the 
skin, itching, flat or raised red bumps on the skin, redness on 
the cheeks and nose, hives
High blood pressure
Although rare, the following side effects have been reported  in subjects treated with 
umbralisib and/or ublituximab:
ileus (inactive bowel) 
pulmonary edema (excess fluid in the lungs) 
drug-induced hepatitis (inflammation of the liver due 
to toxic exposure to medication)  
allergic reaction 
erythrodermic eczematous rash (itchy, red and peeling rash that can be fatal) 
malignant melanoma (skin cancer) 
tumor lysis syndrome (a serious metabolic disorder caused by the breakdown of 
cancer cells and their release in the bloodstream) 
progressive multifocal leukoencephalopathy (a serious brain infection that can lead to 
severe disability and death) 
Serious infections including life-threatening and fatal cases have been observed in studies 
with ublituximab taken in combination. Contact your study doctor immediately if you have any 
of the following signs or symptoms that may be associated with an infection: 
changes in body temperature 
fever 
chills 
nausea or vomiting 
cough 
Consent and Authorization Form
Page 14 of 23shortness of breath 
body ache 
weakness or fatigue 
stiff neck 
confusion 
sensitivity to light
Risks of the Study Procedures
Blood collection
Blood sampling and needle punctures carry some risk. Possible side effects include, but 
are not limited to, fainting, bleeding, bruising, discomfort, dizziness, infection and/ or pain 
at the puncture site.
Having an IV inserted in your vein
In this study we will insert a needle, connected to a plastic tube, into a vein in your arm. 
We will use the tube to take blood
 samples or give you fluids. You will feel some pain when 
we first insert the tube into your vein. You may have some redness, swelling, or bruising 
where the tube goes under your skin. In some cases, this type of tube can cause an 
infection where it goes under the skin. In rare cases, 
it can cause a blood clot in the vein.
You will have this tube inserted for about four or five hours.
Catheter Placement 
Study drugs may be given through a central venous catheter (sometimes called a ‘central 
line’ or ‘port’). If you do not already have a catheter in place, we will place one in your chest. 
A catheter is a plastic tube. We will also use your catheter to take blood and give you fluids
Bone marrow biopsy
In this study we will take three samples of bone marrow from your pelvic bone. Before we 
take each sample, we will give you some numbing medication on the
 skin outside your 
pelvic bone (on your hip). After your skin is numb, we will push a special needle into the 
center of your pelvic bone. Then, we will draw the bone marrow up into the syringe. When 
we do this, you will have a pulling feeling as the marrow leaves the bone and goes into the 
syringe. The area around the bone will be sore for a few days. There is a very small 
chance that you will be allergic to the numbing medicine. There is also a very small chance 
that you could bleed or develop an infection.
Electrocardiogram (ECG)
An electrocardiogram (ECG) is a test that records the electrical activity of the heart. Skin 
irritation is rare but could occur during an ECG from the electrodes or the gel that is used.
Imaging (PET, CT scans)
Consent and Authorization Form
Page 15 of 23Procedures such as CT scans, X-rays and/or radioactive drugs  will be used during this 
research study to see how you are doing. The cumulative radiation exposure from these 
tests is considered small and is not likely to adversely affect you or your disease. However, 
the effects of radiation add up over a lifetime. It is possible that having several of these 
tests may add to your risk of injury or disease. When deciding to enter this study, think 
about your past and future contact with radiation. Examples of contact with radiation 
include x-rays taken for any reason or radiation therapy for cancer treatment.
Reproductive Risks
While participating in this research study, you should not become pregnant, nurse a baby, 
or father a baby. Both men and women who are able to have children must use a highly 
effective means of birth control approved by your study doctor.
If you are a female who has stopped having menstrual periods for at least 1 year 
(menopause), please discuss with your study doctor the 
need for birth control. If you 
become pregnant, you must stop taking the study drugs at once and notify your doctor 
immediately. You will not be allowed to continue in the study. You may be asked 
questions about the outcome of your pregnancy and the baby.
You must continue the use of birth control during the entire time of your study participation 
and to at least 120 dayss after
 the last dose of Umbralisib or Ublituximab, whichever is 
later.
If you are a male, you are responsible for informing your partner(s) that the effects of 
Ublituximab and Umbralisib on an unborn fetus
 or embryo in humans are unknown.  You 
and your partner(s) are responsible for using acceptable birth control as described above. 
Discuss with your partner acceptable forms of contraception. If your partner becomes 
pregnant while you are on study, you must notify your doctor immediately. You and your 
partner may be asked questions about the outcome of the pregnancy and the baby. 
Written informed consent for release of medical information from your partner will be 
obtained prior to collecting any information about the pregnancy and baby.
Risks associated with HIV and/or Hepatitis B & C testing
If you test positive for HIV (Human Immunodeficiency Virus) and/or Hepatitis in this study,  
we must report your name to the Colorado Department 
of Public Health and Environment.) 
Risk of Loss of Confidentiality
There is a risk that people outside the research team will see your research information. 
We will do all that
 we can to protect your information, but it cannot be guaranteed.
There may be other risks that could arise  which are not reasonably foreseeable. If new 
information becomes available which could influence your willingness to continue, this new 
information will be discussed with you.
Consent and Authorization Form
Page 16 of 23What are the possible benefits of the study?
This study is designed for the researcher to learn more about the two study drugs. The study 
is not designed to improve your health. However,
 there is no guarantee that your health will 
improve if you join this study. Also, there could be risks to being in this study. If there are 
risks, these are described in the section describing the discomforts or risks. Are there 
alternative treatments?
There may be other ways of treating your cancer.  Instead of taking part in this study:
You may choose to receive treatment with an approved therapy. Standard of care 
therapies for FL and MZL include antibody therapy like rituximab or chemotherapy 
like cyclophosphamide, vincristine and prednisone; and rituximab and bendamustine.
You may choose to participate in a different study with another experimental drug.
You
 may choose to receive comfort/palliative  care.
You may choose to get no treatment at  all
You 
should talk to your doctor about your choices. Make sure you understand all of your 
choices before you decide to take part in this study. You may leave this study and still 
have these other choices available to you.
Who is paying for this study?
TG Therapeutics manufactures and will provide the two drugs, Ublituximab and 
Umbralisib, used
 for the study. This research is being conducted by Dr. Manali Kamdar. 
The research study will only pay for procedures not considered standard of care.
Will I be paid for being in the study?
You will not 
be paid to be in the study.
Will I have to pay
 for anything?
The drug manufacturer, TG Therapeutics, will pay for the cost of the study drugs, 
Ublituximab and Umbralisib. The funding for this study will also pay for any tests or 
procedures that are related to the research study.
There are some medical procedures that you would get for your condition whether you 
were in this study or not, such as clinic visits, diagnostic and lab tests, and imaging. These 
are considered standard of care. You and/or your health insurance may be billed for the 
costs of medical care during this study if these expenses are related to standard of care 
procedures. If you have health insurance, the cost of these services will be billed to your 
insurance company. If your insurance does not cover these costs, or you do not have 
insurance, these costs will be your responsibility.
Consent and Authorization Form
Page 17 of 23Ask your study doctor to discuss the costs that will or will not be covered by this research 
study. This discussion
 should include the costs of treating possible side effects. Otherwise, 
you might have unexpected expenses from being in this study.
Consent and Authorization Form
Page 18 of 23Is my participation voluntary?
Taking part in this study is voluntary. You  have  the right to choose not to take part in this 
study. If you choose to take part, you have the right to stop at any time. If you refuse or 
decide to withdraw later, you will not lose any benefits or rights to which you are entitled.
If you leave this study, you will still receive your  normal medical care. The only medical 
care that you will lose is the medical care you are getting as part of this study. You might 
be able to get that same kind of medical care outside of the study. Ask your study doctor.
Can I be removed from this study?
The study doctor may decide to  stop your participation without your permission if the study 
doctor thinks that being in the study may cause you harm, or for any other reason.
What happens if I am injured or hurt during the study?
If you have an injury while you are in this study, you should call Dr. Kamdar immediately. 
Dr. Manali Kamdar 
at 720-848-0752 (office hours) or 303-266-2519 (24 hour contact 
number).
We will arrange to get you medical care if you have an injury that is caused by this 
research. However, you or your insurance company will have to pay for that care.
Who do I call if I have questions?
The researcher carrying out this study is Manali Kamdar, MD.  You may ask any questions 
you have now. If you have questions, concerns, or complaints later, you may call Dr. 
Manali Kamdar at 720-848-0752 (office hours) or 303-266-4162 (24 hour contact number).   
You will be given a copy of this form to keep.
You may have questions about your rights as someone in this study. You can call Dr. 
Kamdar with questions. You can
 also call the responsible Institutional Review Board 
(COMIRB). You can call them at 303-724-1055.
A description of this clinical trial will be  available on http://www.Clinical Trials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. At 
most, the Web site will include a summary of the results. You can search this Web site at 
any time.
Optional Consent for Specimen Banking for Future Research
Dr. Kamdar
 would like to keep some blood, tissue from biopsies, and/or archived tissue 
that was taken during previous biopsy procedures. If you agree, the samples will be kept 
Consent and Authorization Form
Page 19 of 23and may be used in future research to learn more about cancer. The research that is done 
with your samples
 is not designed to specifically help you. It might help people who have 
cancer and other diseases in the future. Reports about research done with your samples 
will not be given to you or your doctor. These reports will not be put in your health records. 
The research using your samples will not affect your care.
The choice to let Dr. Kamdar keep the tissue samples for future research is up to you. No 
matter what you 
decide to do, it will not affect the care that you will receive as part of the 
study. If you decide now that your samples can be kept for research, you can change your 
mind at any time and contact your study doctor to let him know that you do not want Dr. 
Kamdar to use your samples any longer, and they will no longer be used for research. 
Otherwise, they may be kept until they are used up, or until Dr. Kamdar decides to destroy 
them.
When your samples are given to other researchers in the future, Dr. Kamdar will not give 
them your name,
 address, phone number or any other information that will let the 
researchers know who you are.
Sometimes samples are used for genetic research (about diseases that are passed on in 
families). If your samples are used for this kind of research, the results will not be told to 
you and will not be put in your health records. Your samples will only be used for research 
and will not be sold. The research done with your samples may help to develop new 
products in the future, but there is no plan for you to be paid.
Because your genetic information is unique to you, there is a small risk that someone 
could connect the information back to you. Also, genetic research and broadly sharing data 
may involve risks to you or people like yourself that are unknown at this  time.The possible 
benefits of research from your samples include learning more about what causes cancer 
and other diseases, how to prevent them and how to treat them. The greatest risk to you is 
the release of your private information. Dr. Kamdar will protect your records so that your 
name, address and phone number will be kept private. The chance that this information 
will be given to someone else is very small. There will be no cost to you for any data or 
sample collection and storage by Dr. Kamdar.
Please read each sentence below and think about your choice. After reading each 
sentence, circle “yes” or “no.” If you have questions, please talk to your doctor or nurse. 
Remember, no matter what you decide to do about the storage and future use of your 
samples, you may still take part in the study.
I give my permission for my blood and tissue to be stored in a central tissue bank for future 
use by the study investigators:
Consent and Authorization Form
Page 20 of 231.I give my permissions for my blood and tissue samples to be kept by Dr. 
Kamdar for use 
in future research to learn more about how to prevent, 
detect, or treat lymphoma.
Yes No  Initials
Who will see my research information?
The University of
 Colorado Denver (UCD) and its  affiliated hospital(s) have rules to protect 
information about you. Federal and state laws including the Health Insurance Portability 
and Accountability Act (HIPAA) also protect your privacy. This part of the consent form 
tells you what information about you may be collected in this study and who might see or 
use it.
The institutions involved in this study include:
University of
 Colorado Denver
University
 of Colorado Hospital
We cannot do this
 study without your permission to see, use and give out your information. 
You do not have to give us this permission. If you do not, then you may not join this study.
We will see, use and disclose your information only as described in this form and in our 
Notice of Privacy 
Practices; however, people outside the UCD and its affiliate hospitals 
may not be covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information 
but confidentiality cannot be guaranteed.
The use and disclosure of your information has no time limit. You can cancel your 
permission to use and disclose your information at any time by writing to the study’s 
Principal Investigator (PI), at the name and address listed below. If you do cancel your 
permission to use and disclose your information, your part in this study will end and no 
further information about you will be collected. Your cancellation would not affect 
information already collected in this study.
Manali Kamdar, MD 
Anschutz Medical Campus 
1665 N. Aurora Court
Mail Stop F754 
Aurora, CO 80045
Consent and Authorization Form
Page 21 of 23Both the research records that identify you and the consent form signed by you may be 
looked at by others who have a legal right to see that information, such as:
Federal offices such as the Food and Drug Administration (FDA) and the Office of 
Human Research Protections (OHRP) that protect 
research subjects like you.
People at the Colorado Multiple Institutional Review Board (COMIRB).
The study doctor and the rest of the study  team.
TG Therapeutics, Inc. is the manufacturer of Ublituximab and Umbralisib and is 
also providing a grant of funding support.
Officials at the institution where  the research is conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all 
of the rules for  research.
We might talk about this research study at meetings. We might also print the results of this 
research study in relevant journals. But we will always keep the names of the research 
subjects, like you, private.
You have the right to request access to your personal health information from the 
Investigator.
Information about you that will be seen, collected, used and disclosed in this study:
Name and demographic  information  (age, sex,  ethnicity, address, phone number, 
etc.
Portions of your previous and current  medical records that are relevant to this study, 
including but not limited to diagnosis(es), history and physical, laboratory or tissue 
studies, radiology studies, procedure results.
Research visit and research test  records.
Tissue samples and 
the data with the samples.
Billing or financial information.
What happens to Data, Tissue, Blood and Specimens that are collected in this 
study?
Scientists at the University of Colorado Denver and the hospitals involved in this study 
work to find the causes and cures of disease. The data, tissue, blood and specimens 
collected from you during this study are important to this study and to future research. If 
you join this study:
The data,  tissue, blood,  or other  specimens  given by you to the investigators for 
this research no longer belong to you.
Both the investigators and any sponsor of this research may study your data, 
tissue, blood, or other specimens collected from
 you.
If data, tissue, blood, or other specimens are in a form that identifies you, UCD or 
Consent and Authorization Form
Page 22 of 23the hospitals involved in this study may use them for future research only with 
your consent or Institutional Review Board (IRB) approval.
Any product or idea created by the researchers working on this study will not 
belong to you.
There is no plan for you to receive any
 financial benefit from the creation, use or 
sale of such a product or
 idea.
HIPAA Authorization for Optional Additional Study Procedures –In this form, you 
were given the option to agree to additional, optional research procedures. You must 
also give us your permission, under HIPAA rules, to use and disclose the information 
collected from these optional procedures, as described above.
Some of these optional procedures may involve genetic testing or the use of your genetic 
information. Your genetic information will not be released to others. If you decline to give us 
permission to use and disclose your information, you cannot take part in these optional 
procedures, but you can still participate in the main study. Please initial next to your choice:
 I  give permission for my information, from the optional procedures I have agreed 
to above, to be used and disclosed as described in this section.
 I  do not give permission for my information for any optional procedures to  be 
used and disclosed; I understand that I will not participate in any optional 
procedures.
Agreement to be in this study and use my data
The research project and the procedures associated with 
it have been explained to me. 
The experimental procedures have been identified and 
no guarantee has been given about 
the possible results. I will receive a signed copy of this consent form for my records.
I agree to participate in this study. My participation is voluntary  and I do not have to sign 
this form if I do not want to be part of this research study.
Subject Signature: Date:  
Subject Print  Name: 
Consent form explained by: Date:  
Print Name:  
C o n s e nt a n d A ut h ori z ati o n F or m
P a g e 2 3  of 2 3-------------------------------------------------- U s e O nl y if A p pli c a bl e ------------------------------------------------
Si g n at ur e Li n e f or wit n e s s; r e q uir e d f or c o n s e nt of n o n-r e a di n g s u bj e ct s a n d c o n s e nt u si n g  a s h ort f or m, 
if y o u r e q u e st e d s u c h c o n s e nt pr o c e d ur e s
Wit n e s s  of  Si g n at ur e 
Wit n e s s of  c o n s e nt  pr o c e s s 
Wit n e s s  Si g n at ur e: D at e: 
Wit n e s s Pri nt  N a m e:   